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ABBREVIATIONS 
 
ACK1   activated Cdc42Hs-associated kinase 1 
Akt/PKB  murine thymoma viral oncogene homolog 1/ Protein Kinase B 
ALL   acute lymphoblastic leukemia 
AML   acute myeloid leukemia 
CHIP   carboxyl terminus of Hsc70-interacting protein 
c-Kit/SCFR  mast/stem cell growth factor receptor 
c-Met   hepatocyte growth factor receptor 
Dbl   diffuse B-cell lymphoma 
DH   Dbl-homology domain 
DN   dominant-negative 
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor 
EMT   epithelial-mesenchymal transition 
Erk   extracellular signal-regulated kinase 
ESCC   oesophageal squamous carcinoma 
FGFR   fibroblast growth factor receptor 
GAP   GTPase activating proteins 
GBM   glioblastoma multiform 
GDI   guanine nucleotide dissociation inhibitors 
GDP   guanosine diphosphate 
GEF   guanine nucleotide exchange factor 
GPCR   G protein-coupled receptor 
Grb2   Growth factor receptor-bound protein 2 
GSK3   glycogen synthase kinase 3 
GST   glutathione S-transferase 
GTP   guanosine-5’-triphosphate 
GTPase  guanosine triphosphate phosphohydrolase 
Hsc70   heat shock cognate protein Hsc70 
Hsp90   heat shock protein Hsp90 
IGF-IR   insulin-like growth factor receptor 
INTS   intersectin 
IR   insulin receptor 
JNK/SAPK  c-Jun N-terminal kinase/stress actvated protein kinase 
KD   kinase-dead 
LC-MS  Liquid chromatography-mass spectrometry 
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LPA   lysophosphatidic acid 
MAPK   mitogen-activated protein kinase 
MII   myosin II    
MTM1   myotubularin 1 
mTORC1  mammalian target of rapamacin-raptor complex 1 
mTORC2  mammalian target of rapamacin-rictor complex 2 
NB   neuroblastoma 
NPDL   nodular poorly differentiated lymphoma 
NSCLC  non-small cell lung cancer 
onco-Dbl  oncogenic Dbl 
PDGF   platelet-derived growth factor 
PDGFR  platelet-derived growth factor receptor 
PDK1   phosphoinositide-dependent kinase-1 
PH   Pleckstrin-homology domain 
PI3K   Phosphatidylinositol-3 kinase 
PI3KC2β  Phosphatidylinositol 3-kinase C2 domain containing subunit beta 
PNET   peripheral neuroectodermal tumor 
proto-Dbl  prototype Dbl 
PTB   phosphotyrosine-binding 
PtdIns   phosphatidylinositol 
PtdIns(3)P  PtdIns 3-phosphate 
PtdIns(3,4)P2  PtdIns 3,4-bisphosphate 
PtdIns(3,4,5)P3 PtdIns 3,4,5-trisphosphate 
PtdIns(4,5)P2  PtdIns 4,5-bisphosphate 
PTEN   phosphatase and tensin homologue deleted on chromosome 10 
RTK   receptor tyrosine kinase 
S6   ribosomal protein S6 
S6K1   ribosomal protein S6 kinase 1 
SCF   stem cell factor 
SCLC   small cell lung cancer 
SH2   Src homology-2 
SH3   Src homology-3 
SHIP   SH2-containing phosphatase 
SNP   single-nucleotide polymorphism 
Sos   son of sevenless 
WT   wild-type 
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SUMMARY 
 
 Class II PI3K (phosphoinositide 3-kinase) isoforms have not been extensively 
investigated since the whole family of PI3Ks was discovered in the 1980s, and class II PI3K 
family members are still the least studied among all PI3Ks. To date the interest of the 
scientific community was mostly focused on class I PI3K enzymes especially due to their well 
established role in the development of several human disease including diabetes and cancer. 
However, an increasing amount of data has emerged recently suggesting an important role 
of class II PI3Ks in physiological and pathological processes. Together with receiving more 
attention, the understanding of their cellular functions will considerably increase. There is not 
much known yet about the mechanisms of class II PI3Ks activation and their downstream 
targets. Interestingly, accumulating data in the literature suggest that due to synthesis of 
distinct phosphoinositide or through different intracellular localization than other PI3K 
isoforms, class II PI3Ks possibly regulate biological processes or different steps in the same 
process distinct from class I and III PI3Ks. The molecular mechanisms underlying their action 
however still remain unrevealed. 
 PI3KC2β belongs to class II PI3Ks and its cellular functions have been associated 
with pro-migratory and pro-survival signals, as well as cell proliferation. Following ligand 
stimulation, the enzyme is recruited to the activated receptor tyrosine kinases (RTKs) via 
Grb2 or Shc adaptor proteins. At the plasma membrane PI3KC2β generates mostly 
PtdIns(3)P or PtdIns(3,4)P2 and forms multi-protein complexes, whose assembly lead to 
activation of the Rho GTPases and regulation of the Akt/PKB signaling pathway. How exactly 
PI3KC2β contributes to the above-mentioned functions has not been precisely described. 
However, its mechanism of action seems to be related to the kinase multi-domain structure, 
which differs much from the structures of class I and class III PI3Ks. The most characteristic 
features of the enzyme are its lack of association to regulatory subunits, which is 
accompanied by a high molecular mass and elongated N- and C-terminal extensions, which 
play a regulatory role for PI3KC2β catalytic activity. The knowledge about PI3KC2β structural 
features still needs to be translated into a precise mode of action. 
 In my studies I have investigated the regulatory mechanism linking PI3KC2β to the 
activation of the Rho family of small GTPases through the Dbl guanine exchange factor 
(GEF) in NIH3T3 mouse fibroblasts, where PI3KC2β over-expression induced marked cell 
morphology changes in the cytoskeletal organization, including strong stress fibers formation, 
enlargement of the cell body, increased cell spreading and ruffles formation. I could 
demonstrate formation of a PI3KC2β/Dbl complex in mouse fibroblasts and human cancer 
cells. I showed that the N-terminal regulatory domain of PI3KC2β can interact with Dbl 
through its spectrin and pleckstrin holomogy (PH) domains revealing an interesting and novel 
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model of regulation. The association of PI3KC2β with Dbl however was not direct and did not 
depend either on the PI3K activity of the enzyme or on EGF and PDGF stimulation, 
suggesting a more complex mechanism of PI3KC2β-mediated Dbl activation and implication 
of additional interaction partners. Moreover, an interaction of PI3KC2β isolated from A-431 
epidermoid carcinoma cells with oncogenic form of Dbl was found, indicating a potentially 
important role of the kinase in Dbl-dependent tumorigenesis. 
 In order to gain further insights into the PI3KC2β mechanism of regulation and 
function in cellular responses I have investigated for the first time the role of tyrosine 
phosphorylation of PI3KC2β in human cancer cells. Among four newly identified tyrosine 
phosphorylation sites three residues (Y68, Y127, Y228) were found in the N-terminal domain 
of the enzyme, whereas one (Y1541) was localized in the C-terminal extension. 
Simultaneous mutation of Y127 and Y228 in PI3KC2β wild-type increased HT-29 colon 
cancer cell proliferation, cell-cell junctions formation and activation of Akt/PKB pathway. 
Moreover, the cellular changes resulting from Y127 and Y228 mutation were similar to the 
effects of PI3KC2β kinase domain mutation when compared to PI3KC2β wild-type, indicating 
a possible role of tyrosine phosphorylation of the enzyme’s N-teminal domain in the 
regulation of its kinase activity. Therefore, I propose that phosphorylation of Y127 and Y228 
in the N-terminus of PI3KC2β wild-type negatively regulates cell proliferation, cell-cell 
junctions formation and activation of Akt/PKB pathway. Future work would be needed to 
elucidate the details of this regulatory mechanism and its function in tumor cells. 
 All together, these results unveil new aspects of PI3KC2β mechanisms of regulation, 
which have not been investigated before. They further provide new insights into the possible 
role of PI3KC2β in human cancer. Last but not least, they contribute to the growing 
understanding of the role of class II PI3Ks in physiological and pathological processes in 
human biology.  
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ZUSAMMENFASSUNG 
 
Seit der Entdeckung der Proteinfamilie der PI3Ks (Phosphoinositid-3-Kinasen) in den 
achtziger Jahren des letzten Jahrhunderts, wurden die Isoformen der Klasse II der PI3Ks 
nicht ausgiebig untersucht und sie repräsentieren noch immer die am Wenigsten untersuchte 
Klasse der PI3Ks. Im Forschungsinteresse stand bislang hauptsächlich die Klasse I PI3K 
Enzyme, da diese eine gut etablierte Rolle in der Entwicklung verschiedener menschlicher 
Erkrankungen spielen, einschliesslich Diabetes und Krebs. Nichtsdestotrotz deuten eine 
zunehmende Anzahl von Studien neulich an, dass die Klasse II PI3Ks eine wichtige Rolle in 
verschiedenen physiologischen und pathologischen Prozessen spielen. Die wachsende 
Aufmerksamkeit für diese Klasse PI3Ks hat zwar zu einem besseren Verständnis über ihre 
zellulären Funktionen beigetragen, dennoch wurden die genauen Aktivierungsmechanismus 
und die Zielmoleküle dieser Enzyme bisher nicht vollständig enthüllt. Anhäufende Daten 
deuten darauf hin, dass die Klasse II PI3Ks sich von der Klasse I PI3K erstens in die 
intrazelluläre Lokalisation und zweitens in die Synthese anderer Phosphoinositide 
unterscheiden. Infolgedessen regulieren sie möglicherweise andere biologische Prozesse 
bzw. verschiedene Schritte im selben Prozess als die restliche PI3K Enzyme.  
Die PI3KC2β-Isoform gehört zur Klasse II PI3Ks. Ihre zellulären Funktionen wurden bisher 
mit migrations- und überlebensfördernden Signalen, sowie mit der Zellproliferation assoziiert. 
Nach Ligandenstimulation wird das Enzym zu den aktivierten Rezeptortyrosinkinasen (RTKs) 
über die Adaptorproteine Grb2 oder Shc rekrutiert. An der Plasmamembran generiert 
PI3KC2β hauptsächlich PtdIns(3)P oder PtdIns(3,4)P2 und bildet Multiproteinkomplexe, 
welche zur Aktivierung der Rho GTPasen und schlussendlich zur Regulierung des Akt/PKB 
Signalweges führen. Wie genau PI3KC2β zu den oben genannten Funktionen beiträgt, 
wurde noch nicht vollständig beschrieben. Allerdings scheint der Aktionsmechanismus mit 
der Multidomänenstruktur der Kinase zusammen zu hängen, welche stark von den 
Strukturen der Klasse I und III PI3Ks abweicht. Die charakteristischen Merkmale des Enzyms 
sind die fehlenden Assoziationen zu den  regulatorischen Untereinheiten, welche von einer 
hohen molekularen Masse und verlängerten N- und C-terminalen Erweiterungen begleitet 
werden. Die N- und C-terminalen Erweiterungen spielen eine wichtige Rolle bei der 
Regulierung der katalytischen Aktivität von PI3KC2β. Der Zusammenhang zwischen den 
strukturellen Merkmalen von PI3KC2β und ihrem Wirkungsmechanismus sollte trotzdem 
noch eingehender untersucht werden. 
In der vorliegenden Dissertation wurde der Regulationsmechanismus untersucht, 
welcher PI3KC2β mit der Aktivierung der Rho-Familie kleiner GTPasen via den Dbl-
Guaninaustauschfaktor verknüpft. Diese Experimente wurden in NIH3T3 
Mausfibroblastenzellen ausgeführt, in welchen die Überexpression von PI3KC2β zu 
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markanten Änderungen der Zellmorphologie in der Zytoskelettorganisation führte, 
einschliesslich starker Stressfasernbildung, Vergrösserung des Zellkörpers, erhöhte 
Zellausbreitung und Bildung von Membranausstülpungen. Die Bildung eines PI3KC2β/Dbl-
Komplexes in Mausfibroblasten und menschlichen Krebszellen wurde bewiesen. 
Desweiteren wurde es gezeigt, dass die N-terminale, regulatorische Domäne von PI3KC2β 
mit Dbl durch dessen Spektrin- und Pleckstrinhomologie (PH)-Domänen interagieren 
können, was ein interessantes Regulierungsmodell einbringt. Die Komplexbildung zwischen 
PI3KC2β und Dbl war jedoch nicht direkt und weder von der PI3K-Aktivität des Enzyms, 
noch von der EGF- und PDGF-Stimulation abhängig. Dies deutet somit auf einen 
komplexeren Mechanismus der PI3KC2β-vermittelten Aktivierung von Dbl hin und impliziert 
die Anwesenheit von zusätzlichen Interaktionspartnern. Zudem wurde eine Interaktion 
zwischen PI3KC2β, isoliert aus A-431 Epidermoidkarzinomzellen, und der onkogenen Form 
von Dbl gefunden, was eine potentiell wichtige Rolle der Kinase in der Dbl-abhängigen 
Tumorentstehung hinweist.  
Um weitere Einblicke in den Regulationsmechanismus und die Funktion der 
zellulären Reaktionen von PI3KC2β zu gewinnen, wurde zum ersten Mal die Rolle der 
Tyrosinphosphorylierung in der aus menschlichen Krebszellen isolierten PI3KC2β-Isoform 
untersucht. Von den vier neu identifizierten Tyrosinphosphorylierungsstellen wurden drei 
(Y68, Y127, Y228) in der N-terminalen Domäne und eine (Y1541) in der C-terminalen 
Erweiterung des Enzyms lokalisiert. Die gleichzeitige Mutation von Y127 und Y224 in 
PI3KC2β-Wildtyp erhöhte die Proliferation, die Bildung von Zell-Zellverbindungen sowie die 
Aktivierung des Akt/PKB-Signalweges in HT-29 Darmkrebszellen. Im Vergleich zum 
PI3KC2β-Wildtyp waren die Veränderungen, die aus Y127 und Y228 Mutationen resultierten, 
zudem ähnlich zu den Effekten, die aus Mutationen in der PI3KC2β-Kinasedomäne 
entstanden. Dies deutet auf eine mögliche Rolle der Tyrosinphosphorylierung der N-
terminalen Enzymdomäne in der Regulierung der Kinaseaktivität hin. Dadurch kann man 
schliessen, dass die Phosphorylierung von Y127 und Y228 im N-Terminus des PI3KC2β-
Wildtyps die Zellproliferation, die Bildung von Zell-Zellverbindungen und die Aktivierung des 
Akt/PBK-Signalweges negativ reguliert. Zwangsläufig ist weitere Arbeit nötig, um die Details 
dieses regulatorischen Mechanismus und dessen Funktion in Tumorzellen aufzuklären. 
Zusammenfassend liefern die Ergebnisse der vorliegenden Dissertation neue 
Erkenntnisse über den Regulationsmechanismus von PI3KC2β, welche bisher noch nicht 
untersucht wurden. Sie bieten zusätzlich neue Einsichten in die mögliche Rolle von PI3KC2β 
in menschlichen Krebserkrankungen. Nicht zuletzt tragen sie zum wachsenden Verständnis 
der Rolle der Klasse II PI3Ks in physiologischen und pathologischen Prozessen in der 
Humanbiologie bei. 
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1. INTRODUCTION 
 
1.1. Role of the Kinome and Tyrosine Phosphorylation in Cell Signaling 
 
The understanding of signaling pathways in human cells and translation of this 
knowledge to improved human disease treatments is one of the most challenging tasks faced 
by the biologists and clinicians nowadays. Many aspects of signal transduction biology and 
biochemistry have been recognized and combined into a small number of unified principles, 
which help to interpret the system’s complexity. However, still much remains to be learned in 
this area of research. 
Intracellular signaling cascades are initiated by the ligand stimulation of cell surface 
receptors and are finalized in the nucleus with an induction of respective genes expression. 
The phosphorylation and dephosphorylation of proteins and lipid substrates play a 
fundamental role in signal transduction and are involved in almost all cellular processes such 
as proliferation, differentiation, adhesion, survival, cell cycle progression, metabolic 
homeostasis and transcriptional activation [1, 2]. The rapid and reversible nature of 
phosphorylation provides precise control of protein activity, cellular localization, stability, 
conformation and interaction with other proteins. Tyrosine phosphorylation is mediated by the 
90 tyrosine kinases of the 518 protein kinases comprising the human kinome [1]. 58 of the 90 
human tyrosine kinases are receptor tyrosine kinases (RTKs), while the remaining are 
classified as non-receptor tyrosine kinases [2]. In the last group, the Src non-receptor 
tyrosine kinase was the first tyrosine kinase identified [3]. Protein tyrosine phosphatases 
(PTP) act simultanously to tyrosine kinases antagonizing their activity by removing 
phosphate from phospho-tyrosines [4]. There are around 81 active PTPs identified with the 
ability to dephosphorylate phospho-tyrosine. Only the tightly controlled collaboration of 
protein kinases and phosphatases ensures the maintenance of cell homeostasis. Any 
perturbations in this perfectly balanced system may lead to human diseases progression, in 
particular cancer, which is characterized by aberrant signal processing. The role of tyrosine 
phosphorylation seems to be more diverse than it was originally assumed [2]. Most of the 
proteins become phosphorylated at different sites with different kinetics. Thus, 
phosphorylation of the same protein may be differently regulated at distinct sites leading to 
the integration of variety of upstream and downstream signals. Each of these 
phosphorylation sites can further play different functions [5], as it was already shown for 
many well-studied signaling proteins, for instance FAK or Src [6, 7]. It is therefore more 
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accurate to study site-specific phosphorylation rather than phosphorylation of the whole 
protein to gain a more precise knowledge about protein regulation.  
During the last decade mass spectrometry (MS) has become a main method of choice for the 
in vivo investigation of phosphoproteome dynamics. Hypothesis-free mass spectrometry-
based analysis of in vivo phosphorylation in a number of different cell lines and tissues under 
various conditions revealed thousands of simultaneously occuring tyrosine phosphorylation 
events in multiple proteins [5, 8-10]. Among all these proteins there are kinases and 
phosphatases, transcriptional and cytoskeletal regulators, ubiquitin ligases, GEF/GAPs and 
RNA-binding proteins. Many of the tyrosine phosphorylation sites have been already 
recognized and some were even functionally characterized, but there are still plenty left, 
which await identification and functional description [5].  
 
1.2. Receptor Tyrosine Kinases 
 
In the group of 58 known human receptor tyrosine kinases (RTKs) we can distinguish 
20 subfamilies among which the most studied are the families of epidermal growth factor 
receptor (EGFR/ErbB), insulin receptor (InsR/IGF1R), platelet-derived growth factor receptor 
(PDGFR), vascular entothelial growth factor receptor (VEGFR), fibroblast growth factor 
receptor (FGFR), angiopoietin receptor (Tie) and ephrin receptor (Eph) [11]. All RTKs share 
the same molecular architecture that includes a ligand-binding extracellular domain, a single 
transmembrane helix, and a cytoplasmic protein tyrosine kinase domain that catalyses 
phosphate transfer from ATP to tyrosine residues. Additionally, carboxy (C-) terminal and 
juxtamembrane regulatory regions can be distinguished. RTKs play a key regulatory role in 
the cells. The structure, the mechanism of RTKs activation and components of the signaling 
pathways, which they trigger are evolutionary conserved from worms to humans [11]. The 
vast majority of RTKs consist of a single polypeptide chain while members of the insulin-
receptor family are disulphide-linked heterodimers [12]. Regardless of the monomeric or 
dimeric form of the inactive receptor, the ligand binding is required to stabilize individual 
receptor molecules into an active hetero-dimers or oligomers. Ligand-mediated dimerization 
is therefore essential to promote RTKs activation [11]. However, it is not sufficient enough to 
induce activation of the intracellular kinase domain [13]. Due to dimerization, two kinase 
domains are brought together close enough to activate each other through trans-
phosphorylation in the activation loop [11]. This mechanism plays a crucial regulatory role in 
the activation of most RTKs. However, an allosteric activation of the tyrosine kinase domain 
without phosphorylation of the activation loop is also possible. The EGFR represents the best 
example of such mechanism. The tyrosine kinase domains of two EGFR molecules form an 
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asymetric head-to-tail dimer, which is stabilized by the juxtamembrane segment [11, 14, 15]. 
Binding of one kinase domain called “Activator” to its partner domain denoted as “Receiver” 
results in conformational changes in the later one, which in turn adopts an active state [15]. 
Subsequent trans-autophosphorylation events in the juxtamembrane region and the C-
terminal tail play an important role in terms of full RTK activation and downstream signal 
transduction. Respective tyrosine sites are phosphorylated in a precise order, which 
significantly increases receptor tyrosine kinase domain catalytic activity and creates the 
phoshotyrosine-based docking sites that recruit downstream signaling molecules [11]. In 
some RTKs (FGFR) an additional phase of autophosphorylation occurs, which maximally 
stimulates the tyrosine kinase domain for phosphorylation of downstream targets [16].  
 
1.2.1. Phosphotyrosine Binding Motifs in Signal Transduction 
 
Autophosphorylation of tyrosine residues in the cytosolic tail of RTKs is crucial for the 
recruitment and activation of a variety of signaling proteins, which recognize and specifically 
bind to the phosphorylated tyrosines via Src homology-2 (SH2) and phosphotyrosine-binding 
(PTB) domains [11, 17]. SH2- and PTB-domain-containing proteins function as molecular 
intergators of cell signalling pathways from the exterior to the interior of the cell recruiting 
diverse signaling molecules to the activated RTKs. Their binding specificity is directed 
respectively by the carboxyterminal or amino-terminal sequences that flank the 
phosphotyrosine residues on the receptor [18]. SH2 domains are divided into three classes: 
phospholipase C-γ1 (PLC-γ1)-like, Src-like and Grb2-like depending on the structural 
features of the binding surface [19]. Among SH2-domain-containing molecules we can 
distinguish intracellular, non-catalytic adaptor proteins such as Grb2 (growth factor receptor-
bound protein 2), SHC, Crk and Nck. Moreover, enzymes with  phospholipase (PLC-γ), 
tyrosine kinase (Src family of proteins), phosphatase (SHP-2) and ubiquitin ligase (c-Cbl) 
activity are included to that group [18]. The functional diversity of SH2-domain-containing 
proteins reflects the complexity of signaling pathways, which can be triggered downstream of 
activated RTKs. Ras/MAPK (mitogen-activated protein kinase) and PI3K 
(Phosphatidylinositol 3-Kinase)/Akt pathways are just two examples. 
Many adaptors or proteins, which function as molecular scaffolds in signaling pathways can 
be found in the group of PTB-domain-containing molecules [18]. SH2-domain-containing 
docking protein SHC and insulin receptor substrate-1 (IRS-1) were the first identified 
members in this family [20]. PTB domains recognize NPXpY amino-acid sequences and 
were found in numerous signaling molecules [18]. Similarly to the SH2 motifs, they mediate 
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the activation of various signaling pathways such as the Ras/MAPK pathway, insulin 
receptor, Tek/Tie2, EGF and ErbB2 receptors downstream pathways. 
 
1.2.2. Adaptor and Docking Proteins 
 
Adaptor proteins can selectively recognize activated receptors with their SH2 
domains, but simultanously they recruit cytoplasmic effectors with their Src-homology-3 
(SH3) motifs, which bind to proline and arginine-rich sequences [21, 22]. Two SH3 domains 
of Grb2 associate with the Ras guanine-nucleotide exchange factor (GEF) son-of-sevenless 
(Sos), what results in formation of GTP-bound Ras and subsequent activation of the MAPK 
pathway [23]. Due to combined binding properties, simple adaptors control complex cellular 
behaviour by interactions with multiple partners in response to stimuli from the extra- and 
intra-cellular environemnt. Grb2 participates in the activation of many signaling pathways. 
Comprehensive quantitative and time-dependent studies of changes in protein interactions 
with Grb2 revelaed 108 Grb2-associated proteins including lipid or protein kinases, 
phosphatases, GTPase guanine nucleotide exchange factors (GEFs), GTPase activating 
proteins (GAPs), adaptor and scaffolding proteins [22]. Many of them are involved in growth 
factor-specific signaling networks, which control distinct cellular functions like metabolism or 
cytoskeletal architecture. Some of the proteins like IRS4, p85 and p110α/p110β seem to be 
part of a core Grb2 signaling machinery. They showed increased association with Grb2 upon 
cell stimulation with the majority of growth factors, while Grb2 interactions with other proteins 
(EGFR, FRS2 and GAB1) were more growth-factor specific [22]. SH2- or PTB-domain-
containing proteins can also associate to activated receptors indirectly through docking 
proteins, which become phosphorylated by the receptor, which they interact with [11, 24]. 
Docking proteins (FRS2, IRS1, Gab1) have the ability to associate with the plasma 
membrane through the membrane targeting of the N-terminal region (either by myristoylation 
or pleckstrin homology (PH) domain). Due to presence of whole array of tyrosine 
phosphorylation sites they serve as a binding platform for SH2- and PTB-domain-containing 
signaling molecules [11, 24]. 
With multiple tyrosine phosphorylation sites in all receptors and a wide range of proteins 
interacting with them, activated RTKs can transmit the signal from the exterior to the interior 
of the cell and stimulate diverse signaling cascades. Between these signaling pathways 
crosstalks often occur, which place RTKs in the position of key regulatory nodes in the 
complex and dynamic signaling networks [11].  
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1.3. Phosphatidylinositol 3-Kinases 
 
Phosphatidylinositol 3-Kinases (PI3Ks) are additional key players in the intracellular 
signaling pathways, which makes membrane-to-cytosol communication even more complex 
[25]. They belong to the family of evolutionary conserved lipid kinases, which operate 
downstream of activated RTKs and G protein-coupled receptors (GPCRs) [25]. Thus, PI3Ks 
function at the level of the plasma membrane, where they phosphorylate phosphoinositides 
(PtdIns) at the 3-OH group of the inositol ring. As a result, these lipid kinases give rise to the 
formation of second messengers such as PtdIns(3)P (PtdIns 3-phosphate), PtdIns(3,4)P2 
(PtdIns 3,4-bisphosphate) and PtdIns(3,4,5)P3 (PtdIns 3,4,5-trisphosphate) [26], which 
become targets for PH (pleckstrin homology), PX (Phox) and FYVE zinc finger-binding 
modules [27, 28]. Thus, PtdIns(3,4,5)P3 controls the localization and function of numerous 
effector proteins, which after recruitment to the plasma membrane get activated. As a result, 
they promote various local cellular responses, such as assembly of signaling complexes, 
initiation of protein kinase cascades and actin polymerization [29, 30]. The Akt/PKB Ser/Thr 
kinase plays a central role in the PI3K pathway. It directly binds to PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 via its PH domain and becomes phosphorylated by phosphoinositide-
dependent kinase 1 (PDK1) at Thr308 [31, 32]. However, to acquire full catalytic activity Akt 
must be phosphorylated at Ser473 by the mammalian target of rapamacin complex 2 
(mTORC2) [33]. Upon activation, Akt phosphorylates a wide range of target proteins, which 
affect important cellular processes [25, 29, 30]. Through the regulation of the tuberous 
sclerosis complex 1 and 2 (TSC1 and TSC2) Akt controls autophagy, cell cycle, as well as 
cell growth. Control of the cell growth is based on the modulation of the protein translation 
machinery through the mammalian target of rapamycin complex 1 (mTORC1) and its 
downstream targets, p70S6 kinase and 4E-binding protein 1 (4EBP1) [34]. Akt-mediated 
phosphorylation of murine double minute 2 protein (MDM2) increases MDM2 activity and in 
turn promotes degradation of the p53 tumor suppressor protein, which regulates apoptosis, 
cell cycle arrest and DNA-repair mechanisms [35]. Apoptosis-related substrates of Akt 
include also transcription factors from the forkhead (FOXO) family [29, 36], the proapoptotic 
protein BAD [35, 37] and the nuclear factor-kappa B (NF-κB) transcription factor [35]. Their 
phosphorylations lead to the prevention of apoptosis and promotion of cell survival through 
distinct molecular mechanisms. By inhibition of glycogen synthase kinase 3 (GSK3) Akt 
controls cell cycle and glucose metabolism in the insulin signaling pathway [29, 38]. An 
overview of the PI3K signaling pathway is given in Fig. 1-1. 
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Figure 1-1. PI3K signaling pathway. PI3Ks are recruited to the plasma membrane by activated 
RTKs. They bind to phosphorylated receptors and generate PtdIns(3,4,5)P3, which in turn become a 
targets for multiple PH-domain containing proteins including Ser/Thr kinases Akt and PDK1. PDK1 
phosphorylates Akt at Thr308, but to be fully activated Akt requires mTORC2 phosphorylation of Ser473. 
Fully active Akt phosphorylates a number of downstream effector molecules leading to their activation 
or inhibition and thus resulting in cell growth, survival and proliferation through various molecular 
mechanisms. PI3Ks can also control cytoskeletal rearrangements through RAC1/CDC42, in an Akt-
independent manner. Abbreviations: RTKs, receptor tyrosine kinases; PH, pleckstrin homology 
domain; PDK1, 3-phosphoinositide-dependent kinase 1; mTORC1, mammalian target of rapamycin 
complex 1; mTORC2, mammalian target of rapamacin complex 2; FOXO, forkhead box, class O 
proteins; BAD, BCL-2 antagonist of cell death; Rheb, RAS homologue enriched in brain. Adapted from 
Chalhoub and Baker, 2009 [30].  
 
 
PI3K/Akt signaling is under the tight control of two different types of phosphatases, 
which balance PI3Ks activities by dephosphorylation of (PtdIns(3,4,5)P3) [29]. The Src-
homology 2 (SH2)-containing phosphatase (SHIP) dephosphorylates the 5-position of the 
inositol ring producing PtdIns(3,4)P2, whereas the phosphatase and tensin homologue 
deleted on chromosome 10 (PTEN) dephosphorylates the 3-position of PtdIns(3,4,5)P3 
producing PtdIns(4,5)P2 [29, 39].  As specified above, PtdIns(3,4)P2 can play a role of second 
messenger independently of PtdIns(3,4,5)P3 By generation of PtdIns(3,4)P2 SHIP proteins do 
not terminate PI3K signaling, but convert one signal to another. PTEN, on the other hand, 
completely inactivates the PI3K signal not giving a chance for induction of further signaling 
cascades [39]. Thus, SHIP and PTEN phosphatases play an important role in antagonizing 
the PI3K pathway and maintaining cell signaling homeostasis. Loss of SHIP2 leads to 
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increased sensitivity to insulin [40], whereas loss of PTEN function has been often found in 
many types of advanced human cancers [30]. In addition to PTEN and SHIP, myotubularins 
were found to antagonize PI3Ks activity by dephosphorylation of PtdIns(3)P [41]. 
Myotubularins recently have received a lot of interest in the context of actin cytoskeleton 
remodeling and membrane trafficking [42]. 
In the last years, the physiological functions of PI3Ks have been widely studied in cell 
line–based systems and model organisms. They appear to be extremly important in diverse 
cellular responses including cell proliferation, differentiation, chemotaxis, survival, 
intracellular trafficking and glucose homeostasis. Furthermore, the enzymes are involved in 
the embryonic development and immunity. Therefore, aberrant PI3K activity is associated 
with a wide range of human diseases including cancer, diabetes, heart and respiratory 
disorders, as well as inflammation [43]. Somatic mutations in PIK3CA and PIK3R1, encoding 
respectively p110α and p85, promote the activation of the PI3K/Akt pathway and are 
frequently found in human cancers [44]. Similarly, PIK3CA gene amplifications significantly 
contribute to cancer progression. Most of the mutations in p110α are located in two “hot spot” 
regions in exon 9 and 20, which encode the helical and kinase domain, respectively. 
Mutations in the helical domain disrupt the inhibitory effect of p85 on the p110α catalytic 
subunit, whereas mutations in the kinase domain increase the p110α enzymatic activity [44]. 
The second leading mutation in human cancer occurs in the PTEN gene. It leads to 
phosphatase inactivation and thus hyper-activation of PI3K/Akt pathway, which enhance 
tumor cells survival and proliferation. Usually, the expression of PTEN is altered through loss 
of heterozygoty (LOH), point mutations, homozygous deletion or epigenetic silencing via 
promoter methylation [45]. Somatic mutations or amplifications of Akt were also frequently 
found in cancer. The most common mutation (E17K) affects the lipid binding site (PH 
domain) causing constant association to the plasma membrane, even in the absence of 
PtdIns(3,4,5)P3 [46]. 
 
1.3.1. Classification of the PI3K Family Members 
 
It took around 10 years of research since the first PI3Ks were discovered until they 
became classified in the 1990s [25]. The PI3K family consists of 8 catalytic subunits, which 
emerged from the PCR-based cloning studies and biochemical purification strategies. They 
were used to identify sequence homologies between lipid kinases and to characterize PI3K 
enzymatic properties, respectively [25]. All members of the family show structure similarities. 
They possess a core sequence consisting of C2, helical and catalytic kinase domains [47]. 
On the other hand, PI3Ks differ in their substrate preferences in vitro and their association 
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with regulatory subunits. Based on these criteria PI3Ks have been divided into three 
functional classes:  class I (p110α, p110β, p110δ and p110γ), class II (PI3KC2α, PI3KC2β 
and PI3KC2γ) and a single class III (Vps34) enzyme [43, 48]. Class I is further divided into 
class IA and IB, depending on the receptor type, which regulates their activity. All PI3Ks are 
conserved throughout evolution. Class I and class II are found in multicellular eukaryotes 
(invertebrates and vertebrates such as C.elegans, D.melanogaster, mouse and human), 
whereas simple unicellular eukaryotes (e.g. yeasts) and all plant species investigated so far 
possess only a sole class III PI3K [43, 48]. Many members of the family are ubiquitously 
expressed in humans, while others are confined to specific cells and tissues [43, 48]. For a 
detailed classification, PI3Ks substrate specificity, upstream regulators, cellular function, 
tissue distribution, as well as PI3Ks domain structure see Table 1-1 and Fig. 1-2. In addition 
to the three PI3K classes, a class IV of PI3K-related proteins (PIKKs) exists in all eukaryotes. 
It includes mTOR (mammalian target of rapamacin), ATM (Ataxia telangiectasia mutated), 
ATR (Ataxia telangiectasia mutated related) and DNA-PK (DNA-dependent protein kinase) 
Ser/Thr kinases, whose sequences suggest a common evolution from lipid kinases and in 
turn similar regulation [48-50]. Most of the PIKKs function at the genomic level sensing the 
presence of DNA damage and maintaining its integrity [49, 50]. mTOR is an exception, 
because it is involved in cell growth, protein synthesis and autophagy signaling.  
 Class I PI3K was the first to be identified and cloned, and thus the best understood 
until now. Enzymes of this class can phosphorylate in vitro PtdIns, PtdIns(4)P and 
PtdIns(4,5)P2 giving rise to PtdIns(3)P, PtdIns(3,4)P2, and PtdIns(3,4,5)P3, respectively. In 
vivo PtdIns(4,5)P2 is the main substrate and respectively PtdIns(3,4,5)P3 is the main product 
[43, 51]. They are cytosolic proteins, which are recruited to the membrane upon ligand 
stumulation, where they bind to activated receptors or adaptor proteins [48]. Depending on 
the regulatory partners and mechanism of activation (including the receptor type they bind), 
class I PI3Ks is divided into class IA and class IB. Class IA PI3Ks comprises a group of 
catalytic (p110α, p110β, p110δ) and regulatory (p85α, p85β, p55γ, p55α, p50α) subunits, 
which in human are encoded by three genes: PIK3CA, PIK3CB, PIK3CD and PIK3R1, 
PIK3R2, PIK3R3, respectively. Due to alternative splicing the three genes encoding the 
regulatory subunits can give rise to five different isoforms. 
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Table 1-1. Classification of PI3K family members based on their substrate specificity, 
regulation and cellular functions. 
 
Classification of PI3Ks 
 
 Isoforms Gene name 
Substrate 
specificity Regulator 
Cellular 
function Expression 
 
Class 
IA 
 
Regulatory 
 
p85α, p55α, 
p50α  
p85 β  
p55γ 
 
Catalytic 
 
p110α 
p110β 
p110δ 
 
 
 
 
PIK3R1 
PIK3R2 
PIK3R3 
 
 
 
PIK3CA 
PIK3CB 
PIK3CD 
 
 
 
PtdIns 
PtdIns(4)P 
PtdIns(4,5)P2 
 
 
 
• RTKs 
• GPCRs 
(p110β) 
• Ras 
 
 
 
• proliferation 
• metabolism 
• migration 
• survival 
• immunity   
(p110δ) 
 
 
 
Ubiquitous 
 
 
 
p110δ 
mainly in 
leukocytes 
 
Class 
IB 
 
Regulatory 
 
p101 
p84/p87 
 
Catalytic 
 
p110γ 
  
 
 
 
PIK3R5 
PIK3R6 
 
 
PIK3CG 
 
 
 
PtdIns 
PtdIns(4)P 
PtdIns(4,5)P2 
 
 
 
• GPCRs 
• Ras 
 
 
 
• inflammation 
• platelet  
aggregation 
• immunity 
 
 
 
Mainly in 
leukocytes 
 
Class 
II 
 
Catalytic 
 
PI3KC2α,  
PI3KC2β  
PI3KC2γ 
 
 
 
 
PIK3C2A  
PIK3C2B  
PIK3C2G 
 
 
 
 
PtdIns 
PtdIns(4)P 
 
 
 
 
• RTKs 
• Cytokine 
receptors 
• Integrins 
• GPCRs 
(LPA) 
 
 
 
• vesicular 
transport  
• cell migration 
• chemotaxis  
 
 
 
Broad 
expression, 
but not 
ubiquitous 
 
PI3KC2γ 
mainly in 
liver 
 
 
Class 
III 
 
Regulatory 
 
Vps15/p150 
 
Catalytic 
 
Vps34 
 
 
 
 
PIK3R4 
 
 
 
PIK3C3 
 
 
 
PtdIns 
 
 
 
 
• GPCRs 
• amino 
acids 
• glucose 
 
 
 
• autophagy 
• vesicular 
transport 
 
 
 
Ubiquitous 
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Figure 1-2. Domain structures of PI3Ks. With the exception of class II enzymes, all PI3Ks consist of 
regulatory and catalytic subunits. PI3K catalytic subunits include a C2 domain and a PI3K core 
structure containing a kinase and helical domain. Class IA regulatory subunits (p85α, p55α, p50α, 
p85β, p55γ) consist of the main p110-binding domain and two SH2 domains, which bind to tyrosine-
phosphorylated residues at the activated RTKs. p85α and p85β additionally contain a SH3 domain, 
which can attach to proline-rich regions of other proteins, and BH domain flanked by two proline-rich 
regions (P). The shorter splicing variants of p85α lack the N-terminal BH- and SH3 domain. Beside 
domains common for all PI3Ks catalytic subunits, class IA catalytic isoforms contain N-terminus p85-
binding domain responsible for the interaction with the regulatory subunit, and Ras-binding domain. 
The catalytic p101γ isoform of class IB has the same domain structure as class IA apart from the lack 
of p85 binding domain. Class IB regulatory isoforms, p101 and p87 do not have any homology to other 
proteins and this far, none of their domains have been identified. Class II PI3Ks comprises of three 
high molecular mass catalytic isoforms (PI3KC2α, PI3KC2β, PI3KC2γ) and are characterized by an 
additional C2 and PX domain within the C terminus and a proline-rich region (P) in the N-terminus, 
which differs between the three isoforms. The catalytic subunit of class III PI3Ks, Vps34, consists of 
the PI3K core structure accompanied by N-terminal C2 domain. The regulatory isoform, Vps15 (also 
known as p150) contain a kinase domain, which is thought to be inactive, and several WD40 repeats 
and HEAT domains. Abbreviations: RTKs, receptor tyrosine kinases; SH2, Src-homology 2 domain; 
SH3, Src-homology 3 domain; BH, BCR homology domain; PX, Phox domain. Adapted from Blajecka 
et al. 2011 (Appendix). 
 
 
The catalytic isoforms, together with five regulatory subunits can form heterodimers with 
each other  and can potentially give rise to fifteen distinct p85-110 combinations [47]. They 
become activated through direct interactions with broad variety of RTKs, or in some cases 
(such as p110β) also by interaction with GPCRs [47, 51]. Binding with the receptor releases 
the basal inhibition of p110 by p85 and brings the p85-p110 complex in the close proximity to 
16 
 
its substrate PtdIns(4,5)P2 at the plasma membrane [52, 53]. The p85 N-terminal binding 
domain of p110 isoforms is used for interactions with regulatory subunits, while the Ras-
binding domain mediates enzyme activation through the Ras GTPase [47, 54]. The class IA 
regulatory isoforms consist of a p110-binding domain that is flanked by two SH2 domains, 
which bind specifically to phosphorylated tyrosine residues on autophosphorylated receptors 
or on target docking proteins (such as IRS1) [17]. In addition to that, N-terminal extension of 
p85α and p85β subunits consisting of SH3 and proline-rich motifs can be found, which 
mediate binding to other signaling molcules. The breakpoint cluster region-homology (BH) 
domain plays a role of GTP-ase activating protein (GAP) for small GTPases [47, 54]. Class IB 
is represented by a single member p110γ encoded by the PIK3CG gene. p110γ has been 
identified only in mammals. It lacks a p85-binding domain, but has three regulatory subunits: 
p101, p84 and p87PIKAP, which have no identifiable domains and do not show homology to 
any other proteins. Due to these structural differences, the class IB enzyme is not activated 
by RTKs, like class IA enzymes. Its activation is linked exclusively to GPCRs [47, 54]. p110γ 
is translocated to the membrane (Gβγ subunit of GPCR) from the cytosol through the 
interaction with its regulatory subunit p101, which is required for p110γ activation [55]. Class 
IB PI3K can be also activated via Ras-mediated mechanisms by allosteric modulation [56]. 
The importance of class I PI3K in physiological processes has been widely investigated. 
Animal model studies have greatly contributed to our understanding of their function. As 
indicated by murine knock-outs of the PIK3CA and PIK3CB genes, which appeared to be 
lethal at the embryonic stage, p110α and p110β are essential for basic cellular functions in 
the organisms [57, 58]. p110α seems to be important for cell survival whereas p110β is 
essential for cell proliferation. Both isoforms also play an important role in insulin signaling in 
a kinase-dependent and independent fashion, respectively [51, 59, 60]. On the other hand, 
the class IA p110δ and class IB p110γ are key players in inflammation. Mice deficient in 
p110δ were viable, but had severely impaired T and B cell function [61]. p110γ has been 
shown to be involved in the regulation of thymocyte development, T cell activation, neutrophil 
migration and the oxidative burst [62, 63]. 
Class III PI3K in human consists of a sole 100 kDa catalytic subunit and a single 150 
kDa regulatory subunit [64]. It was first identified in a Saccharomyces cerevisiae screen for 
genes required for vacuolar protein sorting and vacuole seggregation [65]. Originally isolated 
as a mutant in yeasts, it was called vacuolar protein-sorting defective 34 (Vps34) and it is 
encoded in human by the PIK3C3 gene. It phosphorylates only PtdIns generating PtdIns(3)P 
and forms a heterodimer with the regulatory subunit, termed as Vps15/p150. Vps15 is 
myristoylated, which results in the attachment of the Vps34-Vps15 complex to intracellular 
membranes. Moreover, Vps15 acts as Ser/Thr kinase and its activity is essential for Vps34 
function [47]. Vps34 acts downstream of GPCRs forming multiprotein complexes and its 
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activation can be regulated by nutrients (amino acids or glucose). In general, it is involved in 
intracellular trafficking like autophagy, endocytosis and phagocytosis. It was also shown to 
regulate the mTOR/S6K1 pathway in response to amino acids avaibility suggesting a 
possible involvement in cell growth control [66]. The class III Vps34 is present in all 
eukaryotes [47]. 
 
1.4. Class II PI3Ks    
 
Class II PI3Ks were identified in 1990s based on the PCR-based search for the lipid 
kinase domain sequence homologies with other PI3Ks known at that time (p110α, p110β, 
p110γ, Vps34). The functional or physiological context of class II PI3Ks discovery was 
missing. For that reason they are the least studied and understood among all PI3K family 
members. There are still plenty of questions concerning their regulation and function, which 
remain unanswered. For instance, what is the class II PI3Ks definitive substrate and product 
in vivo upon different ligands stimulation? Are the class II PI3Ks redundant with other PI3Ks 
or do they rather act cooperatively? What is the significance of their unique domain structure 
for their precise mechanism of action? Fortunately, the interest in solving all these issues is 
now growing, which hopefully will lead to an increase in our knowledge about this interesting 
class of PI3K enzymes [67]. 
 
1.4.1. Identification and Expression  
 
In mammals there are three class II isoforms identified: PI3KC2α, PI3KC2β and 
PI3KC2γ encoded respectively by PIK3C2A, PIK3C2B and PIK3C2G genes [47, 48, 67]. A 
single representative member of class II PI3Ks is present in multicellular invertebrate 
organisms such as C.elegans and D.melanogaster. In worms it is exemplified by F39B1.1 
hypothetical protein (GenBank accession no. NM_078128), whereas in the fruit fly by 
PI3K_68D/Cpk.  In vertebrate genomes exemplified by human or mouse we can find all three 
representatives of class II enzymes [48]. The first discovery of class II PI3Ks began with the 
identification of PI3K_68D/Cpk in D. melanogaster [68, 69]. Soon after, murine analogue 
Cpk-m and p170 were cloned from the mouse brain and liver cDNA libraries and from the 
insulin-sensitive mouse 3T3-L1 adipocytes, respectively [69, 70]. These isoforms displayed 
lipid kinase activity in vitro towards PtdIns and PtdIns(4)P and were characterized by the 
presence of Ca2+-independent C2 domain at the carboxy-terminus. The different substrate 
specificity and structural features compared to other known PI3Ks led scientists to believe 
that distinct PI3K isoforms exist, which may play divergent roles in cell biology. These 
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assumptions were confirmed when the first human class II PI3K isoforms were identified. 
HsC2-PI3K (named later PI3KC2β) was isolated from a cDNA library of the breast tumor cell 
line MCF7 [71], and further from the U937 (human leukemic monocyte lymphoma) cDNA 
library [72]. The HsC2-PI3K gene was localized on chromosome 1 (1q32) and the mRNA 
tissue distribution appeared to be ubiquitous with the highest expression level in thymus and 
placenta [71]. PI3KC2β used as substrates PtdIns and PtdIns(4)P in the presence of Mg2+ 
and showed sensitivity to low concentration of wortmannin similarly to class IA PI3Ks. 
However, it was slightly more resistant to the LY294002 inhibitor than p110α/p85 subunits 
[72]. In contrast to PI3KC2β, PI3KC2α was rather insensitive to wortmannin and LY294002 
at concentrations, which inhibited the catalytic activity of other PI3K isoforms [73]. PI3KC2α 
(localized at chromosome 11p15.5-p14) was cloned from U937 cells and was found to be 
widely expressesd in tissues. The highest expression levels were observed in heart, placenta 
and ovary [73]. It could phosphorylate PtdIns and PtdIns(4)P in vitro and to some extend 
PtdIns(4,5)P2 in the presence of phospatidylserine. The whole picture of class II PI3K 
members was complemented when PI3KC2γ was identified in mouse, rat and human [74-
76]. The human PIK3C2G gene was mapped to chromosome 12p12 and displayed an 
expression pattern restricted to the liver, breast and prostate [76]. In contrast to PI3KC2α and 
PI3KC2β, high expression of PI3KC2γ was confined to the liver also in mouse and rat, 
suggesting a tissue-specific role of this isoform [74, 75].  
 
1.4.2. Substrates Preferences In vitro and In vivo 
 
Since the first studies concerning class II PI3Ks substrate specificity were published it 
is generally accepted that the main substrates in vitro of this class of enzymes comprise of 
PtdIns and PtdIns(4)P. However, some indications exist that PtdIns is the class II PI3Ks 
preferential substrate [67]. As mentioned above, PI3KC2β phosphorylated PtdIns and 
PtdIns(4)P in the presence of Mg2+, but in fact the kinase activity towards PtdIns(4)P was 
only 10% of that oriented towards PtdIns [72]. Addition of phosphatidylserine, 
phosphatidylcholine, or phosphatidylethanolamine significantly increased the enzyme activity 
toward PtdIns in comparison to PtdIns(4)P. Moreover, only PtdIns but not PtdIns(4)P were 
phosphorylated by PI3KC2β and PI3KC2α, when Ca2+ was added to the in vitro kinase assay 
as a source of divalent cation [77]. The hypothesis that PtdIns(3)P is the major product of 
class II PI3Ks was also supported by several in vivo studies. It was demonstrated in the rat 
skeletal muscle L6 cells and 3T3-L1 adipocytes that insulin induce PtdIns(3)P synthesis in 
the TC10 guanine exchange factor–mediated mechanism [78]. This PtdIns(3)P production 
appearded to be resistant to high concentrations of wortmannin and LY294002, which 
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suggested PI3KC2α’s involvement in this process. This was indeed proven in later studies, 
where PI3KC2α downregulation completely abolished insulin-dependent generation of 
PtdIns(3)P, while it did not block formation of PtdIns(3,4)P2 and PtdIns(3,4,5)P3, [79]. Thus, 
PtdIns(3)P seemed to be the exclusive PI3KC2α product upon insulin stmulation. Moreover, 
in further research on neuroexocytosis, PtdIns(3)P was found as PI3KC2α main product [80, 
81]. Nevertheless, in recent studies in MIN6 pancreatic β-cells it was observed that in 
response to insulin release upon glucose stimulation PI3KC2α generates PtdIns(3,4)P2 
and/or PtdIns(3,4,5)P3, which become second messengers for selective PKBα/Akt1 
activation [82]. PI3KC2α signaling towards PKB/Akt involves insulin receptor B type (IR-B) 
and leads to stimulation of B-cell glucokinase (βGK) gene transcription and to an increase in 
the activity of Akt substrate AS160 [82]. This results indicate that although PI3KC2α 
preferentialy uses PtdIns as a substrate in vivo, the generation of PtdIns(3,4)P2 cannot be 
completely excluded. PtdIns(3)P also seems to be the main in vivo product of PI3KC2β. It 
was shown to produce PtdIns(3)P at the plasma membrane in response to lysophosphatidic 
acid (LPA) stimulation of HeLa and ovarian cancer cell line SKOV-3 [83]. siRNA 
downregulation of PI3KC2β inhibited the LPA-dependent GFP-2XFYVE plasma membrane 
translocation. GFP-2XFYVE is able to bind only to PtdIns(3)P. Therefore, an expression of 
GFP-2XFYVE in HEK293 cells stably transfected with PI3KC2β completely abolished 
PI3KC2β-dependent formation of lamellipodia and filopodia due to the blockade of 
PtdIns(3)P signaling [84]. Moreover, synthesis of PtdIns(3)P was also demonstrated by the 
nuclear fraction of PI3KC2β, whose activation occurs at the G2/M phase of the cell cycle [85]. 
All these results taken together confirm the hypothesis that PtdIns(3)P is the main product of 
PI3KC2β activity in vivo, at least upon the LPA stimulation. However, more data concerning 
stimulation with other growth factors are needed to fully support this conclusion. No 
information is available so far about in vitro and in vivo products of PI3KC2γ. 
 
1.4.3. Structural Characteristics 
 
Class II enzymes share the same core sequence (C2, helical and catalytic domains) 
with other PI3Ks, but some of their structural features differ considerably [47, 48, 67]. The 
major contrast is that class II proteins are monomers of high molecular mass and they do not 
associate with any regulatory subunits. Lack of the regulatory subunit-binding domain is 
compensated by the N- and C-terminal extensions, which possess other domains enabling 
interactions with proteins or with the plasma membrane via phospholipids. The C-terminal 
extension is highly conserved between the three isoforms and it contains a Phox homology 
(PX) domain, known to bind phosphoinositides [86], and an additional C2 domain, whose 
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function is not fully understood. However, the C2 C-terminal region is the most distinctive 
feature of class II PI3K’s structure. Generally, C2 domains have membrane-targeting 
properties and single or multiple copies are present in a variety of intracellular proteins 
involoved in signal transduction or membrane trafficking [87]. It can bind to a remarkable 
number of ligands and substrates, such as Ca2+, phospholipids, inositol polyphosphates, as 
well as cytosolic proteins. Initially, it was identified in the protein kinase C (PKC) as a Ca2+-
dependent lipid binding module. However, soon it became clear that it can also act in a Ca2+-
independent fashion. It was unexpectedly observed that the C2 domain of PKCδ binds 
directly to phosphotyrosine peptides providing new possibilities for the C2 domain-dependent 
regulation of molecular processes [88]. The C2 C-terminal domain of the class II PI3Ks binds 
phospholipids independently of Ca2+ [72, 87, 89]. Moreover, in the case of PI3KC2α and 
PI3KC2β it contains a nuclear localisation signal (NLS), which directs the proteins to nuclear 
speckles or the nuclear matrix, respectively [90, 91]. In contrast to the C-terminal extension, 
class II PI3K’s N-terminal extensions differ between the isoforms. For instance, PI3KC2α’s N-
terminal sequence contains a clathrin-binding motif [92], as well as PI3KC2β, which displays 
four potential clathrin-binding fragments [93]. However, only D.melanogaster PI3K_68D/Cpk 
and human PI3KC2β possess type II polyproline stretches (PPLPPR), which can serve as 
targets for SH3-domain-containing proteins such as Drk or Grb2 adaptor proteins, 
respectively [68, 69, 71, 94, 95]. The N-terminal sequence of PI3KC2α differs much from the 
previously described PI3K_68D/Cpk and murine proteins [73]. The most important feature is 
that it does not contain the polyproline region II, although numerous proline residues are 
present [73]. PI3KC2γ on the other hand, does not show homology with any of the known 
proteins and its function remains unknown [74]. Based on the sequence similarity to class I 
PI3Ks, a Ras-binding domain was distinguished in the class II isoforms [67]. Nonetheless, no 
interaction with GTP- or GDP-bound form of Ras could be observed, as for the PI3KC2β [72]. 
To see the structure of class II PI3Ks refer to Fig. 1-2. 
 
1.4.4. Mechanisms of Activation 
 
Class II PI3Ks, in particular PI3KC2α and PI3KC2β, are activated via cellular 
stimulation with various types of ligands, which is followed by recruitment of the isoforms to 
the plasma membrane. Among PI3KC2α stimuli we can distinguish hormones such as insulin 
[79, 96], chemokines like monocyte chemotactic protein 1 (MCP1) [97], cytokines such as 
leptin and TNFα [98] and some of the growth factors, for instance epidermal growth factor 
(EGF) [77]. Analogously, PI3KC2β is mostly activated by growth factors like EGF, platelet-
derived growth factor (PDGF) and stem cell factor (SCF) [77, 99]. However, it was also 
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shown to become activated upon lysophosphatidic acid (LPA) stimulation, which is a 
phospholipid derivative stimulating G protein-coupled receptors (GPCRs) [83]. Interestingly, 
both PI3KC2α and PI3KC2β are activated by insulin, although in contrast to PI3KC2α, 
PI3KC2β’s biological role in the IR pathway was not studied [79, 82, 100]. Both of the 
isoforms are downstream targets of integrins. A decrease in PI3KC2α activation was 
observed in migrating vascular smooth muscle cells (VSMC) after blockade of the αvβ3 
integrin [101], whereas an increase in PI3KC2β activity was detected after αIIbβ3 integrin and 
fibrinogen–dependent human platelets aggregation [102]. All these data taken together 
suggest that class II PI3KC2α and PI3KC2β are activated downstream of RTKs [77, 79, 96, 
99] and GPCRs [83, 97]. Unfortunately, no data are available concerning PI3KC2γ activation.  
 
 
 
 
Figure 1-3. PI3KC2β protein-protein interactions and translocation to the membrane. In 
quiescent cells PI3KC2β is complexed with Grb2 in A-431 cells through the Grb2 SH3 C-terminal 
domain (A). Upon EGF stimulation, the multiprotein complex of PI3KC2β-Grb2-Abi1-Eps8-Sos1 is 
recruited to the activated EGFR either directly on Y1068 through association with Grb2 (B) or indirectly 
on Y992 through interaction with Shc (C). Formation of this macromolecular complex promotes 
PI3KC2β lipid kinase activity and induces signal transduction to Rac GTPase, which in turn leads to 
cell-cell adherens junction assembly and F-actin polymerization. Adapted from Katso et al. 2006 [103].  
 
 
Plasma membrane translocation plays an important role in the mechanism of PI3Ks 
activation where association of the kinases with activated growth factor receptors takes 
place. Binding of the kinases to membrane receptors is often mediated by interactions with 
adaptors or scaffolding molecules, GTP-binding proteins and guanine nucleotide exchange 
factors (GEFs). For instance, PI3KC2β was shown to bind multiple RTKs, which was 
followed by enzyme activation. Among these receptors we can find c-Kit, c-Met and IGF-IR in 
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small cell lung cancer cells (SCLC), as well as PDGFR and EGFR in HEK293 and A-431 
cancer cells [77, 99]. Detailed studies of PI3KC2β interaction with the EGFR in A-431 cells 
revealed an indirect association through Grb2 and Shc adaptor proteins [94]. Moreover, an 
Eps8/Abi/Sos1 ternary complex, playing a role of guanine exchange factor for Rac, was 
involved in the interaction in a lipid kinase activity-independent manner [103] (Fig. 1-3). 
Increased PI3KC2β activity was reported upon EGF stimulation in Eps8, Abi1 and Shc 
immunoprecipitates. Beside that, PI3KC2β association with the modular scaffolding protein 
interesctin (ITSN) increased the enzyme activity measured by PI3K assays and Akt 
activation under both basal and EGF-stimulated conditions in neuroblastoma cancer cells 
[104]. All these results, taken together suggest an important function for protein-protein 
interactions in class II PI3K activation at the plasma membrane. 
Furthermore, the domain structure of class II PI3Ks is also crucial for the enzyme 
activation. Since class II kinases do not have the possibility to bind regulatory subunits such 
as class I PI3Ks, they developed extended N- and C-termini carrying additional protein 
domains, which could possibly play this role [67]. Examples of such regulation can be found 
in each isoform of class II PI3K. For instance, deletion of PI3KC2α’s clathrin-binding N-
terminal domain extremely enhanced the enzyme’s kinase activity toward PtdIns when 
compared to PI3KC2α wild-type in the absence of clathrin. This result suggests that the N-
terminal extension plays a role of negative regulator of PI3KC2α activity. When clathrin was 
added to the in vitro kinase assay in the presence of full-length PI3KC2α, a positive 
regulation was observed [92]. The role of clathrin-binding module and binding of clathrin itself 
in the control of PI3K enzymatic activity seems to be meaningful, which is supported by the 
fact that clathrin-binding motifs in the PI3KC2β N-terminus have been linked to its increased 
activation [93]. Furthermore, the proline-rich regions of the PI3KC2β N-terminal extension 
have been shown to be important for the kinase activity. Deletion of the first proline-rich 
region rendered the enzyme catalytically inactive, and blocked PI3KC2β interaction with the 
activated EGFR and Grb2. Again, this emphasizes importance of the associated proteins for 
the regulatory role of the class II PI3K. Further deletions that removes the second and third 
proline-rich motifs increased PI3KC2β activity [93]. Analogously, removal of the unique C2 C-
terminal domain from PI3KC2β resulted in elevated PI3K activity suggesting that it functions 
as a negative regulator of the catalytic domain [72]. In PI3KC2γ, both the N-terminal and C-
terminal extensions were shown to be essential for the enzyme activity [74]. 
There is not much information about post-translational modifications, which could 
contribute to class II PI3Ks activation. Tyrosine phosphorylation of PI3KC2α upon insulin 
stimulation was observed in CHO-IR cells, although this has not been further investigated 
[96]. Similarly, PI3KC2β tyrosine phosphorylation upon SCF, HGF, FGF2 and insulin 
stimulation was detected in SCLC cell line H-209 [99]. Both isoforms were also 
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phosphorylated on tyrosine in A-431 and HEK293 cells under basal and EGF-stimulated 
conditions, although much more of PI3KC2α and PI3KC2β was immunoprecipitated by anti-
phosphotyrosine antibody from cell lysates after EGF treatment [77]. Interestingly, tyrosine 
phosphorylation of PI3KC2β isolated from nuclei and nuclear envelopes of ATRA-
differentiated HL-60 cells was observed, which further correlated with an increase in the 
activity of PI3KC2β and accumulation of nuclear PtdIns(3)P. These results suggest that 
tyrosine phosphorylation might be essential for enzyme activation. However, this hypothesis 
needs further investigations. 
Translocation from the cytosol to the plasma membrane seems to be crucial for the 
activation of class II PI3Ks [67]. Since both PI3KC2α and PI3KC2β contain nuclear 
localization signal (NLS) in their C-terminal C2 domains, it cannot be excluded that the 
kinases may become activated after relocation to the nucleus [90, 91]. However, localization 
of the kinases in different subnuclear compartments (nuclear speckles and matrix, 
respectively) raises the possibility that PI3KC2α and PI3KC2β might play distinct intranuclear 
functions. Increase in PtdIns(3)P levels as a result of PI3KC2β activation was found in the 
membrane-depleted nuclei during compensatory liver growth. Interestingly, proteolysis 
mediated by calpains may contribute to this activation, but only in the absence of cell 
membrane and cytosolic fractions, which possibly contain factors, which inhibit proteolysis 
[105]. It is likely that the enzyme activation in the nuclear matrix occurs as a result of the C2 
C-terminal domain cleavage, which was shown to play a negative regulatory role for 
PI3KC2β activity [72, 106]. A similar mechanism of calpain-mediated PI3KC2β activation was 
described in the nuclei and nuclear envelopes of HL-60 leukemia cells during the G2/M 
transition of the cell cycle [85]. Moreover, a significant increase in the activity of the enzyme 
was detected in the nuclei and nuclear envelopes isolated from all-trans-retinoic acid 
(ATRA)-differentiated HL-60 cells [107]. Stimulation of HEK293 cells expressing recombinant 
PI3KC2β with EGF increased the enzyme level and activity in the nuclei and revealed 
PI3KC2β co-localization with lamin A/C in the nuclear matrix [91].  
A novel mechanism of regulation of PI3KC2β activity was described recently [108]. An 
interaction of PI3KC2β with TRIM27 (tripartite-motif-containing protein) was obsereved, 
which resulted in increased ubiquitination at the Lys48 of the lipid kinase. However, 
polyubiquitination did not induce protein degradation, but inhibited its catalytic activity [108]. 
 
24 
 
1.4.5. Cellular and Physiological Functions of Class II PI3Ks  
 
Due to the in vivo generation of phospholipid products distinct from class I PI3Ks, 
class II PI3Ks most likely activate different downstream signaling pathways. Whether they 
control the same or different cellular processes is not clear. However there are reports in the 
literature, which confirm that class I and class II PI3Ks can act together to regulate the same 
cellular responses [67]. With respect to the class III PI3Ks, class II enzymes share the same 
substrate in vivo (PtdIns), but distinct cellullar compartmentalization of both classes of 
enzymes exludes functional redundancy. Next to PtdIns(3,4)P2 and PtdIns(3,4,5)P3, 
PtdIns(3)P can also act as dynamic intracellular second messenger, which could be involved 
in many signaling pathways [109]. Since class II PI3KC2α and PI3KC2β produce the same 
lipid products, are both ubiquitously expressed, bind to clathrin with their N-terminus, and are 
both recruited to the activated EGFR, it is very likely that they play complementary roles in 
some biological functions. Indeed, both enzymes were shown to control cell growth and 
survival pathways. Down-regulation of PI3KC2α induced apoptotic changes in Chinese 
hamster ovary (CHO-IR) cells, HeLa cells and hepatocellular carcinoma cell line [110-112]. 
Reduced cell proliferation and reduced anchorage-independent growth were additionally 
observed [112]. On the contrary, over-expression of PI3KC2α enhanced mesenchymal stem 
cell survival under hypoxic conditions in the infarcted myocardium [113]. Increased 
proliferation and resistance to anoikis were detected in A-431 epidermoid carcinoma cells 
over-expressing wild-type PI3KC2β in comparision to parental cells. Interestingly, both of 
these responses were not mediated by Akt activation [103]. Additionally, over-expression of 
PI3KC2β in intersectin-silenced mouse N1E-115 and human IMR5 neuroblastoma cells, 
rescued the survival of N1E-115 cells during differentiation and restored anchorage-
independent growth of IMR5 cells [104, 114].  
Other physiological functions of PI3KC2α and PI3KC2β do not seem to overlap. 
PI3KC2α’s biological role is mostly associated with insulin signaling and glucose transport 
[79, 82, 115], endocytosis [92, 116], neurosecretory granule release and VSMC contraction 
[80, 81, 117-119], whereas PI3KC2β controls mainly cell migration processes [83, 84, 103], 
cell-cycle progression [85] and K+ channel activation [108, 120]. The biological functions of 
PI3KC2γ are not known to date. The only report describing a possible role of this isoform in 
chemotaxis and abnormal homing of leukemic cells has been published recently [121]. The 
authors suggest that down-regulation of PI3KC2γ by p185(Bcr-Abl) may suppress SDF1α-
induced chemotaxis, leading to abnormal homing of leukemic cells [121]. 
Since PI3KC2β is the main subject of this thesis, its cellular and physiological 
functions will be described in more detail than for other class II PI3Ks. As mentioned above, 
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cell migration is the major process, which is regulated by this isoform. PI3KC2β over-
expression in HEK293 cells decreased the expression of the αIVβ1 integrin subunits and cell 
adhesion [84]. These changes correlated with increased cell migration supported by 
lamellipodia and filopodia formation, which was dependent on PtdIns(3)P and activation of 
the Cdc42 RhoGTPase [84]. In other studies, a LPA-dependent pool of PtdIns(3)P was 
generated through PI3KC2β activation and was involved in the cell migration of ovarian and 
cervical cancer cell lines [83]. Furthermore, over-expression of the kinase in A-431 
epidermoid carcinoma cells revealed Rac-mediated increase in membrane rufflng and 
migration speed of the cells when compared to A-431 parental cells either in the presence or 
absence of EGF [103]. On the other hand, transfection of kinase-dead PI3KC2β into the A-
431 cell line reduced cell migration speed. Accumulation of F-actin and E-cadherin at cell-cell 
junctions, as well as lamellipodia formation was also observed in the cells over-expressing 
the kinase, while the kinase-dead transfected cells displayed perinuclear E-cadherin 
assembly [103].  
Despite the unquestionable role of PI3KC2β in the cell migration and adhesion processes, its 
involvement in T-cell activation was recently discovered [120]. The enzyme can be activated 
downstream of the T-cell receptor (TCR). This further stimulates the activation of the K+ 
channel KCa3.1, which maintains a negative membrane potential necessary for accurate 
Ca2+ entry into the cells. siRNA down-regulation of PI3KC2β considerably suppressed 
KCa3.1 activity, which was due to decreased levels of PtdIns(3)P [120]. The detection of 
increased PI3KC2β activity in the nuclei and nuclear envelopes of HL-60 cells progressing 
into the G2/M-phase indicates a possible enzyme involvement in the cell cycle control [85]. 
However, its specific functions in this proccess were not examined to date. 
Mouse knock-out models have contributed to the knowledge of class II PI3K’s 
functional relevance. PI3KC2γ is the least studied member of the family. Therefore, knock-
out or knock-in in vivo transgenic models for this isoform are missing. A recently published 
murine knock-out of PI3KC2α revealed that the PI3K is essential for normal postnatal 
development, support of podocyte function and maintenance of normal renal homeostasis 
[122]. PI3KC2α-depleted mice were considerably smaller than the wild-type animals. 
Approximately 30% of PI3KC2α -/- individuals died by 6 months of age in comparison to 5% 
of wild-type animals. Severe symptoms of renal failure and a wide range of kidney lesions 
were detected in PI3KC2α-depleted mice [122]. In the case of murine PI3KC2β knock-out, a 
potential role in epidermal differentiation was investigated. However, no phenotype was 
observed in either suprabasal or basal epidermal layers. PI3KC2β-deleted mice were viable 
and fertile and were characterized by the lack of any abnormalities in epidermal growth, 
differentiation, barrier function and wound healing [123]. 
  
26 
 
1.4.6. Involvement of Class II PI3Ks in Cancer 
 
There are only few reports describing the role of PI3K class II isoform PI3KC2α in 
cancer. Its importance for cell growth and survival was shown in hepatocellular carcinoma 
[112]. Silencing of PI3KC2α significantly reduced cell proliferation and colony formation and 
increased caspase-3 activity, suggesting the PI3K involvement in apoptotic pathway. An 
interesting hypothesis explaining PI3KC2α role in cancer cell growth was suggested recently 
by Schepeler and colleagues [124]. They revealed that in colorectal cancer cells PI3KC2α is 
suppressed at the translational level by miR-30e-3p. In connection with this hypothesis they 
proposed a model where PI3KC2α becomes up-regulated upon down-regulation of the 
microRNA, which is possibly followed by an increase in colorectal cancer cell growth. In this 
model, the Wnt pathway may also play an important role, but this interpretation requires 
further verification. Moreover, PI3KC2α was also detected in acini and ducts of pancreatic 
ductal adenocarcinoma and in healthy tissue. However, higher expression of the kinase was 
observed in acini with high cellular atypia and in dysplastic ducts [125]. Among other genes, 
PI3KC2A was found to be highly expressed in the side population cells (SP) within the 
human breast cancer MCF7 cell line, which is known to be enriched in cancer stem-like cells, 
and display greater tumorigenicity in vivo in comparison to non-SP MCF cells [126]. Like in 
all other aspects, also in terms of malignant transformation, there is little information 
available so far about class II PI3KC2γ. There is only one publication, which demonstrates 
PI3KC2γ repression in the p185 (Bcr-Abl)–transformed murine Ba/F3 leukemia cell line. The 
authors suggested that p185 (Bcr-Abl)-mediated inhibition of PI3KC2γ contributes to the 
attenuation of chemotaxis and abnormal homing of leukemic cells [121]. Interestingly, very 
recent studies in non-small cell lung cancer (NSCLC) identified intronic mutations in 
PI3KC2A and PI3KC2G genes, however mutations of PI3KC2G were more common [127]. 
PI3KC2β is quite extensively studied in the context of cancer. It may be either over-
expressed and amplified or under-expressed and deleted, although the consequences of 
these genetic alterations are not always described. Over-expression of the kinase in colonic 
epithelial cells led to oncogenic transformation represented by increased soft-agar colony 
formation and formation of transformed foci on cell monolayers [128]. Increased expression 
of the PI3KC2β enzyme was detected in different acute myeloid leukemia (AML) cell lines 
depending on molecular and cytogenetic abnormalities, which they bear [129]. Moreover, 
over-expression of the PI3KC2B gene was detected in therapy-related AML, a neoplastic 
disorder arising from a multipotential hematopoietic stem cell [130]. Decreased expression of 
PI3KC2B in acute lymphoblastic leukemia (ALL) possessing a chromosomal translocation 
involving the mixed-lineage leukemia gene (MLL, HRX, ALL1) was observed in comparison 
to convenvtional acute lymphoblastic leukemia (ALL) [131]. Deletion of PI3KC2B in ALL was 
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correlated with a decrease in MSH2 protein level (DNA mismatch repair enzyme), which 
consequently led to impaired DNA mismatch repair capacity in human leukemia cells [132]. 
Beside leukemias, PI3KC2B alterations were also examined in invasive intraductal papillary 
mucinous neoplasm (IPMNs) of the pancreas, where over-expression of the gene was 
detected [133]. On the other hand, PI3KC2B DNA copy number gain was identified in ovarian 
cancer, which was higher than the copy number gain for other PI3K family members. 
However, a significant up-regulation of mRNA in ovarian cancer versus normal ovary was 
observed only for PIK3R3 (p55γ subunit) [134]. 
Over-expression or amplification of genes often correlates with drug resistance in 
cancer cells, which need to promote additional signalig pathways to overcome drug-induced 
stress. Amplification of PI3KC2B (1q32) was identified in 6 glioblastomas of 103 analysed. 
However, only in 4 of these cases amplification was accompanied by mRNA over-expression 
[135]. Gain at 1q32.1 (PI3KC2B/MDM4) was also reported by Nobusawa et. al. [136]. Further 
analysis of 1q32 chromosome sections revealed a single region of amplification 
encompassing MDM4, GAC1, PI3KC2β and PEPP3 genes, with MDM4 being the main 
amplification target always associated with over-expression [137]. Amplification of 
PI3KC2B/MDM4 has been reported in glioblastoma multiform (GBM) [138], where PI3KC2B 
and IGF1 expression significantly correlated with cellular resistance towards erlotinib, which 
is an EGFR tyrosine kinase inhibitor [139]. Down-regulation of PI3KC2β with siRNA in ERα 
(oestrogen receptor α)-positive MCF7 breast cancer cells and their further treatment with 
tamoxifen, an inhibitor of ERα signaling, sensitized the cells to the drug, suggesting that the 
kinase may be involved in tamoxifen resistance in breast cancer cells [140]. The involvement 
of PI3KC2β in mechanisms of drug resistance was recently supported by studies in 
oesophageal squamous carcinoma (ESCC) cells after the enzyme over-expression or 
silencing. PI3KC2β over-expression in Eca109 cells caused a 4-fold reduction in sensitivity to 
cisplatin and increased protection against apoptosis, whereas the kinase silencing rescued 
Eca109 cells’ sensitivity to the drug and made them more susceptible to programmed cell 
death. Originally, the Eca109 parental cell line does not express PI3KC2β and due to that it 
was much more sensitive to cisplatin than other ESCC cell lines displaying the protein 
expression [141]. On the other hand, knock-down of PI3KC2B in human leukemia cells CEM 
increased the resistance of these cells against specific chemotherapeutics, which was 
associated with reduction of MSH2 and thus suppression of DNA mismatch repair capacity 
[132].  
Over-expression of class II PI3KC2β in subsets of patient tumor samples and cell 
lines from AML, glioma, medulloblastoma, neuroblastoma, and small cell lung cancer not 
only reduced sensitivity to some chemotherapeutic agents, but also influenced some of the 
cellular responses. Pharmacological inhibition or siRNA-induced suppression of the enzyme 
28 
 
activity impaired cell proliferation and survival of AML, brain tumors and neuroendocrine 
malignancies [129]. In small cell lung cancer (SCLC) PI3KC2β contributed to stem cell factor 
(SCF)-stimulated Akt/PKB activation and cell growth, which was completely abolished when 
SCLC cells were transfected with a kinase inactive PI3KC2β construct [99]. Moreover, the 
PI3KC2β pathway turned out to be essential for neuroblastoma tumorigenesis by rescuing 
anchorage-independent growth of intersectin-silenced neuroblastoma cells [114]. Anchorage-
independent growth or in other words protection of cancer cells against anoikis were shown 
to be regulated by over-expression of PI3KC2β in A-431 epidermoid carcinoma cells. 
Enhanced membrane ruffling and migration speed of these cells were also identified as a 
result of Rac-dependent mechanisms [103]. Cancer cell migration and related processes, 
such as cell invasion, protection against anoikis and cell adhesion are the most frequently 
observed cellular responses under the control of PI3KC2β [83, 129]. Recent results from 61 
PI3KC2β-positive and –negative ESCC patients tissues revealed that there is a significant 
association between PI3KC2β protein levels and metastasis [141]. 68.2% PI3KC2β-positive 
cases showed metastasis compared to only 31.8% of PI3KC2β-negative cases. These 
results strongly suggest that PI3KC2β may play an important role in metastasis by regulation 
of cancer cell migration and invasion. 
Interesting data concerning PI3KC2β mutations in cancers have started to emerge 
recently. Frequent somatic missense exonic mutations of PI3KC2B have been found in 
adenocarcinomas and squamous cell carcinomas of non-small cell lung cancer (NSCLC), 
making the kinase a promising druggable target for NSCLC therapy [127]. Moreover, single-
nucleotide polymorphisms in the promoter region and in the first two introns of PI3KC2B 
were identified. SNPs were shown to be significantly associated with prostate cancer risk, 
especially for men diagnosed before age of 65 or for men with a family history of prostate 
cancer [142].  
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1.5. Cytoskeletal Rearrangements in Cancer Cell Migration and Adhesion 
 
The ability of the cell to remodel its own cytoskeleton is an important feature, which is 
involved in the processes of cell migration and cell adhesion to other cells or to the 
substratum. These, on the other hand, are crucial for many physiological and pathological 
processes such as embryonic morphogenesis, wound healing, immune surveillance, tissue 
homeostasis, but also cancer, atherosclerosis, rheumatoid arthritis and many other disorders 
[143]. To metastasize to distinct organs and invade distal tissues giving rise to secondary 
tumors formation, cancer cells must be able to detach from the primary tumor mass, invade 
into the blood or lymphatic vessels, escape from the vessels and attach to the substratum in 
a new environment. For all these steps tumor cells need to constantly reorganize their 
cytoskeleton and change cell polarity. These processes require the activation of multiple 
signaling pathways, among which PI3Ks and RhoGTPases play a pivotal role [143, 144]. 
Intercellular adhesion is mediated by cadherins, a large family of transmembrane molecules, 
which require Ca2+ for their homophilic interactions mediated by the extracellular domains on 
the surface of the neighboring cells [145]. Clusters of E-cadherin homodimers at the cell-cell 
junctions can also bind to the actin cytoskeleton through cytoplasmic adaptor proteins. The 
assembly of E-cadherin complexes involves the activation of small GTPases, as well as 
recruitment of PI3Ks [145-147]. Loss of cellular adhesion in the epithelial structure is an early 
event in primary carcinogenesis and is linked to the onset of most solid tumors [148]. Upon 
loss of adherens junctions, primary tumor cells undergo epithelial-to-mesenchymal transition 
(EMT), which enable them to migrate into the circulatory or lymphatic system and  to 
metastasize into distinct organs. Sometimes, aggregates of E-cadherin-positive cells get into 
the bloodstream, which helps the tumor cells survive mechanical and immunocytotoxic 
stresses [148].  
 
1.5.1. Rho GTPases and Their Regulators 
 
The Rho family of GTPases belongs to the superfamily of Ras-related small GTPases 
(~21 kDa) and consists of more than 20 members among which RhoA, Rac1 and Cdc42 are 
the best studied [149, 150]. They are highly conserved in evolution from lower eukaryotes to 
plants and mammals and are implicated in many basic cellular processes such as actin and 
microtubule cytoskeletal organization, cell cycle, cell migration and adhesion, vesicular 
trafficking, phagocytosis and transcriptional regulation of gene expression [150]. The 
expression and activity of Rho GTPases are frequently deregulated in cancer playing a major 
30 
 
role in tumor cell motility, invasion, metastasis and inflammation, as well as proliferation and 
survival [149, 151]. 
Rho GTPases act as molecular switches cycling between an active GTP-bound conformation 
and an inactive GDP-bound from [150]. Most of the Rho GTPases are modifed at their C-
terminus by a prenyl moiety, which acts as a lipid anchor and localizes them to the 
membrane [152]. When small G proteins are active, they can interact with effectors to induce 
downstream signaling responses. The process of spatio-temporal activation and inactivation 
of Rho GTPases is tightly controlled by associating proteins termed guanine nucleotide 
exchange factors (GEFs), that catalyze the exchange from GDP to GTP, thereby contributing 
to turning on Rho GTPases downstream signaling [152]; GTPase activating proteins (GAPs) 
that terminate the signaling by inducing intrinsic GTP hydrolysis [152]; and guanine 
nucleotide dissociation inhibitors (GDIs), which inhibit GDP dissociation and whose role is to 
remove small G proteins from the membrane and solubilize them back to the cytosol [153] 
(Fig. 1-4). RhoA, Rac1 and Cdc42 are the most well characterized Rho GTPases, which are 
under the control of PI3Ks [144]. 
 
 
 
 
 
Figure 1-4. Regulation of the Rho GTPase activity. Rho GTPases are considered functional when 
they are bound to GTP, and not functional when they are GDP-bound. GEFs catalyze GDP to GTP 
exchange utilizing abundance of intracellular GTP, and regulate the activity of downstream effectors. 
These effectors are responsible for triggering different cellular responses such as actin cytoskeletal 
organization, cell-cycle progression or expression of various genes. GAPs stimulate the intrinsic 
hydrolytic activity of Rho GTPases promoting the GDP-bound inactive state and terminating signal 
transduction. GDIs inhibit GDP dissociation and sequester Rho GTPases in the cytosol, before they 
become targets for GEFs. Abbreviations: GEF, guanine exchange factor; GAP, GTPase activating 
proteins; GDI, guanine nucleotide dissociation inhibitors; Pi, inorganic phosphate. 
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Rac is responsible for the generation of lamellipodia or ruffles along the edge of the cell. 
RhoA regulates stress fibers formation, which are elongated actin bundles that promote cell 
attachment to the extracellular matrix by generation of focal adhesions. Cdc42 induces 
filopodia formation, thin spike-like membrane extensions responsible for the recognition of 
the extracellular environment [154]. 
 The over-expression or increased activity of RhoGTPases, which was found in human 
cancer, led researchers to believe that GEFs and GAPs significantly contribute to tumor 
progression by promoting aberrant GTPase activation [151, 155]. Recently, mutation of 
proline 29 to serine in highly conserved switch I domain of Rac1 has been found in sun-
exposed melanomas [156]. In the studied cohort, it was the third most frequent activating 
mutation after those of BRAF and NRAS, which was predominant in male patients when 
compared to females. This gender difference was unique for RAC1P29S and it was not 
found for mutations in BRAF or NRAS. Moreover, RAC1P29S alteration increased binding of 
RhoGTPase to downstream effectors and thus promoted melanocyte cell proliferation and 
migration [156]. There are around 85 GEFs and 80 GAPs identified in mammals [149, 150]. 
Several GEFs were mutated or aberrantly expressed in human cancer. One of the well 
known examples is the Rho-specific GEF Bcr, whose gene, as a result of the fusion with the 
Abl tyrosine kinase gene (fusion-gene known as Philadelphia chromosome), contributes to 
leukemia development [157]. The Rac-specific GEFs Tiam1 and Vav, which regulate 
Rac/Rho/Cdc42 are other examples, which were found deregulated in human cancer. The 
first one was identified as an invasion and metastasis-inducing gene in a murine T-lymphoma 
cell line, and the other one showed a wide range of effects on development and progression 
of human malignacies mostly due to its over-expression [155]. Considering their high 
oncogenic potential GEFs have been proposed as therapeutic targets for cancer [155].  
GEFs catalyze GDP dissociation from small G proteins by modification of the nucleotide-
binding site, which leads to a decrease in nucleotide affinity and its subsequent replacement 
with GTP [152]. The mechanism of GEFs activation strongly depends on their multi-domain 
structure. The minimal functional module consists of Dbl homology-Pleckstrin homology 
tandem domains (DH-PH), which display functional interdependence. They are respectively 
responsible for the intrinsic GEF catalytic activity toward RhoGTPases and intracellular 
distribution into the plasma membrane or into the cytoskeletal matrix, where the substrates of 
Dbl family proteins reside [158]. Beside the DH-PH motif, GEFs possess other protein 
domains, which are responsible for the specific cellular functions of the different family 
members. All these domains can bind to each other at the intramolecular way, but they can 
also serve as a binding platform for other proteins or lipid products. In this way GEFs 
become an integral part of large macromolecular complexes that are precisely coordinated 
for the highly dynamic spatio-temporal activation of Rho GTPases [158]. 
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 1.5.2. The Role of Class I PI3Ks in the Regulation of Rho GTPases in Cancer 
 
PI3Ks collaborate with Rho GTPases in actin remodeling to establish cell polarity, 
definie the leading edge of the cell, regulate the cell migration, as well as protrusion and 
adhesion formation [144]. Numerous positive feedback loops and crosstalks exist between 
Rho GTPases and PI3Ks pathways, which integrate and amplify cell signaling. Rho GTPase 
may be activated in a PI3K- independent and –dependent fashion through GEFs such as 
Vav, Sos, Tiam, αPIX, p-Rex1 [159]. Upon stimulation of RTKs, GPCRs and extracellular 
matrix (ECM)-cell or cell-cell adhesion receptors (e.g. integrins, cadherins), GEFs may bind 
to PI3Ks lipid product PtdIns(3,4,5)P3 [144].  
 
 
 
 
 
 
Figure 1-5. Class I PI3Ks role in Rho GTPases activation. Stimulation of RTK, GPCR and adhesion 
receptors activate class I PI3Ks, which generate PtdIns(3,4,5)P3 second messengers. Phosphorylated 
lipids become targets for the Rho GEFs, which are recruited to the plasma membrane and promote 
activation of Rho GTPases residing at the membrane proximity. Activation of Rho GTPases causes 
induction of various cellular responses. 
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When GEFs are recruited to the membrane, they form multi-protein complexes with PI3K, 
RhoGTPases, as well as actin-binding proteins [160], which localize them to dynamic actin 
structures and ensures efficient RhoGTPase activation [160, 161]. p85 regulatory subunit of 
class IA was shown to interact with Rac-specific GEF complex Eps8/Abi1/Sos1, in which Abi1 
is responsible for the interaction, whereas Sos1 binds to PtdIns(3,4,5)P3 and induces its 
GEF’s activity towards Rac [161]. Inactivation of p110α, but not of p110β, impaired 
endothelial cells migration in vitro and in vivo through RhoA-dependent signaling during the 
angiogenesis [162]. In neutrophils of transgenic mice, which were deficient of class IB p110γ, 
lack of generation of PtdIns(3,4,5)P3 and significantly reduced motility upon GPCR 
stimulation were observed [163]. Further pharmacological inhibition of p110δ with IC87114 
compound suppressed polarized morphology of neutrophils, fMLP-stimulated PtdIns(3,4,5)P3 
production and directional chemotaxis [164]. PI3K signaling inhibition with wortmannin or 
LY294002 has been extensively used to demonstrate their impact on cell polarity, migration 
and disruption of actin structures. Deregulation of PI3Ks in cancer influence RhoGTPases 
signaling leading to over-activation of the pathway. This, in turn, has been shown to 
contribute to most steps of cancer initiation and progression [151]. Class I PI3Ks role in the 
regulation of Rho GTPases is given on Fig. 1-5. 
 
1.5.3. The Prototypic Dbl GEF and Its Oncogenic Counterpart 
 
The dbl oncogene (MCF-2) was the first GEF identified based on DNA isolation from 
the human diffuse B-cell lymphoma (~66 kDa) and subsequently from nodular poorly 
differentiated lymphoma (NPDL-dbl) (~76 kDa) and the human mammary carcinoma cell line 
MCF-7 [165-167]. Further transfection of these DNAs into NIH3T3 cells induced cellular 
transformation uncovering Dbl’s oncogenic potential. The dbl oncogene encodes a protein of 
478 amino-acids that is produced as a result of loss of the first 497 amino-acids of proto-dbl 
(925 amino-acids, 115 kDa) located on chromosome X. Beside this modification, the genesis 
of all independently found onco-dbl forms involves acquisition of different fragments of genes 
from another human locus (chromosom 3) adding 50 amino-acids to the N terminus [166, 
168, 169]. However, it is the loss of the 497 amino-acids and not the fusion with distal genes 
fragments, which is crucial for increased transforming activity of the dbl oncogene in NIH3T3 
cells [168]. Over-expression of proto-dbl is sufficient to transform NIH3T3 cells and to 
produce tumors in nude mice. However, truncation of the N-terminal portion of the protein 
markedly enhances its transforming activity and tumorigenicity [168, 170]. Both proto- and 
onco-Dbl are cytoplasmic proteins, which function at the plasma membrane, but also 
associate wih the cytoskeletal matrix [171]. Both are mostly phosphorylated on serines, 
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although proto-Dbl is phosphorylated to lesser extent. The half-life of proto-Dbl is significantly 
shorter than the half-life of onco-Dbl, suggesting poor stability and rapid turnover [171]. All 
these differences may be related to distinct conformations of both proteins. The oncogenic 
Dbl conformation might be more prone to phosphorylation and confer greater stability either 
by increased protein-protein interactions or by enhanced resistance to proteases [171].  
 The expression of proto-dbl seems to be highly tissue-specific. Among the range of 
normal human tissues tested proto-dbl mRNA was detected only in fetal brain and adrenal 
glands, as well as adult testes and ovaries [170]. There are four splicing variants of the 
human proto-dbl, which display various GEF specificities and are differently expressed in 
brain, heart, kidney, spleen, liver, testis, placenta, stomach and peripheral blood [172]. There 
is approximately 75% cDNA and amino acids sequence homology between human DBL and 
its mouse counterpart MCF-2. Mouse mcf-2 mRNA is expressed in brain, kidney, intestine 
and testis [173].  
The GEF activity of onco-Dbl was demonstrated for the first time when it became 
clear that the amino acid sequence of human proto-Dbl between residues 498 and 738 
shares significant similarity with cell-division-cycle protein Cdc24 present in S. cerevisiae, 
which was known to act on the GTP-binding protein Cdc42Sc [174]. Soon after, it was shown 
that oncogenic Dbl catalyzes the dissociation of GDP from human Cdc42 GTPase and 
thereby plays a role of guanine nucleotide exchange factor [175]. These findings were 
followed by additional reports, which showed the activity of onco-Dbl not only toward Cdc42, 
but also RhoA GTPase, whereas the Dbl GEF activity directed toward Rac1 GTP-binding 
protein was not detected [176]. Other studies demonstrated onco-Dbl-mediated dissociation 
of GDP from all three Rho GTPases, but for RhoA and Rac1 it was more rapid than for 
Cdc42 [177]. It seems then that oncogenic Dbl may act on all three Rho GTPases, although 
its activity torward RhoA and Cdc42 is more evident. On the other hand, proto-Dbl GEF 
activity is dependent on particular splice variants, which are expressed in different tissues 
and organs [172]. For instance, the variant 1 of Dbl, which is designated as prototype Dbl 
and is expressed only in the brain, showed the least activity directed toward RhoA, Rac1, 
Cdc42 when compared to the other three splice variants expressed in other organs. Variant 4 
displayed high GEF activity torward Cdc42 and RhoA, whereas variant 3 exhibited weak 
activity toward Cdc42 and Rac1 in contrast to variant 1 [172]. Analogously to human variant 
1, brain-specific mouse MCF-2 was also less active in the GDP-dissociation assay [173]. 
Studying GEF activity of particular Dbl forms in connection with their specific expression 
would certainly lead to interesting insights into Dbl function. 
As in all GEF family members, the minimal functional DH-PH module can be found 
also in the proto-Dbl structure [178-180]. The spectrin domain of proto-Dbl located at the N-
terminus regulates Dbl activity by indirect binding to PH-domain. This interaction blocks the 
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access to the catalytic DH domain and masks intracellular targeting function of the PH 
domain [178-180]. This indirect binding is mediated by chaperone heat shock cognate 
protein (Hsc70) complexed with chaperone Hsp90 and cochaperone CHIP, which is an E3 
ubiquitin protein ligase [179, 180]. A schematic representation of proto-Dbl structure and 
regulation of its activity is shown on Fig. 1-6. 
 
 
 
 
 
 
Figure 1-6. Regulation of proto-Dbl activity and stability by intracellular and intermolecular 
interactions. Proto-Dbl exists in an inactive or partially active state maintained by complex intra- and 
intermolecular interactions. The N-terminal spectrin domain indirectly associates with the PH domain 
through the Hsc70-Hsp90 chaperone complex. This interaction blocks the access to the catalytic DH 
domain, and masks the intracellular targeting function of the PH domain. Upon an activation signal, 
the closed inactive Dbl conformation is opened, Hsc70-Hsp90 chaperone complex is released and the 
GEF gets activated. Hsc70 and Hsp90 function together to stabilize Dbl by recognizing damages or 
misfoldings and convert the GEF to a functional conformation. When there are too many disorders in 
GEF’s structure or conformation, which cannot be repaired or when Dbl is in excess, then Hsc70-
Hsp90 cooperate with the CHIP co-chaperone, which directs the GEF to ubiquitin-mediated 
degradation by the proteasomal pathway. This prevents Dbl abberant signaling. Abbreviations: DH, 
Dbl homology domain; PH, Pleckstrin homology domain; 70, heat shock cognate protein Hsc70; 90, 
heat shock protein Hsp90; CHIP, chaperone-dependent E3 ubiquitin-protein ligase. 
 
 
The Hsc70/Hsp90/CHIP machinery is a well known system, which maintains quality control in 
cells by recognizing misfolded or damaged proteins. It further assists in proteins conversion 
to a functional conformation (Hsc70-Hsp90 role) or directs them to ubiquitin-mediated 
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degradation by the proteasomal pathway (CHIP role) [181]. Since proto-Dbl displays a high 
oncogenic potential, this mode of regulation maintains its steady-state expression at a low 
level and keeps its localization and activity “in check” [180]. Thereby, proto-Dbl, like many 
GEFs, exists in an inactive or partially active state maintained by complex intra- and 
intermolecular interactions [178, 180]. This inhibitory conformation can be altered by 
upstream regulatory signals, which involve membrane targeting [182], oligomerization [183], 
tyrosine phosphorylation upon RTK stimulation [184], interactions with heterotrimeric G-
protein subunits [185-187], protein kinases [184], adaptor or scaffolding proteins [188], as 
well as phosphoinositol phosphates [189], and result in intracellular translocation and 
stimulation of the GEF catalytic activity. In vivo proto-Dbl was shown to play a role in dendrite 
elongation. However, the normal development and function of brain and gonads, known to 
express the GEF, were not altered in Dbl-null mice, which were fertile and viable [190]. 
1.5.4.  Dbl’s Role in Cancer 
 
Although proto-Dbl overexpression is sufficient to cause cell transformation, the 
transforming potential of onco-Dbl is much higher and its expression has much more 
dramatic consequences for the cell [170]. Oncogenic Dbl activation is triggered by the 
truncation of N-terminal sequence of proto-Dbl including the spectrin module, which results in 
constitutive activation of the catalytic DH-PH core [168, 178]. Onco-Dbl escapes the control 
of the Hsc70/Hsp90/CHIP machinery, which translates into its increased stability and 
protection against ubiquitination and degradation [180]. Consistent with this, oncogenic Dbl 
becomes constitutively expressed, accumulates in the cells at high levels and in turn causes 
continuous activation of downstream GTPases and their signaling pathways leading to cell 
transformation [180]. Which events exactly trigger oncogenic Dbl formation is not known. 
Early studies, which led to onco-Dbl identification revealed that 5’ rearrangements of two 
separately isolated oncogenes (66 kDa and 76 kDa) were not detected in the original tumors, 
where the DNA for NIH3T3 transformation was isolated from, suggesting that oncogenic 
truncation might be triggered by gene transfer in vitro or is present only in a small minority of 
cells in vivo [166]. DNA fragments found in these tumors corresponded to fragments 
observed in normal human placenta DNA [166]. However, further efforts to study Dbl 
contribution in naturally occuring tumors were undertaken. Dbl expression was investigated 
in tumors of neuroectodermal origin. Proto-Dbl mRNA was detected in almost all Ewing’s 
sarcoma cell lines and tumors tested, as well as in lung metastasis of this cancer [191]. In 
contrast, proto-Dbl transcripts were not found in neuroepitheliomas and neuroblastomas 
suggesting its potential role as diagnostic marker of Ewing’s sarcomas [191]. Furthermore, 
proto-Dbl mRNA was not detectable in tumors of hematopoietic origin, but its preferential 
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expression in neuroectodermal and neuroendocrine tumors and also normal tissues of 
neuroectodermal origin was confirmed [192]. However, it was not found in gliomas, 
neuroblastomas (NB), Merkel’s tumors and medulloblastomas, suggesting that proto-Dbl 
expression is not common for all neuroectodermal tissues, but only for some specific tissues 
of such origin [192]. Interestingly, it was shown that the expression level of proto-Dbl in the 
GEF-positive tumors is not high enough to cause cellular transformation in NIH3T3 
fibroblasts. These results indicate the lack of a pathological role of proto-Dbl in malignant 
transformation [192]. In contrast to previous research, another group demonstrated wide 
expression of onco-Dbl not only in Ewing’s sarcoma, but also in peripheral neuroectodermal 
tumor (PNET), NB, rhabdomyosarcoma, retinoblastoma and other tumors, arguing with the 
fact that Dbl can serve as good molecular marker in neuroectodermal cancer diagnosis [193]. 
Dbl oncogene functions were studied in the lenses of 2 days, 2 weeks, and 6 weeks old 
onco-Dbl transgenic mice [194]. DNA microarray analysis revealed interesting transcriptional 
profiles indicating the up-regulation of genes compatibile with epithelial-mesenchymal 
transition (EMT), angiogenesis and inhibition of apoptosis, which coincided with a strong 
disruption of lens structure and function [194]. Interestingly, the neuroepithelial tissue tumors 
in onco-Dbl transgenic mice developed only in the absence of functional p53 [195]. 
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2. AIMS OF THE STUDY 
 
The role of class II PI3KC2β in oncogenesis has just started to be appreciated. It was 
found to be involved in pro-survival and pro-migratory responses in human cancer cells, as 
well as in proliferation and protection against anoikis [103]. Its involvement in 
chemoresistance mechanisms was also described [139-141]. In terms of molecular 
mechanisms, there is not much known yet about PI3KC2β mode of activation, especially 
about the significance of its uncommon multidomain structure. However, a number of 
possible lipid- and protein-binding sites in the PI3KC2β sequence suggest sophisticated 
mechanism of regulation and a variety of downstream pathways, which may be triggered. 
The existing reports have described PI3KC2β assembly into large protein complexes and link 
the class II PI3K function to RhoGTPases and their associated activating proteins GEFs. 
RhoGTPases are crucial for cell migration and adhesion processes, and are frequently over-
expressed in cancer leading to tumor cells invasion and metastasis. This makes 
RhoGTPases and GEFs promising targets for anti-cancer therapies.  
Studies initiated in our lab had revealed that overexpression of PI3KC2β in NIH3T3 
mouse fibroblast causes strong stress fibers assembly, increased membrane ruffling and cell 
spreading due to Rac1 and RhoA activation. The mechanism underlying these striking 
phenotypical changes revealed the involvement of Dbl GEF and shed a light onto the 
possible mechanism of PI3KC2β-mediated RhoGTPase activation, although the exact 
molecular mechanism remains elusive. Due to the high oncogenic potential of Dbl and 
increasing knowledge about PI3KC2β involvement in cancer, it was interesting to investigate 
what is the role of PI3KC2β in GEF-mediated RhoGTPases signaling.   
Therefore, the aim of the first project was to translate the knowledge about PI3KC2β 
and Dbl structural features into a precise mechanism of action, as well as to further 
understand the functional role of the PI3KC2β/Dbl protein complex in the context of 
cytoskeletal remodelling in mouse fibroblasts. 
Furthermore, the mechanism of PI3KC2β activation, regulation and resulting 
biological functions has never been studied in detail. Very little is known about PI3KC2β 
post-translational modifications, spatial and temporal organization upon cellular stimulation. 
Tyrosine phosphorylation of PI3KC2β was observed in different ligand-dependent contexts: 
for instance, in NIH3T3 and A-431 or HEK293 cells upon stimulation with PDGF and EGF 
respectively, as well as in SCLC and H-209 cells after treatment with SCF, HGF, insulin and 
FGF2 [77, 99]. However, detailed functional investigation of site-specific phosphorylations 
had never been carried out. We were therefore very much interested in defining the function 
of PI3KC2β tyrosine site-specific phosphorylation and its significance for the regulation of 
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PI3KC2β enzymatic activity, interactions with its binding partners and activation of 
downstream signaling pathways. 
Thus, the aim of the second project was to identify and functionally characterize 
specific PI3KC2β tyrosine phosphorylation sites and signaling pathways, which they 
trigger.
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3. RESULTS 
3.1. Phosphoinositide 3-Kinase C2β Regulates RhoA and the Actin Cytoskeleton 
through an Interaction with Dbl (Project I) 
 
3.1.1. Summary 
 
 
 The main function of PI3KC2β has been associated with cell migration and the related 
cytoskeletal remodeling processes. These cellular responses are mostly governed by Rho 
family of small GTPases. In these studies I have investigated the regulatory mechanism 
linking PI3KC2β to activation of Rho GTPases through the Dbl guanine exchange factor 
(GEF) in NIH3T3 mouse fibroblasts. PI3KC2β over-expression in NIH3T3 cells showed 
strong stress fibers formation, enlargement of the cell body, as well as increased cell 
spreading and ruffles formation. The results revealed formation of an endogenous 
PI3KC2β/Dbl complex in NIH3T3, as well as in neuroblastoma cancer cells. However, the 
observed association was neither dependent on the PI3K activity, nor on the EGF and PDGF 
stimulation, suggesting PI3KC2β/Dbl constitutive binding and a scaffolding role of the kinase 
in the complex with the GEF. Subsequently, PI3KC2β/Dbl interaction studies did not show a 
direct association between the N-terminal regulatory PI3KC2β domain and the spectrin- and 
pleckstrin homology (PH)-Dbl domains in the in vitro binding assay, suggesting a possible 
requirement for additional mediators of the interaction. Additionally, no difference in Dbl 
activity was observed in the in vitro GEF activity assay upon isolation of Dbl from HEK293 
cells transfected with PI3KC2β wild-type and dominant-negative (kinase-dead) form. 
Therefore, a more complex mechanism of PI3KC2β-dependent Dbl activation is likely, which 
involves additional interaction partners. Moreover, an interaction of PI3KC2β isolated from A-
431 epidermoid carcinoma cells with oncogenic form of Dbl has been found indicating a 
potentially important role of the kinase in Dbl-dependent tumorigenesis. 
 
 
 
 
Results obtained for this project were accepted for publication in the PLoS ONE peer-
reviewed journal: 
 
Błajecka K, Marinov M, Leitner L, Uth K, Posern G, Arcaro A. Phosphoinositide 3-Kinase C2β 
Regulates RhoA and the Actin Cytoskeleton through an Interaction with Dbl.  PLoS ONE 
(July 2012, accepted) 
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3.1.2. Introduction 
 
The involvement of PI3KC2β in the cell migration and adhesion processes in the 
RTK- or GPCR-dependent manner was discovered in different cell line models, including 
cancer cells. Cell migration and adhesion mechanisms are controlled by Rho family 
GTPases and their associated modulating proteins such as GEFs, GAPs and GDIs. It was 
demonstrated that PI3KC2β can stimulate Rac activity in A-431 epidermoid carcinoma cells, 
which results in an increase in the cells migration speed [103]. This effect was mediated by 
the formation of a PI3KC2β multiprotein signaling complex downstream of EGFR involving 
Grb2 and Shc adaptor molecules, as well as the Eps8/Abi1/Sos1 complex, which plays a role 
of guanine nucleotide exchange factor for Rac. Furthermore, an association of PI3KC2β with 
the modular scaffold intersectin, which can also play a role of GEF, was described [104].  
 
 
 
 
Figure 3-1. Kinase-dependent PI3KC2β effect on cytoskeletal rearrangements in NIH3T3 cells. 
Confocal images of NIH3T3 cells expressing PI3KC2β wild-type (-C2β-WT), kinase-dead dominant-
negative (–C2β-DN) and the empty vector pcDNA3 (-V). Cells grown on cover slips for 24 h in 10% 
FCS and were stained with Alexa Fluor 555 dye to localise F-actin, and an anti-PI3KC2β antibody 
follwed by FITC-labelled anti-rabbit antibody, to localize the kinase. Scale bar represents 40 μm. 
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Preliminary results from our lab revealed that PI3KC2β plays a crucial role in controlling the 
actin cytoskeleton in NIH3T3 cells. Stable over-expression of PI3KC2β in these cells induced 
marked cell morphology changes in the cytoskeletal organization including increased cell 
spreading with strong stress fibers assembly (Blajecka et al. 2012, manuscript accepted) 
(Fig. 3-1). In contrast, the dominant-negative form of PI3KC2β strongly suppressed these 
phenotypical modifications. NIH3T3-C2β WT cells were much more enlarged in comparison 
to cells expressing the empty vector, while reduced cell size was observed in NIH3T3-C2β 
DN cell line (Fig. 3-2). Increased spreading of NIH3T3-C2β WT cells with strong stress fibers 
formation were associated with up-regulation of RhoA and Rac1 activity in 10% FCS and 
upon stimulation with growth factors (Blajecka et al. 2012, manuscript accepted). In order to 
investigate the molecular mechanism of PI3KC2β–dependent RhoGTPases activation in 
NIH3T3 cells, binding of PI3KC2β to a panel of RhoGEFs family members was examined. 
The Rho family GEF Dbl was identified as an interaction partner of PI3KC2β in NIH3T3 
mouse fibroblasts over-expressing PI3KC2β. Grb2 adaptor protein was an additional player, 
which was found in the PI3KC2β protein complex. We were further interested in the precise 
mechanism of PI3KC2β activation leading to the observed phenotypical changes and what is 
the contribution of Dbl GEF in this process. 
 
 
 
Figure 3-2. Cell size differences of PI3KC2β-WT and -DN stably transfected mouse fibroblasts. 
NIH3T3 cells expressing PI3KC2β wild-type (-C2β-WT), kinase-dead dominant-negative (–C2β-DN) 
and the empty vector pcDNA3 (-V) were seeded in DMEM complete medium supplemented with 0.8 
mg/ml G418 selection antibiotic. 24 hrs after plating, morphology pictures were taken with Eclipse 
TS100 inverted microscope (4x and 10x magnification) supplied with a Nikon DXM1200 digital 
camera. 
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3.1.3. Results 
 
Endogenous PI3KC2β interacts with Dbl in mouse fibroblast and human cancer cells 
 
The Rho family guanine nucleotide exchange factor (RhoGEF) Dbl was identified as 
an interaction partner of PI3KC2β in the NIH3T3 mouse fibroblasts stably over-expressing 
the kinase. In order to investigate whether PI3KC2β and Dbl can form protein complex in 
physiological conditions I immunoprecipitated Dbl from the parental NIH3T3 cells and 
subjected it to western blot analysis with PI3KC2β-specific antibody. Results revealed 
PI3KC2β/Dbl complex assembly in mouse fibroblasts, although due to the low expression of 
the PI3KC2β in these cells the signal indicating the interaction was very weak (Fig. 3-3 A). To 
confirm this finding, we selected IMR5, a neuroblastoma cancer cell line, which expresses 
relatively high levels of PI3KC2β and Dbl. The importance of PI3KC2β for neuroblastoma 
tumorigenesis was recently published and the expression of oncogenic dbl in some tumors of 
neuroectodermal origin was investigated before [114, 193]. Thus, we performed co-
immunoprecipitation with anti-Dbl and anti-PI3KC2β antibody in IMR5 cells and we found 
PI3KC2β association with Dbl, which confirmed the formation of an endogenous protein 
complex and the possible relevance of this interaction in the human cancer (Fig. 3-3 B). 
 
 
 
Figure 3-3. PI3KC2β interacts with Dbl GEF for Rho GTPases in mouse fibroblasts and human 
cancer cells. Complex formation of endogenous PI3KC2β and Dbl immunoprecipitated from the 
whole cell extract (WCE) of the parental NIH3T3 cells (A) and from the IMR5 neuroblastoma human 
cancer cells (B) with anti-Dbl, anti-C2β or control IgG antibody. In the case of IMR5 cell line Triton 
0.5% and Brij96 1% lysis buffers were used, while NIH3T3 cells were lysed with Triton 1%. Samples 
were subjected to western blot analysis with the indicated antibodies. EE refers to anti-Glu-tag 
antibody. Asterisk indicates PI3KC2β. 
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In support of this result, lysis buffers of different strength were tested in order to examine the 
complex stability. PI3KC2β/Dbl binding was detected independently of the lysis buffer used 
(Brij96 or Triton 0.5%) demonstrating the stability of this interaction in the neuroblastoma 
cells. 
 
Dbl interacts with the N-terminal domain of PI3KC2β and Grb2 
 
To understand whether PI3KC2β directly influences Dbl activation, we were first 
interested in studying in detail whether the two proteins directly associate with each other 
and what is the molecular mechanism of PI3KC2β/Dbl complex assembly. In order to 
investigate whether PI3KC2β N-terminal and C2 domain C-terminal domains are involved in 
the interaction, we performed pull-down experiment using equimolar amounts of GST-fused 
PI3KC2β N-terminal and C2 C-terminal domains. Purified proteins were further incubated 
with lysates of HEK293 cells transfected with HA-tagged proto-Dbl, empty vector (V) or 
untransfected cells. Results revealed that the N-terminal domain of the PI3K is involved in 
the interaction with Dbl (Fig. 3-4 A). Interestingly, it associated to exogenous, as well as 
endogenous GEF indicating a physiological relevance of this interaction. The N terminus of 
PI3KC2β (in particular proline-rich regions) was previously shown to mediate PI3KC2β 
constitutive association with the EGFR through the SH3 domains of the Grb2 adaptor protein 
[94]. Moreover, PI3KC2β also interacted directly with one of five SH3 domains of intersectin, 
a multidomain scaffolding protein, which can also function as a guanine exchange factor 
[104]. On the other hand, Grb2 was shown to bind various GEFs [22]. It is therefore possible 
that Dbl binds to the PI3KC2β N-terminus through the Grb2 adaptor molecule. However, 
considering the domain structure of Grb2 and Dbl, it is unlikely that they bind directly. Further 
studies were therefore necessary to confirm that hypothesis. Pull-down experiments with 
purified GST-fused Grb2 and lysates of HEK293 cells transfected with HA-tagged proto-Dbl 
showed Grb2 binding to Dbl (Fig. 3-4 B). Grb2 complex formation with endogenous Dbl was 
detected in untransfected HEK293 cells, which again suggested the physiological relevance 
of the interaction. Previously published association of the adaptor molecule with PI3KC2β 
confirmed the accuracy of our results. All these findings demonstrate the formation of a multi-
protein complex comprising PI3KC2β, Grb2, Dbl, which may be functional in untransformed 
cells (NIH3T3, HEK293), as well as in cancer cells (IMR5). Nevertheless, further experiments 
were required to investigate how Dbl structurally contributes to the interaction and whether 
the PI3KC2β and Dbl interactions in this complex are direct or mediated by Grb2 or other 
possible interaction partners. 
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Figure 3-4. Dbl interacts with N-terminal PI3KC2β domain and Grb2. (A) Interaction between the 
PI3KC2β and Dbl was examined by the pull-down (PD) of PI3KC2β GST-fused N-terminal and C2 C-
terminal domains in HEK293 cells transfected with HA-proto-Dbl (Dbl), pcDNA3 empty vector (V) or 
untransfected control (-). Complex formation was shown by immunoblotting with anti-Dbl antibody. (B) 
Interaction between the Dbl and Grb2 was examined by the GST-Grb2 pull-down in HA-proto-Dbl (Dbl) 
transfected and untransfected (-) HEK293 cells. Pull-down samples were subjected to western blot 
analysis with indicated antibodies. Asterisk indicates endogenous Dbl. 
 
 
Dbl spectrin- and PH- domains bind to PI3KC2β in COS-1 cells 
 
Considering the domain structure of Dbl and the complex mechanism of GEFs 
activation and regulation, we were further interested in which part of the Dbl protein 
sequence is involved in the interaction with PI3KC2β. For that reason we co-transfected 
COS-1 cells with GST-fused Dbl N-terminal-, spectrin-, onco-, PH- domains and PI3KC2β 
wild-type and subjected the lysates to pull-down experiments with glutathione-sepharose 
beads. A schematic representation of Dbl mutants is shown on Fig. 3-5 A. Western blot 
analysis of pull-down samples revealed a prominent interaction of the PI3KC2β with the Dbl 
spectrin- and PH- domain (Fig. 3-5 B). These results go in line with previous reports 
describing heat shock cognate protein 70 (Hsc70) as a binding partner of the Dbl amino-
terminal spectrin homology- and PH- Dbl domains. These interactions result in Dbl adopting 
an inactive conformation, which on one hand limits the GEF’s catalytic activity by blocking an 
access of RhoGTPases to its DH- catalytic domain, and on the other hand restrain Dbl 
intracellular distribution [179]. However, it is just one aspect of the complicated Dbl regulation 
machinery and it is difficult to state whether PI3KC2β plays a similar role to Hsc70 in 
regulation of Dbl activity. Interestingly, a weak interaction of the N-terminal domain of Dbl 
with the kinase was observed even though it includes the spectrin domain, which on its own 
was quite strongly bound to PI3KC2β (Fig. 3-5 B). Similarly, the PI3K association to onco-
Dbl, which contains the PH domain, was either not detectable or very faint in different 
repetitions of the experiment (Fig. 3-5 B). Interestingly, no interaction of endogenous Grb2 
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was observed with any of the Dbl domains in COS-1 cells, suggesting that neither does Grb2 
bind to Dbl directly, nor does it mediate PI3KC2β association with the Dbl domains. However, 
when Dbl was purified as a full-length protein, a weak interaction with Grb2 could be 
identified. It is therefore likely that the full-length of GEF is needed for an interaction with 
Grb2 and other possible mediators of the association with PI3KC2β. Further investigations 
were conducted to assess the possible contribution of PI3KC2β to the regulation of Dbl 
activity and function. It is possible that PI3KC2β may compete with Hcs70 and other 
associated proteins for binding to Dbl. This may induce Hsc70-Hsp90 complex disassembly 
and opening of the GEF inactive conformation resulting in Dbl activation. Whether PI3KC2β 
and Dbl protein-protein interactions are direct or are mediated by other possible binding 
partners was subsequently elucidated in an in vitro binding assay. 
 
 
 
Figure 3-5. PI3KC2β binds with high affinity to the spectrin- and PH- Dbl domain. (A) Schematic 
representation of Dbl mutant constructs, which were a kind gift of Prof. Danny Manor from the School 
of Medicine at Case Western Reserve University, Cleveland, USA.  (B) COS-1 cells co-transfected 
with Myc-PI3KC2β and different GST-fused Dbl domains (N-, spectrin-, onco-, PH-) in pEBG vector 
were subjected to gluthatione-sepharose beads affinity-purification and immunobotted with indicated 
antibodies. PC refers to positive control that are COS-1 cells co-transfected with PI3KC2β and HA-
proto-Dbl, and immunoprecipitated with anti-Dbl antibody. 
 
 
Dbl spectrin- and PH- domains do not associate directly with N terminus of PI3KC2β and 
Grb2 
 
The binding of Dbl spectrin and PH domains to PI3KC2β in co-transfected COS-1 cells led us 
to test whether the proteins interact directly with each other or are associated in the complex 
via other interaction partners. Since it was known from previous pull-down assays that Dbl 
binds to the N-terminal domain of PI3KC2β and Grb2, we performed an in vitro binding 
assay, which utilized soluble N-terminus of PI3KC2β or/and Grb2, which were previously 
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expressed and purified from E.coli as GST-fused proteins. Next, purified proteins were 
treated with thrombin to remove GST-tag in order to avoid unspecific dimerization with GST-
tagged Dbl domains. Soluble NT-PI3KC2β and Grb2 were further incubated with 
recombinant GST-fused spectrin- and PH- Dbl domains expressed and purified from COS-1 
cells, and immobilized on gluthatione-sepharose beads (Fig. 3-6 A). In the case of NT-
PI3KC2β, we did not observe a direct interaction with Dbl mutants. On the other hand, Grb2 
showed a weak interaction with Dbl spectrin–domain and stronger association with PH-Dbl 
fragment. The binding was observed in both reactions, when Grb2- was incubated with the 
Dbl domains alone and when co-incubated with NT-PI3KC2β. However, due to a detectable 
interaction of GST control with soluble NT-PI3KC2β and Grb2- we were cautious in 
iterpreting this data as specific. Increasing the reaction buffer strength in the in vitro 
experiments (from Brij96 to Triton 1%) did not help to reduce the unspecific signal. To 
demonstrate the accuracy of the performed in vitro reactions with Dbl mutants, control 
reactions with known-to-bind ptoteins (NT-C2β-GST + Grb2-; Grb2-GST + NT-C2β-) were 
performed exactly in the same way. The control experiment showed the expected 
interactions without any undefined signals indicating accuracy of our experimental procedure 
(Fig. 3-6 B).  
 
 
 
 
 
Figure 3-6. Lack of Dbl direct association with NT-PI3KC2β and Grb2. (A) GST-tagged and 
gluthatione-sepharose beads conjugated spectrin- and PH- Dbl domains, and GST as control, were 
incubated in vitro with GST-truncated soluble PI3KC2β N-terminal domain (NT-C2β-) (~35 kDa) and 
Grb2 (26-31 kDa). To detect PI3KC2β and Grb2 interaction wih Dbl domains samples were subjected 
to immunoblotting with indicated antibodies. The same results were obtained in three experiments 
independently of the buffer used (Brij96 or Triton 1%). One representative blot is shown (Brij96 1% 
was used for the incubation). (B) Control in vitro reactions, which utilized immobilized GST-tagged NT-
C2β domain, Grb2 and GST alone, and soluble GST-truncated NT-C2β- domain and Grb2-, were 
performed. Samples were subjected to SDS-PAGE analysis and the interaction between NT-C2β and 
Grb2 was detected with indicated antibodies by western blot analysis. (C) Representative immunoblot 
of Dbl domains separated on SDSPAGE and analysed by wester blot with anti-GST antibody. 
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The unspecific binding in the negative GST control of the in vitro reaction, the lack of 
potential interacting motifs in Grb2 and Dbl structure, and the fact that we did not observe an 
interaction of endogenous Grb2 with any of the Dbl domains in the gluthatione-sepharose 
beads pull-down in COS-1 cells co-transfected with Dbl mutants and PI3KC2β (Fig. 3-5 B), 
let us to believe that the in vitro interaction of Grb2 with spectrin- and PH- Dbl domain is not 
reliable. Moreover, the lack of a direct association of NT-PI3KC2β with spectrin- and PH- Dbl 
domains in vitro suggests that other interaction partners, but not Grb2 adaptor protein, are 
required for the association of the PI3K with the GEF in living cells. 
 
 
PI3KC2β isolated form A-431 human cancer cells binds to onco-Dbl domain 
 
The indirect PI3KC2β binding to Dbl was demonstrated in NIH3T3, HEK293 and 
additionally in the human cancer cell line IMR5. The detailed interaction with spectrin- and 
PH- Dbl domains was further investigated in COS-1. No association was found with the 
oncogenic Dbl. However, all my experiments aiming at investigation of PI3KC2β/Dbl domain-
specific interactions were performed so far in non-cancerous cell systems such as COS-1 or 
HEK293 cells, which may certainly not reflect the situation in cancer cells at the molecular 
and functional level. Therefore, I purified PI3KC2β from A-431 epidermoid carcinoma cell line 
overexpressing PI3KC2β WT (A-431-C2β) and subjected it for the pull-down with lysates of 
COS-1 cells transfected with Dbl domains, which turned out to be the best system for Dbl 
mutants’ expression. In A-431-C2β cells the kinase associated with Eps8/Abi1/Sos1 complex 
and was localized in the cytosol, but also in the actin cytoskeleton, particularly in cell 
protrusions and ruffling regions of the plasma membrane at the edges of cells colonies [103]. 
Surprisingly, my results showed that PI3KC2β purified form A-431-C2β cells bound only to 
onco-Dbl mutant expressed in COS-1 cells, but not to the spectrin- and PH- domain (Fig. 3-7 
A), as I observed in COS-1 cells co-transfected with PI3KC2β and Dbl mutants (Fig. 3-5 B). 
Unexpectedly, it did not bind to NT- and spectrin- domain, or to PH-Dbl (Fig. 3-7 A), 
suggesting that proteins possibly immunoprecipitated with PI3KC2β from A-431-C2β cells 
function in the complex, which preferentially interact with onco-Dbl than with proto-Dbl 
characteristic domains. It is therefore possible that in cancer cells different molecular 
mechanism exists, which facilitate PI3KC2β binding with oncogenic form of Dbl rather than 
proto-Dbl. It other words, in some cancers carrying an N-terminal domain Dbl truncation 
mutation, PI3KC2β potentially may play an important role in the Dbl-dependent 
tumorigenesis.  
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Figure 3-7. PI3KC2β interact with onco-Dbl when purified from cancer cells. Western blot 
analysis representing pull-down experiment (PD) of Myc-tagged PI3KC2β, immunopurified from A-431 
cells over-expressing PI3KC2β and immobilized on Protein G beads (A), with whole cell extracts 
(WCE) of COS-1 cells transfected with Dbl mutants, namely NT-, spectrin-, onco- and PH- doamins 
(B). Transfection efficiency and interaction of PI3KC2β with onco-Dbl was studied with indicated 
antibodies. 
 
 
The assembly of the PI3KC2β/Dbl complex is not modulated by PI3K activity or cell 
stimulation with EGF or PDGF 
 
The data presented above demonstrated PI3KC2β complex formation with Dbl, which 
potentially explains modulation of Rho/Rac activity in mouse fibroblats over-expressing the 
kinase, and results in the kinase-dependent enlargement of the cell body, generation of the 
stress fibers and ruffles. Although an in vitro binding assay did not show a direct or Grb2-
mediated PI3KC2β association with GEF, it did not exclude a role for the PI3KC2β catalytic 
activity in the control of Dbl. In order to further investigate the significance of PI3KC2β kinase 
activity for its interaction with Dbl, we assessed the ability of PI3KC2β WT and DN to interact 
with Dbl in transiently transfected HEK293 cells and stably transfected NIH3T3 cells. In 
HEK293 cells, both PI3KC2β WT and DN interacted with endogenous or ectopically 
expressed (HA-tag) Dbl in a similar manner (Fig. 3-8 A). This observation was confirmed in 
NIH3T3-C2β-WT and NIH3T3-C2β-DN cells (Fig. 3-8 B), that suggested lack of the PI3KC2β 
kinase activity requirement for complex formation with Dbl. 
Results form our lab showed increased Rho/Rac activity in NIH3T3 cells over-
expressing the kinase upon growth factor stimulation (Blajecka et al. 2012, manuscript 
accepted). Therefore, we next assessed whether the PI3KC2β/Dbl complex was 
constitutively assembled, or induced by cell stimulation with polypeptide growth factors. The 
PI3KC2β/Dbl interaction could be detected in serum-starved NIH3T3-C2β-WT cells, and the 
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interaction was apparently not increased by cell stimulation with EGF or PDGF from 5’ up to 
30’ (Fig. 3-8 C). Phosphorylation of extracellular signal-regulated kinase (Erk) was examined 
on cell lysates as growth factors stimulation control. 
 
 
 
Figure 3-8. PI3KC2β kinase activity and growth factor stimulation is not required for complex 
formation with Dbl. (A) HEK293 cells were transfected with vectors encoding Dbl in combination with 
Myc-PI3KC2β WT or DN, or empty vector. Immunoprecipitates prepared with anti-Dbl or anti-Myc-tag 
antibodies were analysed by western blot with the antibodies indicated. (B) Lysates from NIH3T3-V, -
C2β-WT or -C2β-DN cells were immunoprecipitated with anti-Dbl antibodies and analysed by western 
blot for an interaction with Dbl. (C) NIH3T3-C2β-WT cells were serum-starved (0.5% FCS) for 16 hrs, 
and were stimulated with EGF (20 ng/ml) or PDGF (20 ng/ml) for the indicated lengths of time. 
Immunoprecipitates prepared with anti-Glu (EE) tag antibodies were analysed by western blot with the 
antibodies indicated. Phosphorylation of Erk was investigated as growth factor stimulation control. 
 
 We finally investigated whether the catalytic activity of PI3KC2β contributes to the 
activation of Dbl GEF activity. In transiently transfected HEK293 cells, ectopic expression of 
PI3KC2β WT or DN did not alter the GEF activity of endogenous Dbl towards RhoA (Fig. 3-
9). Taken together, these results indicate that PI3KC2β lipid kinase activity is not required for 
its association with Dbl, and does not modulate Dbl activity measured in vitro.  
 
 
 
Figure 3-9. PI3KC2β does not modulate Dbl activity in vitro. HEK293 cells were transfected with 
vectors encoding Dbl in combination with Myc-PI3KC2β WT or DN, or empty vector. 
Immunoprecipitates prepared with anti-Dbl antibody were analysed for GEF activity towards 
recombinant RhoA. 
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3.1.4. Material and Methods 
 
Reagents and Antibodies 
 
The following antibodies were used: PI3KC2β was described in [72], 9E10 myc epitope, Dbl, 
Grb2, RhoA (Santa Cruz Biotechnology, Santa Cruz, CA, USA); Src (Epitomics, CA, USA); 
β-actin (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland); donkey anti-rabbit IgG or sheep 
anti-mouse IgG secondary antibodies (1:10000 dilution) coupled with horseradish peroxidase 
(Amersham Biosciences). Anti-EE antibody was kindly provided by Julian Downward 
(CRUK). Alexa Fluor 555 was obtained from Invitrogen. Recombinant EGF, PDGF BB were 
purchased from Calbiochem, La Jolla, CA, USA. Guanosine 5’-diphosphate sodium salt 
(GDP) and guanosine 5’-triphosphate sodium salt (GTPγS), thrombin and p-
aminobenzamidine-agarose were purchased from Sigma-Aldrich Chemie GmbH, Buchs, 
Switzerland. 
 
Cell Culture 
Mouse NIH3T3 fibroblast, HEK293 (human embryonic kidney 293), COS-1 (African green 
monkey kidney fibroblast-like) and A-431 epidermoid carcinoma cells over-expressing 
PI3KC2β wild-type were grown in DMEM medium (Life Technologies/Invitrogen) 
supplemented with 10% FCS, 1% penicillin/streptomycin and 1% of L-glutamine (v/v), and 
were passaged every 3 to 5 days by trypsinization. Cell cultures were incubated in a 
humidified atmosphere of 5% CO2 at 37°C. Stably transfected NIH3T3 clones and A-431 
over-expressing PI3KC2β were grown in the presence of 0.8 mg/ml G418 or 1 mg/ml G418, 
respectively. NIH3T3 cell lines stably expressing Glu-tagged PI3KC2β wild-type (WT) and A-
431 cells stably expressing Myc-tagged PI3KC2β wild-type (WT) were described previously 
[77]. 
 
Plasmids 
 
The cDNA constructs encoding NH2-terminal Glu- (MEFMPME) or Myc- (MEQKLISEEDL) 
epitope tags and  dominant-negative kinase-dead PI3K-C2β (DN) were described previously 
[72, 99, 103]. HA-tagged proto-Dbl wild-type and GST-fused Dbl mutant constructs were a 
kind gift of Prof. Danny Manor from the School of Medicine at Case Western Reserve 
University, Cleveland, USA, and were described in [179]. Constructs encoding GST-PI3KC2β 
N-terminal and C2 C-terminal domains, GST-Grb2 and RhoA-CA-GST(V14) were purchased 
from Addgene repository. Construct of GST-rhotekin in pGEX-2T vector was a kind gift of 
Prof. Pontus Aspenström from the Department of Microbiology, Tumor and Cell Biology at 
Karolinska Institutet, Stockholm, Sweden. 
52 
 
Transient Transfections 
 
HEK293 cells were transiently transfected with a Ca2+ phosphate protocol [72], while NIH3T3 
and COS-1 cells were transfected with Lipofectamine 2000 or Lipofectamine LTX 
(Invitrogen), according to the manufacturer’s instructions. 
 
Growth Factor Stimulations   
 
NIH3T3 cells stably expressing PI3KC2β wild-type (WT) were grown to confluency and 
starved overnight (16 hrs) in DMEM containing 0.5% FCS and penicillin/streptomycin/L-
glutamine. Cells were then stimulated with the EGF (20 ng/ml) or PDGF (20 ng/ml) for the 
indicated lengths of time. Cellular lysates were prepared as described below.  
 
Cell Lysis 
 
NIH3T3, COS1, HEK293 and A-431-C2βWT cellular lysates were prepared in Triton 1% 
buffer (50 mM Tris.Cl pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 
0.5% NP-40) supplemented with 7 x concentrated stock of Complete Mini Protease Inhibitor 
Coctail (Roche Applied Sciences) and with the phosphatase inhibitors: sodium fluoride (1 
mM NaF), sodium ortho-vanadate (1 mM Na3VO4) and β-glycerophosphate (10 mM). For the 
studies of endogenous complex formation in IMR5 cells Triton 0.5% and Brij96 1% lysis 
buffers (50 mM Tris.Cl pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Brij96) 
supplemented with 7 x concentrated stock of protease and phosphatase inhibitors were 
used, as indicated in the figure legends. Cell pellet was removed by centrifugation for 30 min. 
(15,000 rpm at 4°C). The lysates were equalized for protein content with the Thermo 
Scientific Pierce BCA Protein Assay Kit and subjected to immunoprecipitation or loaded on 
SDS-polyacrylamide gel (SDS/PAGE) as a whole cell extracts (WCE). Prior loading on the 
gel, samples were supplemented with SDS sample buffer (50 mM Tris.HCl, pH 6.8, 2% or 
5% SDS, 10% glycerol, 200mM DTT, and 0.25% bromophenol blue) and denatured for 5 
min. at 95°C.  
 
Western Blot 
 
Proteins were separated by SDS/PAGE electrophoresis and immunoblotted on 
polyvinylidene fluoride membrane PVDF (Amersham, GE Healthcare, UK). Membranes were 
then blocked in 5% non-fat dry milk in 1x phosphate-buffered saline (PBS) over-night at 4°C. 
Washings were done in 1x PBS-Tween (0.1%). Incubation with the primary antibodies 
(diluted according to the manufacturer's protocol) was performed in 4°C over-night, and with 
the secondary antibodies 1 h at room temperature. Chemiluminescence was detected using 
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SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific Inc., 
Rockford, IL, USA). 
 
Immunoprecipitation 
 
Cells were grown to confluence in 10-cm dishes, washed with ice cold 1x PBS before lysis 
on ice for 20 min. in 0.5-1 ml of Triton 1% lysis buffer (as described above). Insoluble 
material was removed by centrifugation for 30 min. (15000 rpm at 4°C). Immunoprecipitation 
with primary antibodies (diluted according to the manufacturer's instructions) was conducted 
on cell lysates equalized for protein content. Incubation with the respective primary 
antibodies was performed at 4°C for 2 hrs. Protein A or G Sepharose 4 Fast Flow beads 
(Amersham, GE Healthcare, UK) were then added respectively and the incubation was 
continued for 1 h at 4°C. Immunoprecipitates were washed three times in the lysis buffer and 
resuspended in 2x SDS sample buffer (50 mM Tris.HCl, pH 6.8, 2% SDS, 10% glycerol, 
200mM DTT, and 0.25% bromophenol blue). Samples were denatured for 3-5 min. at 95°C 
and analysed by SDS/PAGE and western blot. 
 
Production of GST-Fusion Proteins 
 
GST-fused N-terminal and C2 C-terminal domains of PI3KC2β, Grb2-GST, rhotekin-GST, 
RhoA-CA-GST(V14) in pGEX-2T expression vectors were propagated in Escherichia coli 
BL21 cells. Incubation proceeded at 37°C until OD600 reached 0.5. Protein expression was 
induced with 0.2 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and continued at 30°C for 
3-4h. Bacteria were collected by centrifugation and resuspended in lysis buffer. For 
purification of GST-PI3KC2β-NT, –CT-C2 and GST-Grb2 following lysis buffer was used: 50 
mM Tris HCl pH 7.5, 150 mM NaCl, 5mM EDTA pH 8.0 and 1% Triton supplemented with 7 x 
concentrated stock of Complete Mini Protease Inhibitor Coctail (Roche Applied Sciences) 
and with the phosphatase inhibitors (1 mM PMSF, 10 µM leupeptin, 10 µM pepstatin, 5 mM 
benzamidin, 1 mM DTT, 1 µl/ml aprotinin, 1 mM NaF, 1 mM Na3VO4). For purification of 
rhotekin-GST and RhoA-CA-GST(V14) lysis buffer was changed to: 50 mM Tris-HCl pH 7.5, 
50 mM NaCl, 5 mM MgCl2, 1 mM DTT and 1 mM PMSF. Bacteria were thereafter sonicated 
on ice 3 times for 45 sec with 1 min. intervals. The lysed cells were clarified by centrifugation 
at 15000 for 30 min. at 4°C. GST-fusion proteins were affinity-purified from the resulting 
supernatants by addition of glutathione-sepharose beads (Amersham Biosciences, Upsalla, 
Sweden) followed by incubation at 4°C for 60 min. The glutathione-sepharose beads were 
collected by centrifugation (2000 rpm) at 4°C followed by four washes with washing buffer: for 
GST-PI3KC2β-NT and –CT-C2 and Grb2 lysis buffer was used, and for the rhotekin-GST 
and RhoA-CA-GST(V14) buffer containing 50 mM Tris-HCl pH 7.5, 0.5% Triton X-100, 
100 mM NaCl, 5 mM MgCl2, 2.5 mM CaCl2, 1 mM DTT was employed. After the final wash, 
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the beads containing GST-PI3KC2β-NT and –CT-C2 and Grb2 proteins were resuspended in 
washing buffer supplemented with 50% glycerol and were stored in -20̊C. Rhotekin-GST was 
resuspended in washing buffer supplemented with 10% glycerol. The beads were divided 
into aliquots of 250 μl and stored in -80̊C. RhoA-CA-GST(V14) was cleaved from the GST by 
thrombin digestion, treated with p-aminobenzamidine-agarose to remove thrombin (Sigma-
Aldrich Chemie GmbH, Buchs, Switzerland), snap-frozen and stored in liquid nitrogen. The 
purity of the GST-fusion proteins was assayed by SDS-PAGE. 
GST-tagged NT-, spectrin-, onco- and PH- Dbl mutants were expressed in COS-1 
cells, lysed with HEPES buffer like previously decribed [179] and purified with glutathione-
sepharose beads (GE Healthcare). Beads containing GST-fusion proteins were washed 3-4x 
with ice-cold HEPES buffer and 2x with washing buffer (50 mM Tris pH=7.5, 150 mM NaCl). 
Next, they were resuspended in the washing buffer supplemented with 1mM DTT and 50% 
glycerol and stored in -20°C. 
 
Pull-down Assays for PI3KC2β/Dbl/Grb2 Interaction 
 
After 48 h of culture, untransfected and transfected with HA-proto-Dbl or pcDNA3 empty 
vector HEK293 cells were washed once with ice-cold 1xPBS. Cell extracts were prepared as 
described above. Protein concentration was determined (Thermo Scientific Pierce BCA 
Protein Assay Kit) and equal volume of lysates were immediately supplemented with 
equimolar amounts of GST-NT-PI3KC2β, GST-(CT)C2-PI3KC2β or GST-Grb2 immobilized 
on gluthatione beads.  In the case of pull-down in COS-1 cell line, cells were co-transfected 
with wild-type PI3KC2β and GST-tagged Dbl domains (NT-, spectrin-, onco-, PH) or pcDNA3 
empty vector and HA-proto-Dbl as control. 48 h post-transfection cell extracts were prepared 
as described above and equal amounts of lysates were supplemented with gluthatione-
sepharose beads (Amersham Biosciences, Upsalla, Sweden) or PI3KC2β wild-type 
immobilized on Protein A-Sepharose beads and immunoprecipitated from A-431 cells 
overexpresing the kinase. Pull-down reactions were then incubated with constant rotation for 
2 h at 4°C. Beads were washed four times with ice-cold lysis buffer. 2 x SDS-PAGE sample 
buffer was added to the beads. Samples were heated at 95°C for 3 min. and subjected to 
SDS-PAGE and western blot analysis. 
 
In Vitro Binding Assay 
  
GST-fused Dbl spectrin- and PH-domains proteins and GST alone were incubated in vitro 
with soluble Grb2- and NT-PI3KC2β- domain in 1% Brij 96 lysis buffer (50 mM Tris.Cl pH 7.4, 
150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Brij96) supplemented with 7 x concentrated 
stock of Complete Mini Protease Inhibitor Coctail (Roche Applied Sciences) and 
phosphatase inhibitors (1 mM NaF, 1 mM Na3VO4, 10 mM β-glycerophosphate). Soluble 
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Grb2- and NT-C2β-domain were obtained from GST-fused Grb2 and NT-PI3KC2β domain as 
a result of digestion with thrombin followed by p-aminobenzamidine-agarose treatment to 
remove the enzyme (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). After constant 
rotation for 2 h, at 4°C, the complexes were washed 3 x with Brij 96 1% lysis buffer. 2 x SDS-
PAGE sample buffer was added, samples were heated at 95°C for 3-5 min. and subjected to 
SDS-PAGE followed by western blot analysis.  
 
GEF Activity Assay 
 
HEK293 cells were transiently transfected with plasmids as described above. Cell lysates 
were prepared as above and immunoprecipitated with anti-Dbl antibody and Protein A-
Sepharose beads. The immunoprecipitates were washed twice with lysis buffer and once 
with GEF reaction buffer (20 mM Tris-HCl pH 7.6, 0.5% Triton X-100, 100 mM NaCl, 10 mM 
MgCl2, 1 mM DTT) and resuspended in GEF reaction buffer on ice. The reaction was started 
by the addition of 1 mM GTPγS and 50 μg/ml purified recombinant GDP-loaded RhoA, which 
was obtained as described previously [196]. Following 30 min. incubation at room 
temperature, samples were placed on ice and supernatants collected. Active RhoA was 
isolated from the supernatants by using GST-rhotekin, which was incubated together with 
lysates by constant rotation at 4°C for 30 min. The beads were thereafter washed 4x with ice-
cold washing buffer (50 mM Tris-HCl pH 7.5, 1% Triton X-100, 150 mM NaCl, 10 mM MgCl2, 
µM leupeptin, 10 µM pepstatin and 1 mM PMSF) and analysed by SDS-PAGE and western 
blot. 
 
Microscopy 
NIH3T3 cells stably transfected with PI3KC2β wild-type (WT), kinase-dead dominant-
negative (DN) and the empty pcDNA3 vector (V) were seeded in DMEM complete medium 
supplemented with 0.8 mg/ml G418 selection antibiotic. 24 hrs after plating morphology 
pictures were taken with Eclipse TS100 inverted microscope (4x and 10x magnification) 
supplied with a Nikon DXM1200 digital camera. 
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3.1.5. Discussion  
 
PI3KC2β role in the complex formation with Dbl 
 
The analysis of PI3KC2β interacting molecules in NIH3T3 fibroblasts revealed a novel 
signalling complex implicated in RhoA and Rac1 activation. We identified the RhoGEF Dbl as 
a novel interaction partner of PI3KC2β and we hypothesise that, in collaboration with Dbl, 
PI3KC2β can modulate RhoA and Rac1 activity and thus control cytoskeletal 
rearrangements. Dbl is a crucial RhoGEF with activity towards Cdc42, RhoA and Rac1 [172]. 
It was also the first mammalian RhoGEF to be identified [165], but the mechanism of its 
activation is still not completely understood. In order to relieve its intrinsic auto-inhibitory 
activity, a physical interaction between the GEF’s N-terminal spectrin- and C-terminal PH-
domain has to be released. This change in the inactive conformation of the protein can be 
triggered by diverse regulatory mechanisms including phosphorylation, or interactions with 
other proteins. In my studies, the prominent binding of PI3KC2β to the spectrin- and PH- 
domain of Dbl was similar to the results reported for Dbl binding to the chaperone Hsc70 
[179] (Fig. 3-5 B). Hsc70 together with Hsp90 and the ubiquitin ligase CHIP keep Dbl activity 
in check by either stabilising its inactive conformation or directing the GEF to proteosomal 
degradation [180]. How PI3KC2β contributes to Hsc-70-Hsp90-CHIP machinery is an 
interesting issue. My results concerning Dbl domains interactions with the kinase supported 
the hypothesis that PI3KC2β may compete with Hcs70 and other Dbl-associated proteins for 
binding to the GEF. In turn, it could induce Hsc70-Hsp90 complex disassembly and opening 
of the GEF inactive conformation resulting in Dbl activation. This model of the Dbl activation 
mechanism was also suggested by Bi et al. [178], who showed that protein factors, 
associated to the actin stress fibers, can bind to Dbl PH domain and compete with the N-
terminal sequences, leading to release of N-terminal constraint. However, an in vitro 
examination of the molecular mechanism of PI3KC2β/Dbl complex formation revealed that 
neither the N-terminal sequence of the PI3K, nor Grb2, directly bound to Dbl, although both 
molecules were present in the PI3KC2β complex isolated from living cells (Fig. 3-6). 
Formation of the Dbl/PI3KC2β complex was observed in serum-starved cells and the 
association was not further promoted by EGF or PDGF stimulation (Fig. 3-8 C). In addition, 
no evidence was found for a role of PI3KC2β in the activation of Dbl GEF activity, at least 
when measuring its activity in vitro (Fig. 3-9). It is therefore convincing that PI3KC2β plays a 
different role than direct regulation of Dbl activity in the protein complex. Other molecular 
mechanims involving the kinase and GEF must be involved for an increased Rho/Rac 
activation and observed phenotypes in the NIH3T3 cells. 
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PI3KC2β role in Dbl activation 
 
The biological activity of proto-Dbl is in fact dependent on a combination of 
mechanisms that involve not only intramolecular interactions, but also N- and C-terminal 
domain-dependent turnover of the protein, and the PH domain binding to PtdIns [182]. It is 
possible that PI3KC2β alters the intracellular localization of Dbl by generating PtdIns(3)P or 
PtdIns(3,4)P2 [72], which are considered as the main lipid products of the kinase. PI3KC2β 
potential to generate PI(3,4,5)P3 was shown only in the presence of equimolar amounts of 
phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE). Moreover, the activity of the PI3KC2β toward PtdIns(4,5)P2 
was only about 1% of the whole PI3K activity under this conditions [72]. Interestingly, the Dbl 
PH domain was shown to not bind to PI3KC2β substrates (PtdIns and PtdIns(4)P) and 
product (PtdIns(3)P) in vitro, whereas the binding to PtdIns(3,4)P2 product was not studied 
[189]. In contrast, the PH domain of Dbl associated with PtdIns(4,5)P2 and PtdIns(3,4,5)P3, 
and caused marked inhibiton of Dbl GEF activity, which was directly dependent on 
phospholipids concentration [189]. PtdIns and PtdIns(3)P did not have a significant effect on 
Dbl-mediated GDP dissociation from Cdc42 [189]. It would be therefore interesting to check 
whether the PI3KC2β product PtdIns(3,4)P2 can be of any significance in triggering of proto-
Dbl open, active conformation. However, it is important to mention here that according to the 
current knowledge, PtdIns(3)P is the main in vivo product of PI3KC2β [67]. The generation of 
PtdIns(3,4)P2 by Drosophila, murine and human PI3KC2β was demonstrated in vitro in the 
original studies, but was not investigated later [68, 69, 72]. In addition, the in vitro activity of 
the enzyme towards PtdIns(4)P was much lower than towards PtdIns. Therefore, the clear 
demonstration of PtdIns(3,4)P2 in vivo synthesis by PI3KC2β would be first important thing to 
show. 
The presence of Dbl in the complex with PI3KC2β in the NIH3T3 cells over-
expressing the kinase (Fig. 3-8 B), as well as the increase in Rho/Rac activity (Blajecka et al. 
2012, manuscript accepted) in this cell line suggested that both proteins the GEF and the 
kinase are components of the same signaling pathway. Moreover, overexpression of 
PI3KC2β in mouse fibroblasts induced cell enlargement, stress fibers and ruffles formation 
(Fig. 3-1). A similar phenotype was observed before in NIH3T3 cells transfected with proto-
Dbl or PH-Dbl domain [182, 189]. Cells were flat, elongated and slightly enlarged, the actin 
cytoskeleton was organized in stress fibers and membrane ruffles were visible at the cell 
surface [182, 189]. These results indicate that PI3KC2β and Dbl might be implicated in the 
same pathway controling the same cellular responses, what supports the fact that PI3KC2β 
may indirectly influence the GEF’s activity. The reason why this could not be detected in the 
GEF activity assay may arise from the fact that Dbl may be more active in the cell, but not 
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after immunoprecipitation, during which part(s) of the complex may be lost. It is not unlikely, 
since isolating multiprotein complexes from cells can be problematic, for instance isolation of 
huge mTOR complexes [197] (Prof. Loewith, personal communication). Moreover, another 
possibility exists that in order to see PI3KC2β-dependent Dbl activation, cells would need to 
be stimulated with ligands. Stimulaton of NIH3T3 cells over-expressing PI3KC2β did not 
increase complex formation with endogenous Dbl (Fig. 3-8 C). However, maybe it would be 
needed for Dbl activation. Preliminary results from our lab showed increased Rac1 and RhoA 
activity upon respective stimulation with PDGF or LPA in NIH3T3-C2β-WT cells in 
comparison to NIH3T3-C2β-DN stable cell lines (not shown; Blajecka et al. 2012, manuscript 
accepted). It is possible that, to see the difference in PI3KC2β-WT or –DN-dependent Dbl 
activation, stimulation with ligands would be required. Unfortunately, there is not much data 
available yet concerning proto-Dbl response to external stimuli. One report describes Dbl 
tyrosine phosphorylation and resulting RhoGTPases activation upon EGF stimulation [188]. 
Possible involvement of other ligands in releasing Dbl inactive conformation awaits further 
examination. 
Moreover, some other studies, which used NIH3T3 cells stably transfected with proto-
Dbl, showed PI3K-dependent and proto-Dbl-mediated increase in Rac activation, membrane 
ruffles formation and cell motility [198]. Inhibition of PI3Ks with LY294002 caused enhanced 
proto-Dbl translocation to the membrane colocalizing with the ruffling areas, and increased 
GTPase activation. However, influence of the PI3K on the proto-Dbl activity in vitro was not 
shown. In the light of our results demonstrating lack of direct PI3KC2β-mediated Dbl 
activation, these resuts can suggest indirect involvement of PI3KC2β in the activation of the 
cytoskeletal rearrangements in NIH3T3 through Dbl-dependent mechanism. Whether this 
mechanism involves PI3KC2β-mediated generation of phosphorylated lipids in the 
membrane would need to be investigated.  
Last but not least, the lack of an effect of PI3KC2β in the activation of Dbl GEF 
activity in vitro suggests that other molecules need to be present in the cells, which mediate 
the interaction of the class II PI3K with Dbl and the GEF activation, resulting in the observed 
phenotypes in the NIH3T3 cells. The identity of these putative additional binding partners 
involved in the Dbl/PI3KC2β complex is briefly discussed below.  
 
 
Additional putative binding partners of Dbl/PI3KC2β complex – variations on the theme 
 
One of the PI3KC2β binding partners, which could play a role in Dbl GEF activation, 
is the Grb2 adaptor molecule. It was previously shown to recruit PI3KC2β to the EGFR in the 
plasma membrane in both basal and EGF-stimulated conditions [94]. Moreover, Grb2 was 
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also reported to be crucial for the EGF-dependent Dbl phosphorylation by non-receptor 
tyrosine kinase ACK1 (activated Cdc42Hs-associated kinase), which was co-
immunoprecipitated with Dbl [184, 188]. ACK1 is a widely expressed protein, which belongs 
to the focal adhesion family of kinases. Through its proline-rich motifs ACK1 is recruited to 
the membrane via N-terminal SH3 domain of Grb2 adaptor protein and it is activated 
downstream of the EGFR and PDGFR [184, 188, 199]. Upon activation, it further 
phosphorylates Dbl, which increases its GEF activity torward Cdc42 and Rho [184]. These 
data taken together with my observations that Grb2 is present in the Dbl/PI3KC2β complex in 
the NIH3T3 and HEK293 cells support the model that PI3KC2β builds a complex consisting 
of Grb2, ACK1 and Dbl. Furthermore, this complex may be important for Rho GTPases 
activation in serum-supplemented conditions and upon EGF or PDGF stimulation. Upon EGF 
stimulation PI3KC2β is recruited to the plasma membrane via Grb2, which recruits also 
ACK1 complexed with an active RhoGTPase. ACK1 was in fact shown to phosphorylate Dbl 
only when complexed with Grb2 and Cdc42-GTP [188]. Being in close proximity to GEF, 
ACK1 could therefore bind to Dbl and phosphorylate it leading to signaling cascade 
activation consisting of Cdc42, Rac and Rho that regulates stress fibers and membrane 
ruffles formation in fibroblasts [200]. This model seems to be consistent with my results, 
which showed Grb2 interaction with Dbl in the HEK293 cells pull-down (Fig. 3-4 B), although 
the association was not direct, according to the in vitro binding assay (Fig. 3-6 A). It could 
therefore mean that Grb2 binds to ptoto-Dbl through ACK1 non-receptor tyrosine kinase and 
presence of this protein is necessary for the GEF activation. A schematic model of 
PI3KC2β/Dbl complex formation and its activation mediated by Grb2/Ack1-dependent 
interactions is illustrated on Fig. 3-10. However, one has to be aware that the experiments 
with EGF and PDGF stumulation did not increase PI3KC2β/Dbl association, suggesting 
constitutive complex assembly (Fig. 3-8 C). Therefore, further investigations of the complex 
formation in the NIH3T3 cells co-transfected with PI3KC2β and ACK1 would be required to 
verify this model. In the same conditions, Dbl phosphorylation status and its activity could be 
studied, as well as the role of PI3KC2β in activation of the Grb2/ACK1/RhoGTPase complex. 
As indicated already in the previous section, due to multi-domain structure, activation 
of Dbl is possibly dependent on different molecular mechanisms precisely controlled in the 
spatio-temporal manner. Therefore, involvement of other factors cannot be ruled out. For 
instance in NIH3T3 cells, Dbl binds also to the active α-subunit of the heterotrimeric G 
protein G13, resulting in the activation of RhoA and cytoskeletal rearrangements [186]. 
Proto-Dbl may be activated by Gα13 through a mechanism which involves an association 
with ezrin, an ezrin-radixin-moesin (ERM) family protein, which links the plasma membrane 
to the actin cytoskeleton [187]. When Dbl is activated, it translocates to the membrane. 
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Treatment of cells with LPA induced translocation of proto-Dbl to the plasma membrane, 
which in turn caused changes in the cell morphology, which were characterized by increased 
membrane ruffling and lamellipodia formation, as well as enlargement of the cell body [187]. 
However, when Dbl binds to the Gβγ subunits of heterotrimeric G protein with its N-terminal 
sequence, its GEF activity remains unchanged [185]. Gβγ can directly bind to the N-terminal 
53-99 residues of proto-Dbl but it does not increase Dbl GEF activity towards RhoA and 
Cdc42. Therefore additional factors may be required for full activation of Dbl [185]. 
EGFR/PI3KC2β- and Ack1-dependent signals may cooperate with Gβγ to trigger Dbl 
activation, because numerous types of receptors are likely to be activated simultaneously in 
vivo [201]. 
Dbl is also known to interact with membrane-cytoskeleton linkers, which control actin-
based cellular functions such as cell migration or adhesion [202]. In addition to other GEFs, it 
has been shown recently to associate with an active myosin II (MII) assembled with actin 
filaments in NIH3T3 cells [203]. Non-muscle MII controls RhoGTPases activity and in turn 
stress fibers, cell protrusion and focal complex formation in migrating cells. The interaction of 
MII with Dbl family GEFs blocks their activity toward GTPases. However, PDGF-induced 
inhibition of MII activity leads to the release of βPIX GEF, and in turn promotes transient 
increase of RhoGTPases activity [203]. It would be therefore interesting to investigate 
whether PI3KC2β/Dbl complex formation in NIH3T3 cells is somehow related to myosin II-
dependent regulation of GTPases and cytoskeleton rearrangements. The class II PI3KC2α 
can increase contractility of vascular smooth muscle cells by stimulation of MII interaction 
with actin filaments via Ca2+-dependent Rho signalling pathway [119]. Further studies are 
needed to verify whether PI3KC2β would be able to control RhoGTPases activity by MII 
mode of action.  
Figure 3-10. Hypothetical model of PI3KC2β/Dbl 
complex formation and activation. Upon EGF 
stimulation PI3KC2β is recruited to the plasma 
membrane via C-terminal SH3 Grb2 domain. Through its 
N-terminal SH3 domain Grb2 binds ACK1, which 
become activated upon association to GTP-bound 
Cdc42. Being in close proximity to GEF, ACK1 binds to 
Dbl and phosphorylates it leading to Rho GTPase 
signaling cascade activation that controls cytoskeletal 
remodeling. 
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Potential role of PI3KC2B/Dbl interaction in neuroblastoma 
 
There have been many interesting reports published in recent years about the class II 
PI3KC2β involvement in human cancer. They emphasize an important role of the kinase in 
cytoskeletal rearrangements resulting in increased cancer cell migration, invasion and 
metastasis, but also its function in resistance to chemotherapeutics [83, 103, 139, 141]. 
Amplification or up-regulation of the PI3KC2β gene and protein have been shown in 
numerous types of human cancers not excluding neuroendocrine tumors, which arise from 
endocrine and nervous systems, such as small cell lung cancer and neuroblastoma [129]. 
Various PI3KC2β expression levels in different types of tumors might result from its 
ubiquitous expression and possible involvement in some general molecular mechanisms and 
responses, present in every cell, independently of the tissue and organs. Dbl proto-oncogene 
expression on the other hand, has been confined to the specific tissues of neuroendocrine 
and neuroectodermal origin (gonads and central or peripheral nervous system), as well as to 
some cancers, which derive form that tissues [170, 191-193]. It can therefore play more 
specialized functions than PI3KC2β. Even within the tumors of the same origin it was not 
equally expressed suggesting its unique function. Although in some studies proto-Dbl mRNA 
expression was not found in neuroblastoma specimens and cell lines [191, 192], in other 
research oncogenic Dbl was detected in the IMR32 neuroblastoma cell line [193], suggesting 
cell line specific expression. Similarly, in my results I could show proto-Dbl expression in 
IMR5 neuroblastoma cells, which also displayed relatively high PI3KC2β expression and 
further formed a complex with endogenous Dbl (Fig. 3-3 B). Up-regulation of PI3KC2β 
expression in IMR5 cell line was also shown recently by Russo and O’Bryan [114]. Moreover, 
a strong functional dependence of PI3KC2β and intersectin 1 (INTS1) scaffolding molecule 
has been observed. Over-expression of PI3KC2β in the IMR5 cell line, which was intersectin 
1 (INTS1)-silenced, rescued anchorage-independent growth of these cells, confirming the 
fact that PI3KC2β is essential for neuroblastoma tumorigenesis [114]. A physical interaction 
of the PI3KC2β N-terminus (proline-rich motifs) with INTS SH3 domain was described before 
and it was shown to be important for increase of PI3KC2β activity and Akt-dependent 
regulation of neuron cells survival [104]. My results demonstrate that PI3KC2β interacts with 
Dbl in IMR5 neuroblastoma cells suggesting potential role of the complex in this cancer 
progression. It would be interesting to investigate whether there is a similar functional 
interdependence between the kinase and the GEF as in the case of PI3KC2β and INTS in 
neuroblastoma cells. Beside its multi-domain scaffolding role, INTS can also possess 
guanine exchange factor activity toward Cdc42, which is dependent on the splice variant 
[114]. A direct association of PI3KC2β and Dbl was however not found in the in vitro binding 
assay (Fig. 3-6 A), as well as increased Dbl GEF activity when co-transfected with PI3KC2β 
(Fig. 3-9). It is therefore possible that there is no strong or straightforward interedependence 
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between the two proteins like it was shown for PI3KC2β and INST. Definitely, more studies 
would be needed to reveal potential role and functions of PI3KC2β/Dbl complex formation in 
neuroblastoma.  
 
 
PI3KC2β and onco-Dbl – is there a common pathway in cancer? 
 
An interesting result was obtained when PI3KC2β was immunoprecipitated from A-
431 epidermoid carcinoma cells over-expressing the kinase and incubated with lysates of 
COS-1 cells transfected with Dbl domains. In contrast to pull-downs performed in the non-
cancerous COS-1 cell line, PI3KC2β bound only to onco-Dbl mutant, but not to spectrin- and 
PH- domains (Fig. 3-7). Although these two experiments cannot be fully compared due to a 
slightly different experimental setting, they suggest that in some specific conditions, PI3KC2β 
has a potential to bind not only prototype Dbl, but also its oncogenic counterpart. The 
hypothesis that PI3KC2β immunoprecipitated from A-431-C2β cells function in the complex, 
which preferentially interact with onco-Dbl than with proto-Dbl domains might be supported 
by the fact that regulation of onco-Dbl in many different aspects seems to be very different 
than that of proto-Dbl [182]. Major discrepancies concern proteins localization, stability and 
transforming potential and they all arise from the differences in the domain structure of 
prototype and oncogenic Dbl. The presence in proto-Dbl of the N-terminal domain, which 
interacts with C-terminal PH module, limits membrane localization of the protein and 
completely prevents its cytoskeletal association. The N terminus of proto-Dbl dictates 
perinuclear and cytosolic distribution pattern of the protein, whilst the onco-Dbl localize to the 
plasma membrane and actin cytoskeleton components such as actin stress fibers [178, 182]. 
The PH domain of onco-Dbl is in fact fully exposed and due to that is able to interact with 
cytoskeleton proteins in the absence of lipid binding capacity [182]. It can therefore partially 
explain why PI3KC2β immunoprecipitated from A-431-C2β cells bound preferentially to onco-
Dbl, but not to proto-Dbl domains (Fig. 3-7 A). To some extent PI3KC2β localized to cell 
protrusions and ruffling regions of the plasma membrane, where Eps8 and Abi1 were also 
localized [103]. Since these proteins were isolated together from A-431-C2β cells in one 
PI3KC2β-Eps8/Abi1/Sos1 complex [103], it is likely that they were present also in the 
PI3KC2β immunoprecipitate. It is therefore reasonable to assume that in the pull-down with 
COS-1 cells transfected with Dbl domains, they could become a target for onco-Dbl rather 
than N-terminus and spectrin domains, which do not bind cytoskeletal proteins [178]. In this 
context however it is difficult to explain why PI3KC2β did not bind PH-Dbl domain, since it 
was shown before to colocalize with actin stress fibers and it determines onco-Dbl 
distribution pattern. Therefore additional possibility exists, which includes a contribution from 
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the EGFR. A-431 cells over-express the EGFR and PI3KC2β binds to EGFR through Grb2 
[94].  
Onco-Dbl was not frequently detected in primary cancer specimens or cell lines. It 
was mostly the proto-Dbl transcript of 5 kb size, which was found over-expressed in 
neuroectodermal tumors [191, 192]. However, the 2.8 kb N-terminal-truncated RNA form of 
Dbl was detected in a set of primary tumors, nude mice xenografts and cell lines of variety of 
childhood tumors, such as Ewing’s sarcoma, PNET, NB, rhabdomyosarcoma, 
retinoblastoma, and some of the non-neural tumors, such as synovial sarcoma and 
osteosarcoma [193]. It is still not clear how Dbl oncogenic mutation can be triggered in 
cancer. At the time of onco-Dbl identification, it was not present in the oncogenic form in the 
DNA of the original NPDL or human diffuse B cell lymphoma, but it was detected in the DNA 
after transfection into NIH3T3 cells, suggesting that oncogenic truncation mutation might be 
induced by the process of gene transfer in vitro or might be present in vivo in only a minority 
of tumor cells [166]. However, since onco-Dbl was detected in some tumors, where PI3KC2β 
was found over-expressed [129], and since I have found an interaction between these two 
proteins, we cannot exclude that they may play a potential role also in the onco-Dbl-
dependent tumorigenesis. 
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3.1.6. Conclusions and outlook 
 
The aim of this project was to investigate the mechanism of PI3KC2β/Dbl interaction 
and the role it plays in cytoskeletal remodelling in mouse fibroblasts. An association between 
endogenous PI3KC2β and Dbl in NIH3T3 and neuroblastoma cancer cells IMR5 was 
observed. However, PI3K kinase activity did not seem to be required for the complex 
assembly. Growth factors stimulation did not enhance the interaction, suggesting a 
constitutive complex formation. The PI3KC2β/Dbl binding was mediated by the N-terminal 
regulatory region of the kinase and Dbl spectrin- and PH- GEF domains. These interactions 
resembled an association of proto-Dbl with the Hsc70-Hsp90 chaperone complex, but did not 
appear to be direct, suggesting the involvement of additional binding partners mediating 
PI3KC2β/Dbl association and indicating a more complicated mechanism of PI3KC2β-
dependent Dbl regulation. These results were supported by the lack of GEF activity of Dbl 
toward Rho GTPase in the in vitro GEF activity assay. No difference in Dbl activity was 
observed upon its isolation from HEK293 cells transfected with PI3KC2β wild-type and 
dominant-negative (kinase-dead) form. Therefore, the possibility exists that some additional 
factors are needed to induce Dbl activation in a PI3KC2β-dependent manner. One of the 
candidates could be the ACK1 non-receptor tyrosine kinase, which was shown to 
phosphorylate and thus activate Dbl upon EGF stimulation in a Grb2- and Rho GTPase-
mediated manner. Consequently, the phosphorylation status of Dbl, as well as the 
PI3KC2β/Dbl complex assembly could be investigated upon co-transfection of the ACK1 and 
PI3KC2β-WT and –DN in mouse fibroblasts.  
The role of PI3KC2β in the complex with Dbl remains not completely understood. It is not 
clear whether it plays kinase activity-independent scaffolding role or whether its PI3K 
function is essential for indirect Dbl activation in the multi-protein complex. Taking into 
consideration the complicated mechanism of the GEF regulation it is likely that PI3KC2β lipid 
substrates or products in the plasma membrane may be important for modulation of Dbl 
activity and function. To become fully active GEFs require combination of different molecular 
events and multiple signals, which includes also translocation to the plasma membrane or 
protein-protein interactions. It is possible that, similarly to PI3KC2α, the PI3KC2β isoform 
activates RhoGTPases in NIH3T3 cells in concert with Dbl and actin filament-associated 
proteins such as MII. These and other aspects of the PI3KC2β-dependent machinery in 
NIH3T3 cells such as direct evidence that the PI3KC2β/Dbl complex is needed for the 
observed phenotype would be worth studying. It would be important to clarify whether 
PI3KC2β positively affects RhoA activation and if the Dbl binding is of any function. 
Investigating PI3KC2β/Dbl complex assembly in human cancer cells, such as neuroblastoma 
cells could be another exciting area of reaserch. 
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3.2. Identification and Functional Characterization of PI3KC2β N-terminus Tyrosine 
Phosphorylation Sites (Project II) 
 
3.2.1. Summary 
 
 To date the posttranslational modifications role of class II PI3Ks in the enzymes’ 
regulation and functions in different cellular responses has not been extensively studied. 
PI3KC2β tyrosine phosphorylation has been found in few cancerous and non-cancerous cell 
lines upon RTKs stimulation. In order to investigate PI3KC2β regulation by tyrosine 
phosphorylation, as well as the functional relevance of PI3KC2β tyrosine phosphorylation 
sites, we identified by mass spectrometry four new tyrosine phosphorylation sites in PI3KC2β 
isolated from human cancer cell lines. Y68, Y127, Y228 and Y1541 appeared to be 
consensus sites among different vertebrate species indicating a conservation of their 
function. Mutation of tyrosine 127 and 228 to phenylalanine in the N-terminal regulatory 
region of the PI3KC2β wild-type induced increased cell proliferation and cell-cell adhesions 
formation in HT-29 colon cancer cells stably transfected wih the double mutant. Similar 
results were obtained for PI3KC2β kinase-dead form of the enzyme, indicating kinase-
dependent mechanism of regulation. In contrast, PI3KC2β-WT transfection in HT-29 cells 
had no impact on cell proliferation and adherens junction formation. Furthermore, activation 
of Akt increased upon EGF stimulation of HT-29 cells over-expressing PI3KC2β Y127/228F 
mutant in comparison to cells expressing PI3KC2β-WT. These results suggest that 
phosphorylation of Y127 and Y228 in PI3KC2β-WT may negatively regulate PI3KC2β 
function and downstream signaling through generation of phosphorylated lipids in the plasma 
membrane. Taken together, our findings reveal for the first time that PI3KC2β tyrosine 
phosphorylation of N-terminal regulatory domain contributes to the control of cell proliferation 
and the formation of cell-cell junctions in human cancer cells. 
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3.2.2. Introduction 
 
PI3KC2β belongs to the class II family of conserved phosphoinositide 3-kinases, 
which was shown to be essential for cell migration/adhesion processes, protection against 
anoikis and cell proliferation downstream of RTKs and GPCRs [83, 84, 103]. Association with 
RTKs such us EGFR, PDGF, c-Kit, c-Met and IGF-IR upon ligand stimulation has been 
shown to be necessary for the enzyme activation in a variety of cell line models [77, 99]. 
Tyrosine phosphorylation of PI3KC2β has been observed, but a detailed functional 
investigation of site-specific tyrosine phosphorylations has never been performed. Minimal 
knowledge about the functional context of the other post-translational modifications of 
PI3KC2β comes from open access data bases, which gather the information from a number 
of high-throughput studies. In one of these studies PI3KC2β S155 phosphorylation has been 
found in the set of proteins activated during mitosis, whose phosphorylation is cell cycle-
regulated [204]. In this study, S155 phosphorylation was observed in the M-phase, whereas 
increased abundance of the protein was detected in G1 phase.  
 
Identification of the new tyrosine phosporylation sites in PI3KC2β 
 
In order to understand potential role of tyrosine phosphorylation in the regulation of 
PI3KC2β functions, we have mapped in vivo tyrosine phosphorylation sites within PI3KC2β. 
We employed immunoaffinity purification with P-Tyr-100 antibody followed by tandem mass 
spectrometry (LC-MS/MS) analysis of enriched phospho-tyrosine peptides, from different 
human cancer cell lines, treated with or without pervanadate/calyculin, 10% serum or EGF. 
PhosphoScan/PTMScan has been performed by Cell Signalling Technology (CTS) 
(www.cellsignal.com). Since 10% serum and EGF stimulation are commonly used to induce 
protein phosphorylation, pervanadate and calyculin were respectively used as tyrosine and 
serine/threonine protein phosphatase activity inhibitors to artificially enhance levels of protein 
phosphorylation in the studied cell lines (for detailed list of cell lines and treatments check 
Table 3-1). This functional analysis revealed four novel tyrosine phosphorylation sites within 
the PI3KC2β sequence (Table 3-1). Three of them (Y68, Y127, Y228) were clustered in the 
N-terminal region of the enzyme while the fourth (Y1541) was located in the C-terminal C2 
domain. Fig. 3-11 A and B respectively show the location of newly detected tyrosine 
phosphorylation sites in the sequence and domain structure of PI3KC2β. 
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Table 3-1. PI3KC2β phospho-tyrosine sites (pY) identified in human cancer cell lines 
PI3KC2β pY Site sequence High quality spectra 
Y68 DEPGVDFYSKPAGRR 
Jurkat||pervanadate; 
Jurkat||pervanadate|calyculin; SEM; SEM||10% 
serum 
Y127 KGSLSGDYLYIFDGS HT29||EGF; KG-1; SUP-M2 
Y228 RLLGSVDYDGINDAI 
H1650||EGF|Iressa); H196||EGF; H226||EGF; 
H460||EGF; HT29||Serum starved|EGF; JPV-
CONT||calyculin; Jurkat||anti-CD3|anti-mouse 
Ig|anti-CD28; Jurkat||calyculin|pervanadate; 
Jurkat||pervanadate; 
Jurkat||pervanadate|calyculin; LNCaP||EGF; MO-
91; SEM; SEM||10% serum; SUP-M2 
Y1541 DGNDPDPYVKIYLLP MO-91; SNU-5 
Information about PI3KC2β tyrosine phoshorylation can be found on www.phosphosite.org. 
 
 
The N-terminal phosphorylation of Y68 seems to be important in human T-cell and B-cell 
leukemia cells (Jurkat and SEM, respectively), since it was the only type of cancer where it 
was identified after pervanadate/calyculin or 10% serum treatment (Table 3-1). The Y127 
phospho-site was also observed in leukemic cells (KG-1), although without any treatment, as 
well as in the SUP-M2 lymphoma cell line. On the other hand, EGF stimulation of HT-29 
colorectal carcinoma cells resulted in phosphorylation of the Y127 residue, as well as 
phosphorylation of the Y228 site, which was also found in a number of lung cancer cell lines 
(H1650, H196, H226, H460) or prostate cancer cells (LNCap) upon EGF stimulation. As in 
the case of Y68, phosphorylation of Y228 was further observed in Jurkat and SEM cells after 
pervanadate/calyculin or 10% serum treatment or in MO-91 leukemia or SUP-M2 lymphoma 
cell line in the absence of any treatment. Phosphorylation of the C-terminal Y1541 site was 
detected in MO-91 and SNU-5 gastric cancer cells (Table 3-1). The obtainded results 
indicate that among the identified PI3KC2β phospho-tyrosine sites, Y228 is the most 
frequently phosphorylated in the investigated human cancer cells, suggesting a possibly 
important role for PI3KC2β activation and function. 
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Figure 3-11. Distribution of newly identified pY sites in PI3KC2β amino acid sequence and 
domain structure. (A) Localization of Y68, Y127, Y228 and Y1541 phosphorylation sites in PI3KC2β 
amino acid sequence retrieved from GenBank (accession no. NM_002646). pY residues are 
underlined and indicated in red, proline-rich regions are underlined in black. (B) Domain structure of 
PI3KC2β with indicated positions of defined tyrosine phosphorylation sites and RTKs, Grb2, intersectin 
and clathrin binding regulatory region. PI3K – catalytical domain, PX – Phox domain. 
 
 
PIK3C2B gene homology has been found among different vertebrate species from 
zebrafish through chicken, cow, mouse, rat, dog, monkey, chimpanzee and human (source: 
www.ncbi.nlm.nih.gov/sites/homologene/20582). We were therefore interested whether our 
newly identified phospho-tyrosine sites within human PI3KC2β are conserved throughout 
evolution and thus functionally important. Indeed, multiple sequence alignment between 
H.sapiens and other vertebrate species revealed that all Y68, Y127, Y228 and Y1541 are 
consensus sites, indicating conservation of function in this region (Fig. 3-12). Y228 and 
Y1541 are present in all listed species, whereas both Y68 and Y127 are absent in zebrafish, 
and Y68 is further absent in chicken. 
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Figure 3-12. Conservation of the newly identified PI3KC2β pY sites between different vertebrate 
species. The sequence of human PI3KC2β (GenBank accession no. NP_002637.3) was aligned with 
the sequences from zebrafish (D.rerio) (GenBank accession no. XP_003199535.1), chicken (G.gallus) 
(GenBank accession no. XP_417956.3), cow (B. taurus) (GenBank accession no. XP_002693928.2), 
mouse (M.musculus) (GenBank accession no. NP_001092746.2), rat (R.norvegicus) (GenBank 
accession no. NP_001099421.1), dog (C. lupus) (GenBank accession no. XP_536097.3), rhesus 
monkey (M.mulatta) (GenBank accession no. XP_002802010.1) and chimpanzee (P.troglodytes) 
(GenBank accession no. XP_514126.3) using the NCBI HomoloGene multiple alignment tool 
(www.ncbi.nlm.nih.gov/sites/homologene/20582). pY consensus sites are marked in bold and 
highlighted in yellow. The numbering of Y68, Y127, Y228 and Y1541 residues is based on the 
sequence of human PI3KC2β and may slightly vary for other species.  
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Experimental strategy 
 
Y228 was the most frequently phosphorylated residue within PI3KC2β among the 
identified phospho-tyrosine sites in human cancer cells. Additionally, it appeared to be a 
consensus site conserved throughout evolution among different vertebrates, from zebrafish 
to human, suggesting a possible functional importance. Therefore, as an in vitro model to 
study Y228 functional relevance, we first selected the HT-29 human intestinal cancer cells, 
as one of the cell lines where this phospho-site was detected upon EGF stimulation. 
Similarly, Y127 phosphorylation was found in these cells, which provided an option for 
studying both tyrosine phosphorylation sites simultaneously. HT-29 cells appeared to be a 
good model to work with due to simple and easy culture requirements. This cell line was 
established from a colon adenocarcinoma and is often used to investigate epithelial 
differentiation and cell polarity [205-207]. However, PI3KC2β was shown not to be essential 
for differentiation in vivo at least in the epidermis [123]. PI3KC2β’s role in HT-29 cells might 
be therefore very different. According to previous investigations of PI3KC2β functions in 
human epidermoid carcinoma A-431 cells, PI3KC2β was associated to pro-survival and pro-
migratory responses, as well as to increased cell proliferation [103]. To investigate the 
functional relevance of 127 and 228 phospho-tyrosine sites we decided to generate stable 
clones of HT-29 cells over-expressing PI3KC2β single (Y127F, Y228F) and double 
(Y127/228F) phospho-tyrosine site mutants. Futhermore, functional responses of the newly 
generated HT-29 cell lines over-expressing PI3KC2β mutants and wild-type as control were 
compared in terms of cell proliferation, cell morphology and activation of downstream 
signalling pathways. 
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3.2.3. Results 
 
Generation of phospho-tyrosine (pY) mutants and their validation 
 
To elucidate the functional relevance of tyrosine 127 and 228 phosphorylation sites 
identified in PI3KC2β, we generated tyrosine to phenylalanine (Y/F) mutants, which cannot 
be phosphorylated anymore at the identified tyrosine sites. Single (Y127F, Y228F) and 
double (Y127/228F) Y/F mutants in the full-length enzyme were produced by PCR-based 
site-directed mutagenesis followed by mutant constructs verification by DNA sequencing 
(Top Gene Technologies, Inc., Canada). As a basis for site-directed mutagenesis, the 
previously reported construct of pcDNA3 vector containing the N-terminal Myc epitope tag 
(MEQKLISEEDL) PI3KC2β wild-type cDNA sequence was used [72]. An N-terminal Myc 
epitope tag was therefore included in the pY mutants’ cDNAs to facilitate further isolation of 
the mutated proteins from transfected cells by immunoprecipitation. In order to verify the 
accuracy of the constructs we additionally performed triple restriction digestion with EcoRI, 
XhoI and RsrII enzymes.  
 
 
 
 
 
 
Figure 3-13. Verification of PI3KC2β Y/F mutants constructs in triple restriction digestion. (A) 
Schematic representation of pcDNA3 backbone vector (Invitrogen) used for PI3KC2β wild-type and pY 
mutants generation. EcoRI, XhoI and RsrII restriction sites are indicated in red frames. (B) Predicted 
sizes of potential DNA fragments obtained in the triple restriction digestion and the agarose gel 
presenting the results for Y127F, Y228F single and Y127/228F double mutants, and PI3KC2β wild-
type (WT) control. 
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Fig.3-13 A shows the exact location of the particular restriction sites in the pcDNA3 vector, 
whereas Figure 3-13 B presents the predicted sizes of potential DNA fragments obtained as 
a result of enzymatic digestion, and the actual results after electrophoretic separation on 
agarose gel. The PI3KC2β wild-type plasmid was included as a control. Correct sizes of DNA 
fragments were observed for all plasmids, thus confirming the accuracy of generated mutant 
constructs. 
 
Differential expression of PI3KC2β Y/F mutants at the mRNA and protein level 
 
In order to characterize PI3KC2β Y/F mutants behaviour in the mammalian cell 
systems I transfected the Y127F and Y228F single mutants, as well as the Y127F/Y228F 
double mutant, PI3KC2β wild-type (WT) and pcDNA3 empty vector as controls into HEK293 
cells. Their expression at the mRNA and protein level was further investigated with a qPCR 
and western blot, respectively. Results showed differential expression levels of mRNA (Fig. 
3-14 A), which correlated with the expression of the mutated proteins (Fig. 3-14 B).  
 
 
 
Figure 3-14. Differential expression of PI3KC2β Y/F mutants mRNA and protein in HEK293 cells. 
HEK293 cells were transfected with PI3KC2β Y/F mutants and analysed 24 h post-transfection for 
mRNA expression by real-time PCR (A) and 48 h post-transfection for the protein expression by 
western blot (B). 
 
 
Similarly, I performed transient transfection experiments of pY mutants into HT-29 cells and 
mRNA and protein expression levels were evaluated. Semi-quantitative RT-PCR analysis 
showed quite equal expression of the mutants’ transcripts in comparison to GAPDH control, 
detected with a use of primers specific for exogenous PI3KC2β cDNA containing Myc-tag 
sequence (Fig. 3-15 B). On the other hand, an endogenous PI3KC2β was also detected in 
the HT-29 cell line by the standard RT-PCR. Real-time PCR analysis of Y127F, Y228F, 
74 
 
Y127F/Y228F mutants’ cDNAs revealed differential expression of transcripts detected 48 h 
post-transfection (Fig. 3-15 C). However, the differences between the mutants were minor, 
which was also observed at the protein level (Fig. 3-15 D). The transfection efficiency 
measured by GFP signal analysis by fluorescence microscopy was relatively high (Fig. 3-15 
A). 
 
 
 
Figure 3-15. mRNA and protein expression level of PI3KC2β Y/F mutants in HT-29 cells. HT-29 
cells were transfected with single (Y127F, Y228F) and double (Y127F,Y228F) PI3KC2β mutants and 
control vector pmaxGFP (A,B) or pcDNA (C,D). (A) Transfection efficiency visualized by GFP signal 
analysis with fluorescent microscope 48 h post-transfection. (B) mRNA expression level of the 
PI3KC2β Y/F mutants and endogenous PI3KC2β transcripts analyzed by standard RT-PCR 48 h post-
transfection. (C) mRNA expression level of the PI3KC2β Y/F mutants analyzed by real-time PCR 48 h 
post-transfection. (D) PI3KC2β Y/F mutants protein expression level analyzed by western blot 48 h 
post-transfection. 
 
 
Generation of stably transfected HT-29 cell lines expressing PI3KC2β Y/F mutants 
 
For further investigation of the impact of tyrosine phosphorylation on the PI3KC2β 
functions and signaling, we decided to establish HT-29 cell lines stably transfected with the 
Y127F and Y228F single mutants and Y127/Y228F double mutant. As a control, we further 
generated PI3KC2β wild-type (WT), PI3KC2β kinase-dead (KD) and pcDNA3 empty vector 
(V) expressing HT-29 cells. Stable clones were selected in a medium containing 1mg/ml 
geneticin (G418). Transfection efficiency was evaluated by quantifying both mRNA and 
protein level by qPCR and western blot, respectively. Based on this analysis we selected two 
stable clones for each PI3KC2β mutants exhibiting a 3-5 fold higher expression of the gene 
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than HT-29 cells transfected with the empty vector control (Fig. 3-16). The clones, which 
expressed the highest level of PI3KC2β were further expanded and subjected for 
phosphorylation studies, as well as investigation of cellular responses. 
 
 
 
Figure 3-16. Positive clones of PI3KC2β transfectants displaying the highest mRNA expression 
level among all stable cell lines. HT-29 cells were transfected with PI3KC2β Y/F single and double 
mutants (Y127F, Y228F and Y127F,Y228F), wild-type (WT) and kinase-dead (KD) constructs, as well 
as pcDNA3 empty vector as control. Stably expressing clones were selecetd with G418 (1mg/ml) and 
expanded for further screening by real-time qPCR and western blot. 
 
 
Phosphorylation of endogenous PI3KC2β in HT-29 cells 
 
PI3KC2β was previously shown to be tyrosine phosphorylated in different cell lines 
such as NIH3T3, A-431, HEK293, SCLC and H-209 [77, 99]. Among the range of human 
cancer cell lines used for our pY screen, PI3KC2β was found to be tyrosine phosphorylated 
in HT-29 human colon adenocarcinoma cells. In order to confirm the mass spectrometry 
results, I performed immunoprecipitation of the endogenous PI3KC2β from HT-29 cells upon 
EGF stimulation followed by the whole protein tyrosine phosphorylation analysis. Indeed, 
increased tyrosine phosphorylation after stimulation with EGF in comparison to starved cells 
was observed (Fig. 3-17). 
 
Figure 3-17. Tyrosine phosphorylation of the endogenous PI3KC2β in 
HT-29 cells. HT-29 cells were cultured in 10% FCS containing medium for 
24 h. Next, they were serum-starved (1% FCS) over-night, and were 
stimulated with EGF (50 ng/ml) for 10 min. Cell lysates were equalized for 
protein content and subjected to immunoprecipitates prepared with anti-
PI3KC2β antibody were analysed by western blot with the indicated 
antibodies. 
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Phosphorylation of the PI3KC2β Y127/228F mutant in stably transfected HT-29 cells 
 
HT-29 cells provided us an opportunity to study Y127 and Y228 phospho-sites 
simultaneously under the same conditions. Therefore, in order to verify the phosphorylation 
status of pY PI3KC2β mutants, I first concentrated my efforts on characterizing the 
Y127/228F mutated protein in comparison to the PI3KC2β -WT, -KD and empty vector as 
controls. For that purpose, I used two HT-29 cell lines expressing the PI3KC2β Y127/228F 
double mutant, which originate from two separate stable clones. I starved the cells over-night 
in 0.5% FCS and 1 h in FCS-free medium and further stimulated them for 5 min. with EGF at 
the concentration of 150 ng/ml, which was used previously in HeLa cells for determining of 
phosphorylated peptides by mass spectrometry [208]. Under these conditions PI3KC2β Y228 
phosphorylation site was identified. Immunoprecipitation with an anti-Myc-tag antibody was 
performed on the indicated cell lines and the samples were further subjected to tyrosine 
phosphorylation analysis by western blot (Fig. 3-18 A). The Myc-tag antibody was further 
used after stripping the membranes to determine PI3KC2β immunoprecipitation efficiency 
from the whole cell lysates. The results revealed double bands at the size of PI3KC2β. Of 
these two the upper one was assigned to PI3KC2β, as confirmed by overlap of phospho-Tyr 
with Myc-tag antibody signal. As shown before, different Y127F/Y228F stable clones did not 
express the same mRNA and protein levels (Fig. 3-16 and 3-18 B). It was therefore quite 
difficult to assess their tyrosine phosphorylation status. For this reason, we focused our 
attention on the 1/15 HT-29 stable cell line expressing Y127/228F double mutant and HT-29 
cells expressing PI3KC2β-WT. As indicated in the whole cell extracts (WCEs) and Myc-tag 
immunoprecipitation (Fig. 3-18 A, B), the expression levels of the mutated kinase in 1/15 HT-
29 cells was similar to the WT protein expression in contrast to 5/15 HT-29 stable cell line. 
Relative quantification of the ratio of phospho-Tyr and Myc-tag bands intensities in HT-29 
1/15 cells and wild-type expressing HT-29 cell line upon immunoprecipitation revealed that 
PI3KC2β Y127/228F mutant is less phosphorylated than the wild-type enzyme (Fig. 3-18 A, 
bottom panel). This effect was observed in both, starved and EGF stimulated cells, but 
interestingly under FCS-free conditions the difference was more evident. PI3KC2β-KD 
tyrosine phosphorylation was not taken into consideration for calculating the ratio between p-
Tyr and Myc-tag bands intensities. Although its phosphorylation was detected, the Myc-tag 
immunoprecipitation signal was not visible (Fig. 3-18 A, upper panel). All together, these 
results show attenuated tyrosine phosphorylation of the PI3KC2β Y127/228F mutant in 
comparison to the PI3KC2β-WT. According to this difference, different cellular responses 
were further invesigated.  
In addition to phospho-status investigations, activation of the PI3K/Akt pathway was 
also studied upon EGF stimulation in the WCE of PI3KC2β Y127/229F HT-29 cell lines (1/15 
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and 5/15) in comparison to PI3KC2β-WT, -KD and -V expressing cells (Fig. 3-18 B). 
Increased phosphorylation of Akt on serine 473, as well as its downstream targets glycogen 
synthase GSK3α/β and S6 ribosomal protein was observed in all analysed cell lines upon 
EGF stimulation. Total Akt and S6 protein abundance seemed to be equal, whereas 
expression of GSK3α/β showed some discrepancies between the cell lines. In both clones of 
HT-29 cells over-expressing Y127/228F mutant (1/15 and 5/15) the expression level of total 
GSK3α/β was enhanced upon over-night starvation in 0.5% FCS and 1 h starvation in FCS-
free medium, as well as in PI3KC2β-KD expressing cells (Fig. 3-18 B). PI3KC2β-WT and 
empty vector transfected cell lines showed equal total GSK3α/β expression independently of 
EGF stimulation. 
 
 
 
Figure 3-18. Tyrosine phosphorylation of the PI3KC2β Y127/228F mutant in the HT-29 stable 
cell lines. HT-29 cell lines stably expressing PI3KC2β Y127F/Y228F double mutant, wild-type (WT), 
kinase-dead (KD) and the empty vector (pcDNA3) were starved over-night in 0.5% FCS and then for 1 
h without any FCS in the medium. Further, cells were stimulated with EGF (150 ng/ml) for 5 min. and 
immediately lysed on ice. Lysates were equalized for protein content and subjected to 
immunoprecipitation (IP) with anti-Myc-tag antibody (A). Tyrosine phosphorylation of the PI3KC2β was 
assessed by immunoblotting with the indicated antibodies. The level of phosphorylation was quantified 
by the relative p-Tyr and Myc-tag bands intensities ratio. (B) Whole cell extracts (WCE) of stimulated 
cells were analyzed for the exogenous PI3KC2β proteins expression and the PI3K/Akt pathway 
activation with the indicated antibodies. 1/15 and 5/15 represent two stable clones of the PI3KC2β 
Y127F/Y228F double mutant. 
 
 
PI3KC2β Y127/228F mutant increases proliferation of HT-29 colon cancer cells  
 
In order to investigate whether the differences in phosphorylation between the wild-
type PI3KC2β and double mutant Y127/228F correlate with changes in cells proliferation, the 
MTS assay was performed in HT-29 stable cell lines in the presence of 10% FCS and upon 
serum starvation in 0.5% FCS containing medium (Fig. 3-19 A, B). Two stable clones of 
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PI3KC2β Y127/228F mutant (1/15 and 5/15) were used for this study to exclude clonal 
variation. The proliferation of HT-29 1/15 and 5/15 cell lines was significantly higher as 
compared with HT-29 PI3KC2β-WT expressing cells and this difference was observed both 
in medium containing high (10%) and low (0.5%) serum (Fig. 3-19 A, B). Similarly, the growth 
rate of HT-29 PI3KC2β-KD cells was markedly elevated, when compared to HT-29 PI3KC2β-
WT cells, showing the same tendency as cells stably transfected with PI3KC2β Y127/228F 
double mutant. Surprisingly, there was no significant difference in proliferation between HT-
29 PI3KC2β-WT and empty vector expressing cells. They were proliferating slower than the 
other stable cell lines and this was not dependent on the number of passages, which was 
similar for all generated lines. The over-expression of PI3KC2β-WT was not sufficient to 
cause any changes in proliferation of the HT-29 cells. Only the simultaneous loss of Y127 
and Y228 phosphorylation or inactivation of PI3KC2β kinase activity induced a significant 
increase in cell proliferation (Fig. 3-19 A, B), indicating that PI3KC2β-mediated control of HT-
29 cells proliferation is therefore equally dependent on both, tyrosine phosphorylation at 
residues 127 and 228 and on lipid kinase activity of the protein. Due to elevated cell 
proliferation response in HT-29 cells expressing PI3KC2β-KD, lack of PtdIns(3)P generation 
seems to be important for the obtained effects. Whether phosphorylation of tyrosine 127 and 
228 directly contributes to PI3KC2β lipid kinase activity would require further investigations. 
Expression of both PI3KC2β Y127/228F and –KD mutants exerts a positive effect on the 
investigated cellular response and thus tyrosine phosphorylations of PI3KC2β N-terminal 
domain, as well as its catalytic activity seem to negatively regulate cell proliferation in the HT-
29 cells. 
The observed discrepancies between proliferation of PI3KC2β mutants (Y127/228F, KD) and 
PI3KC2β-WT stable cell lines were independent of time. In the 10% FCS medium HT-29 1/15 
and 5/15 and HT-29 PI3KC2β-KD cells proliferated more than HT-29-C2β WT at all time 
points. Only the proliferation of the HT-29-C2β 1/15 cells in 10% FCS after 72 h of culture 
was slightly decreased (Fig. 3-19 A). For the other two time points (24 and 48 h) cell 
proliferation rate between the cell lines was similar in 10% serum, as well as upon starvation 
at 48 and 72 h (Fig. 3-19 B). At 24 h of starvation a significant difference in cell proliferation 
could be observed only between HT-29 PI3KC2β-KD and HT-29 PI3KC2β-WT cells. 
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Figure 3-19. Cell proliferation of HT-29 cells stably transfected with PI3KC2β Y127/228F mutant. 
HT-29 cell lines stably expressing PI3KC2β Y127F/Y228F double mutant, wild-type (WT), kinase-dead 
(KD) and the empty vector (pcDNA3) were either cultured in 10% FCS containing medium (A) or were 
grown in the 10% FCS medium for 24 h and then starved in 0.5% FCS (B) for 24, 48 and 72 h, 
respectively. 1/15 and 5/15 represent two clones of the PI3KC2β Y127F/Y228F double mutant. Cell 
proliferation was assessed by the MTS cell viability assay. Data are mean ± SD from three 
independent experiments, *p<0.05. 
 
 
PI3KC2β Y127/228F mutant induces cell-cell adhesions formation in HT-29 colon cancer 
cells  
  
PI3KC2β has been shown before to be involved in the establishment of E-cadherin 
mediated cell-cell junctions in A-431 cancer cell of epithelial origin [103]. Therefore, in order 
to further understand the potential function of PI3KC2β 127 and 228 tyrosine residues in cell-
cell contacts formation, the phenotypical changes in the actin cytoskeleton of the stably 
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transfected HT-29 cell lines were investigated. Mutation of both PI3KC2β Y127 and Y228 
sites visibly increased F-actin accumulation at the cell-cell contacts, which was not observed 
in the case of PI3KC2β-WT transfected cells (Fig. 3-20). A similar lack of cytoskeletal 
changes was observed in the cells expressing the empty pcDNA3 vector. Moreover, the 
phenotype of PI3KC2β-KD expressing HT-29 cells was similar with the phenotype displayed 
by stable cell lines expressing Y127/228F PI3KC2β mutant (data not shown), suggesting the 
same tendency of changes, as were observed in cell proliferation assay (Fig. 3-19 A, B). This 
morphological difference was observed in two independent PI3KC2β Y127/228F clones (1/15 
and 5/15), therefore it is unlikely that it might be due to clonal variation. These results 
suggest that in PI3KC2β both N-terminal pY residues (Y127, Y228), as well as its catalytical 
kinase activity might be important for the suppression of E-cadherin-dependent actin 
accumulation at the cell-cell junctions of HT-29 colon carcinoma cells. Whether the negative 
regulation exerted by phosphorylation of Y127 and Y228 in PI3KC2β is achieved by 
PtdIns(3)P synthesis or is mediated by other mechanism, which is lipid-kinase independent, 
is not clear at present. 
In epithelial cells in culture, the localization and the cellular effect of PI3K activation 
depends on the degree of confluence. PI3K were shown to be recruited to newly established 
E-cadherin-mediated cell-cell contacts in Caco-2/15 human epithelial colorectal 
adenocarcinoma cells when they reached confluence [209]. Furthermore, PI3Ks seem to be 
more important for the assembly of cell-cell contacts than the maintenance of mature 
adherens junctions [209]. All HT-29 stable cell lines were grown for 72 h until they reached 
confluence, so the stage, when the E-cadherin-dependent cell-cell adherens junctions 
formation and PI3K accumulation is initiated. Interestingly, PI3KC2β Y127/228F mutant 
transfected cells displayed similar F-actin accumulation at the cell-cell contacts also before 
they reached 100% confluence, when they were still growing in compact colonies not in the 
monolayer of cells (according to my observations).  
All these results taken together confirm previous observations that Y127 and Y228 in N 
terminus of PI3KC2β-WT can negatively regulate not only HT-29 cells proliferation, but also 
cell-cell adherens junction formation. A similar mode of regulation seems to be achieved by 
PI3KC2β catalytic activity, suggesting that PtdIns(3)P generation might be important. The 
exact mechanism of control of cell proliferation and cell-cell contacts formation would require 
further investigations. Whether these PI3KC2β-dependent processes are regulated in HT-29 
cells by the same or different signaling pathways would also need to be studied.   
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Figure 3-20. Cell-cell junction formation in HT-29 cells stably transfected with PI3KC2β 
Y127/228F mutant. HT-29 cell lines stably expressing PI3KC2β Y127F/Y228F double mutant, clone 
1/15 (A) and clone 5/15 (C). Inset window enlarged in (B) and (D) respectively, shows F-actin 
accumulation at cell-cell contacts. HT-29 cell lines stably expressing PI3KC2β-WT (E) and pcDNA3 
empty vector (F). All cell lines were cultured in 10% FCS containing medium for 72 h until they 
reached 100% confluency. Morphology pictures were taken with Eclipse TS100 inverted microscope 
supplied with a Nikon DXM1200 digital camera. 
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PI3KC2β Y127/228F mutant induces Akt/PKB signaling pathway activation in HT-29 colon 
cancer cells  
 
In order to shed a light on the molecular background of the differences in cell 
proliferation and cell-cell contacts formation between PI3KC2β Y127/228F mutant and the 
wild-type expressing HT-29 cells, the activation of Akt and SAPK/JNK signaling pathways 
was investigated. Akt/PKB is the central regulator of cell growth, proliferation and survival, 
which directly binds to PI3Ks products, namely PtdIns(3,4,5)P3 and PtdIns(3,4)P2 [25]. c-Jun 
N-terminal kinase/ stress actvated protein kinase (JNK/SAPK) is a downstream target of 
RhoGTPases, which control cytoskeletal rearrangement processes [210]. Assembly of E-
cadherins requires activation of small GTPases, as well as PI3Ks, and it stimulates Akt/PKB 
pathway activation [146, 147, 209]. 
Akt pathway activation was investigated in HT-29 stably transfected cell lines upon over-night 
FCS starvation (0.5% FCS) and further stimulation with EGF for 10 min. Subsequently, whole 
cell exctracts were subjected to western blot analysis with specific antibodies. Our results 
revealed increased Akt phosphorylation at Ser473 upon EGF stimulation in HT-29 cells 
expressing the Y127/228F mutant, compared to PI3KC2β-WT (Fig. 3-21).  
 
 
 
 
 
Figure 3-21. Akt/PKB signaling pathway activation in HT-29 cells stably transfected with 
PI3KC2β Y127/228F mutant. HT-29 cell lines (1/15 and 5/15 representing two clones) stably 
expressing PI3KC2β Y127F/Y228F mutant, wild-type (WT) and the empty vector (pcDNA3) were 
seeded and cultured in 10% FCS containing medium for 24 h. Next, they were starved over-night in 
0.5% FCS and then for 1 h without FCS. Further, cells were stimulated with EGF (10 ng/ml) for 10 
min. Cell lysates were equalized for protein content and subjected to immunoblotting. Activation of Akt 
and SAPK/JNK signaling pathways was assessed with indicated antibodies. Figure represents the 
results of three independent experiments. 
 
 
Interestingly, Akt phosphorylation in HT-29 cells transfected with PI3KC2β-WT was 
decreased compared to pcDNA3 and this difference was observed in independent 
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experiments, also when cells were treated with higher concentrations of EGF (Fig. 3-18 B). 
Total Akt abundance was equal in all samples, which supports the obtained results. There 
were also no changes in the expression of total JNK upon EGF stimulation (Fig. 3-21), but 
increased phosphorylation of JNK was observed after EGF treatment. However, there were 
no differences in JNK phosphorylation between the investigated cell lines indicating that 
mutation of Y127 and Y228 in PI3KC2β do not affect JNK pathway activity. No differences 
between the cell lines were also observed at the level of S6 ribosomal protein 
phosphorylation, neither on Ser236/236 nor on Ser240/244, although it showed increased 
phosphorylation upon EGF stimulation when compared to serum-starved cells (Fig. 3-21). 
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3.2.4. Material and methods 
 
Antibodies and Reagents 
 
The following antibodies specific for indicated proteins and diluted according to the 
manufacturer's protocol were used: PI3KC2β was described in [72], Myc-tag (9E10) (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), phospho-Tyr, clone 4G10 (Upstate/ Millipore, 
CA, USA), phospho-Akt (Ser473), phospho-S6 protein (Ser 235/236) and (Ser 240/244), S6 
protein, phospho-GSK3α/β (Ser21/9), phospho-SAPK/JNK (Thr183/Tyr185), SAPK/JNK (Cell 
Signaling Technology, Inc., Danvers, MA, USA), Akt (Santa Cruz Biotechnology, CA, USA), 
GSK3α/β (Epitomics, CA, USA), β-actin (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) 
and donkey anti-rabbit IgG or sheep anti-mouse IgG secondary antibodies (1:10000 dilution) 
coupled with horseradish peroxidase (Amersham Biosciences).  
Recombinant EGF was purchased from Calbiochem, La Jolla, CA, USA, while EcoR1, XhoI 
and RsrII restriction enzymes were purchased from Fermentas, Maryland, USA or 
EnglandBioLabs, UK. 
 
Cell Lines 
 
HEK293 (human embryonic kidney 293) and Ht-29 (human colon adenocarcinoma) cells 
were grown in the presence of 10% FCS, 1% penicillin/streptomycin and 1% of L-glutamine 
(v/v) in the DMEM and McCoy’s medium, respectively (Life Technologies/ Invitrogen). Stably 
transfected Ht-29 clones were cultured in the medium supplemented with 1mg/ml of 
geneticin (G418). Cell cultures were maintained in a humidified atmosphere of 5% CO2 at 
37°C and were passaged every 4 days. 
 
Plasmids  
 
The cDNA of N-terminal myc-tagged (MEQKLISEEDL) PI3KC2β wild-type was cloned into 
pcDNA3 vector (Invitrogen) using EcoRI and XhoI sites as described in Arcaro et al. 1998. 
Ctalytically inactive kinase-dead PI3KC2β mutant was developed by mutation of the highly 
conserved asparate (DFG) to an alanine residue in the activation domain (D1213A, DN) as 
described by Katso et al. 2006. PI3KC2β tyrosine to phenylalanine (Y/F) single and double 
mutants (Y127F, Y228F and Y127F/Y228F) were generated based on the above mentioned 
PI3KC2β wild-type construct by site-directed mutagenesis followed by mutations validation 
by DNA sequencing (Top Gene Technologies, Inc., Canada). 
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Enzymatic Restriction Digestion 
 
Two-step digestion of PI3KC2β constructs with three different restriction enzymes was 
employed. 1 μg of plasmid DNA was first subjected to double digestion for 2 hrs at 37̊C with 
EcoRI and XhoI enzymes (10U each), in appropriate restriction enzyme buffer, in total 
volume of 20 μl, following manufacturer’s instructions (Fermentas, USA). Resulting DNA 
fragments were further precipitated with 3M NaAc pH=5.2 and 100% EtOH, and subjected to 
third digestion with RsrII (4U) enzyme (Fermentas, USA). After incubation for 2 hrs at the 
37̊C, digested DNA fragments were analyzed by 1.2% agarose gel electrophoresis, and 
stained with GelRed (Biotium, Hayward, CA, USA). 
 
Transfections  
 
Transient transfections of PI3KC2β phospho-tyrosine (pY) mutants, wild-type (WT) and 
pcDNA3 empty vector (V) were performed with Lipofectin (HEK293) and Lipofectamine LTX 
(HT-29) (Invitrogen) according to manufacturer’s instructions. 
Stable clones were derived from HT-29 cells transfected with PI3KC2β phospho-tyrosine 
(pY) single and double mutants (Y127F, Y228F and Y127F/Y228F) using Lipofectamine 
2000 (Invitrogen) according to manufacturer’s instructions. 48 h post-transfection cells were 
split into selection medium containing G418 at concentration 1mg/ml. Cells were cultured in 
the selection medium for 2-3 following weeks. Medium was changed each 72 hours. When 
the single G418 resistant colonies appeared they were further selected and expanded. After 
2-3 passages, expression of PI3KC2β tyrosine to phenylalanine (Y/F) mutants was verified 
by qPCR and western blot. 
 
RNA Extraction and mRNA Level Analysis 
 
Total RNA was extracetd using Rneasy Mini Kit (Qiagen, Basel, Switzerland) and transcribed 
into cDNA using High-Capacity cDNA Reverse Transcription Kit following manufacturer’s 
instructions (Applied Biosystems, Foster City, CA, USA). Assays-on-Demand Gene 
Expression products (Applied Biosystems) were used to measure mRNA expression level of 
human PI3KC2β (Hs00898524_m1) and GAPDH (Hs99999905_m1) as a reference gene 
control. Relative mRNA expression levels were calculated using the comparative threshold 
cycle (CT) method. Semi-quantitative analysis of PI3KC2β endogenous and exogenous gene 
expression in HT-29 cells was performed with the One-Step RT-PCR Kit (Qiagen) with use of 
following primers: forward primers 5’ CAGAAGCTTATTTCCGAAGAGG 3’, (for exogenous 
cDNA expression) and 5’ CTGGAAGTCCCTGGAGTCAG 3’ (for endogenous cDNA 
expression); reverse primer 5’ CTGCTTGGCTCTGTTCTCC 3’ (Microsynth, Balgach 
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Switzerland). PCR products were stained with GelRed (Biotium, Hayward, CA, USA) and 
electrophoretically separated on 1.2% agarose gel.  
 
Growth Factor Stimulation 
 
EGF stimulation was performed to investigate tyrosine phosphorylation of endogenous 
PI3KC2β in HT-29 parental cells and exogenous PI3KC2β pY mutant, WT and KD in HT-29 
stable cell lines. Cells were seeded and let to attach in 10% FCS containing medium for 24 
hrs. Next, they were starved over-night in respectively 1% or 0.5% FCS, and then for 1 h in 
FCS-free medium. Further HT-29 parental cells and HT-29 stable cell lines were stimulated 
with EGF respectively at 50 ng/ml for 10 min. or 150 ng/ml for 5 min., washed with ice-cold 
phosphate-buffered saline (PBS) and immediately lysed on ice.  
 
Cell Lysis 
 
Cell lysates were prepared in Triton 1% buffer (50 mM Tris.Cl pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.5% NP-40) supplemented with Complete Mini 
Protease Inhibitor Coctail (Roche Applied Sciences) and with the phosphatase inhibitors 
sodium fluoride (1 mM NaF), sodium ortho-vanadate (1 mM Na3VO4) and β-
glycerophosphate (10 mM). Cell pellet was removed by centrifugation for 30 min. (15,000 
rpm at 4̊C). The lysates were equalized for protein content with the Thermo Scientific Pierce 
BCA Protein Assay Kit and subjected to immunoprecipitation or loaded on SDS-
polyacrylamide gel (SDS/PAGE) as a whole cell extracts (WCE).  
 
Western Blot 
 
Proteins were separated by SDS/PAGE electrophoresis and immunoblotted on 
polyvinylidene fluoride membrane PVDF (Amersham, GE Healthcare, UK). The membranes 
were then blocked in 3% gelatin (for pTyr-specific antibodies) or 5% non-fat dry milk (all other 
antibodies) in 1×PBS over-night at 4°C. Washings were done in 1× PBS-Tween (0.1%). 
Incubation with the primary antibodies was performed in 4°C over-night, and with the 
secondary antibodies 1 h at room temperature. Chemiluminescence was detected using 
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific Inc., 
Rockford, IL, USA). 
 
Immunoprecipitation 
 
To investigate tyrosine phosphorylation of endogenous PI3KC2β in HT-29 parental cells and 
exogenous PI3KC2β pY mutant, WT and KD in HT-29 stable cell lines upon EGF stimulation 
immunoprecipitation with PI3KC2β and Myc-tag antibody respectively was conducted on cell 
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lysates equalized for protein content. Incubation with the respective primary antibodies was 
performed at 4 °C for 2 hrs. Protein A or G Sepharose 4 Fast Flow beads (Amersham, GE 
Healthcare, UK) were then added for the PI3KC2β rabbit polyclonal and Myc-tag mouse 
monoclonal antibodies, and the incubation was continued for 1 h at 4 °C. The 
immunoprecipitates were washed three times in the lysis buffer and resuspended in 2x SDS 
sample buffer (50 mM Tris.HCl, pH 6.8, 2% SDS, 10% glycerol, 200mM DTT, and 0.25% 
bromophenol blue). Samples were denatured for 3 min. at 100°C and analysed by 
SDS/PAGE and western blot. 
 
Cell Proliferation Assay 
 
HT-29 stable cell lines were seeded in 96-well plates at a density of 5000 cells/well and 
grown for 24-72 hrs in high (10%) or low (0.5%) serum containing medium. For the starvation 
experiment cells were first seeded in 10% FCS containing medium followed by medium 
change with reduced FCS (0.5%) after 24 hrs. Cell proliferation was analysed by the CellTiter 
96® AQueous One Solution Cell Proliferation Assay (MTS assay) (Promega, Madison, WI, 
USA). 
 
Microscopy 
 
HT-29 stable cell lines wre cultured in McCoy’s complete medium supplemented with G418 
(1mg/ml) for 72 hrs until they reached confluency. Morphology pictures were taken under 
Nikon Eclipse TS100 inverted microscope (10 x magnification) supplied with a Nikon 
DXM1200 digital camera (Nikon ACT-1 2.70 software).  
 
Statistical Analysis 
 
Data are mean ± SD of three independent experiments. The GraphPad PRISM 5 software 
was used to calculate statistical significance of differences between groups with one-way 
ANOVA followed by Tukey’s Multiple Comparison post tests. P<0.05 was considered 
significant and is indicated with a single asterisk. 
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3.2.5. Discussion 
 
 
PI3KC2β-mediated control of cell proliferation 
 
The investigation of the impact of PI3KC2β Y127 and Y228 mutations on cell growth 
revealed that proliferation of the HT-29-C2β 1/15 and 5/15 stable cell lines, as well as HT-29-
C2β KD cells was significantly elevated in comparison to the HT-29-C2β WT cell line. On the 
other hand proliferation rate of the last one was comparable to HT-29-C2β V control cells in 
both 10% FCS medium and upon starvation, and at all time points (Fig. 3-19 A, B). These 
results suggest that tyrosine phosphorylation of residues 127 and 228 located in the N-
terminal regulatory region of PI3KC2β may be equally important for regulation of cell 
proliferation signaling as the PI3KC2β-kinase activity itself. Contrasting results concerning 
PI3KC2β involvement in cell proliferation were published before. Whether the kinase activity 
increases or decreases cell proliferation seem to be cell line-specific. In HEK293 cells 
transfected with PI3KC2β-WT a 35% reduction of cell proliferation at day 4 was observed 
when compared to HEK293 cells transfected with PI3KC2β-KD and empty vector [84]. These 
results are consistent with my data, which show a significant increase in HT-29-C2β KD cells 
proliferation in comparison to HT-29-C2β WT cells. Although, in my experiments HT-29-C2β 
V cells behaved like HT-29-C2β WT cells and not like HT-29-C2β KD cell line. The decrease 
in cell proliferation of HEK293-WT cells was consistent with increased caspase-3 activity 
suggesting increased levels of apoptosis [84], which was not studied in context of my HT-29 
stably transfected cell lines. The difference in cell growth resulting from discrepancies in cell 
survival was also shown in A-431 epidermoid carcinoma over-expressing PI3KC2β, which 
were more resistant to anoikis than A-431 parental cell line [103]. A-431-C2β WT cells 
demonstrated ~1.75 fold increase in cell proliferation under both low (1%) and high (10%) 
serum conditions, and the effect was not dependent on JNK or Akt signaling [103]. On the 
other hand, inhibition of endogenous PI3KC2β with the isoform-specific pharmacological 
inhibitors (PI701, PI702) in AML and SCLC cell lines, which highly express the kinase, 
resulted in impaired cell proliferation [129]. These results were further confirmed with 
PI3KC2β siRNA down-regulation in AML cell lines, where reduced cell proliferation was 
further accompanied by increased caspase-3 activity [129]. According to the above studies, 
over-expression of PI3KC2β-WT or -KD either increases or decreases cell proliferation. It is 
possible that differential regulation exists in various cell lines. In this context, a decrease in 
cell proliferation in HT-29-C2β WT cells when compared to HT-29 stable cell lines expressing 
Y127/228F or kinase-dead PI3KC2β mutant is therefore possible. However, explaining why 
HT-29 cells transfected with PI3KC2β-WT and empty vector (V) as control behave similar is 
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a difficult issue, since in the cited studies the difference in HEK293 cell proliferation between 
–WT and –V expressing cells was detected [84]. It should not be forgotten that the newly 
generated HT-29 stable cell lines still express a minimal level of endogenous PI3KC2β. 
Exogenous expression of PI3KC2β-WT increased the protein level in the cells, but this higher 
expression was not sufficent to induce any change in cell proliferation when compared to 
PI3KC2β-V (Fig. 3-19 A, B). The reasons for that might be multiple. For instance, although 
PI3KC2β-WT level is elevated in the cell, co-expression of the PI3KC2β-associated proteins 
would be necessary to exert an effect on cell proliferation. This and other issues would 
certainly require further experimental verification. 
 
 
PI3KC2β-mediated control of cell-cell adhesion 
 
 Involvement of PI3Ks in E-cadherin-mediated cellular aggregation and thus Akt/PKB 
signaling activation was documented previously in epithelial cells [147, 209]. In response to 
cell-cell contact formation a physical interaction between PI3K and E-cadherin-containing 
complexes was observed in immunoprecipitation experiments performed in MDCK cells 
[147]. PI3KC2β engagement in F-actin and E-cadherin cell-cell junction formation was 
furthermore reported [103]. Over-expression of PI3KC2β-WT in the human epithelial 
carcinoma cell line A-431 induced increase in F-actin and E-cadherin at the sites of cell-cell 
contacts, while the PI3KC2β-KD mutant expressing cells lost the ability to stabilize cell-cell 
adhesion. The cells were contacting with each other via filopodia and they were much less 
compact than cells transfected with PI3KC2β-WT [103]. These results are in contrast to what 
I observed in HT-29 colon carcinoma cell lines stably transfected with PI3KC2β-WT or -KD 
mutant. PI3KC2β-WT expressing cells were compact, but generation of F-actin cell-cell 
adhesions was not observed as it was seen in cells transfected with kinase-dead form of the 
protein (Fig. 3-20, KD not shown). Both of the cancer cell lines, A-431 and HT-29 are 
carcinoma cells, which originate from epithelial tissues. According to that, transfection of 
PI3KC2β forms induces changes in cell-cell adhesion, although the effects of PI3KC2β-WT 
and –KD expression in these cells are different. Again, these discrepancies may result from 
the different genetic backgrounds of A-431 and HT-29 cells and might be cell-line specific 
effect, as suggested in the previous section. HT-29 cell line is an EGFR-positive, KRAS wild-
type, BRAF-mutated, as well as APC tumor supressor gene-mutated cell line, whereas A-431 
cells harbor wild-type EGFR gene amplification and KRAS and BRAF wild-type versions 
[211, 212]. TP53 tumor supressor gene is not functional in both cell lines leading to 
increased sensitivity to mitogenic stimuli. However, due to EGFR over-expression, the 
response of A-431 cells to ligand stimulation might be much more rapid, although nanomolar 
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concentrations of EGF were shown to inhibit A-431 cell growth, whereas picomolar 
concentrations promoted it [213]. On the other hand, in the HT-29 cell line missense 
mutations of p110α were found (COSMIC data base, http://www.sanger.ac.uk). Mutations in 
PI3KCA are known to be one of the most frequently found genetic alterations in different 
human cancers including colon tumors [214]. Often they lead to over-activation of PI3K/Akt 
pathway and related pathways, which leads to tumor progression. 
A possible mechanism of PI3K activation in cell-cell junctions formation was proposed 
[147]. It was observed that tyrosine phosphorylation pattern of the p85 regulatory subunit of 
class I PI3K corresponded to the p85 complex formation with E-cadherin in MDCK (Madin-
Darby canine kidney cells) upon cellular aggregation [147]. It was therefore suggested that a 
specific tyrosine kinase may exist, which phosphorylates p85/PI3K and is activated in 
response to E-cadherin mediated cell-cell adhesions formation. Furthermore, this kinase 
might facilitate the recruitment of PI3-kinase to E-cadherin-containing complexes at the level 
of the plasma membrane [147]. PI3KC2β does not associate with a regulatory subunit, but 
instead contains N-terminal extension, which was shown to play a regulatory role for the 
protein catalytic activity [93]. In the mass spectrometry analysis in my studies the PI3KC2β 
N-terminus was found to be tyrosine phosphorylated. It is therefore possible that PI3KC2β 
might be also activated upon formation of cell-cell contacts in epithelial cells. Over-
expression of the wild-type form of the kinase in HT-29 cells did not cause any significant 
changes in the actin cytoskeleton, whereas mutation of Y127 and Y228 induced F-actin 
accumulation at the cell adhesions, suggesting that phosphorylation of these residues is 
important for the fine-tuned regulation of the cell-cell contacts formation (Fig. 3-20). How the 
PI3KC2β-mediated negative regulation mode in HT-29 cells is controlled is not know. 
Tyrosine phosphorylation of p85/PI3K stimulates PI3K activity [215]. Phosphorylation of Y127 
and Y228 in PI3KC2β in HT-29 cells seem to play an opposite role based on the observed 
cellular phenotype. However, which kind of mechanism is involved in this process is 
unknown. Taking into consideration similar phenotypical changes acquired upon PI3KC2β-
KD expression in HT-29 cells, the involvement of the enzyme’s kinase activity should be 
taken into account.  
p85 phosphorylation is catalyzed by Src-family protein-tyrosine kinases Abl and Lck at the 
Y688 [216], while the kinase, which may phosphorylate Y127 and Y228 in PI3KC2β was not 
studies. However, previous observations from our lab suggested that it could be the Src non-
receptor tyrosine kinase, which actually is expressed at the high levels in the HT-29 cells 
[217]. This hypothesis however would need to be confirmed. 
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Influence of PI3KC2β Y127/228F mutant on Akt/PKB pathway activation 
 
 My signaling data cannot be fully compared to the cell proliferation and cell 
morphology studies since cells in these assays were not treated with EGF. However, it is 
important to mention that E-cadherin engagement in cell-cell adhesions stimulates Akt and 
p38 pathways through PI3K-dependent mechanism [209]. Mutation of Y127 and 228F in 
PI3KC2β sequence induced increased activation of the Akt/PKB signaling pathway in HT-29 
cells upon EGF stimulation when compared to PI3KC2β-WT (Fig. 3-21). On the other hand, 
Akt phosphorylation levels in HT-29 cells transfected with PI3KC2β Y127/228F mutant were 
not different from the levels of Akt phosphorylation in empty vector-transfected cells. Again, 
this confirms that the newly identified PI3KC2β tyrosine phosphorylation sites negatively 
regulate the enzyme activation and downstream signaling, but also suggests that the 
enzymatic function of PI3KC2β Y127/228F mutant was affected due to mutation. A similar 
effect was already observed in HEK293 cells transfected with pcDNA3, PI3KC2β-WT and -
KD enzyme [84]. Cells were starved over-night and then stimulated with 10% FBS containing 
medium for 4-24 hrs. Starting from 16 hrs phosphorylation of Akt on Ser473 and Thr308 was 
significantly blunted in HEK293 cells over-expressing PI3KC2β-WT, while in the empty vector 
and PI3KC2β–KD expressing cells it was sustained at the same level. According to authors, 
an analogous effect was obtained when the same HEK293 cells were stimulated with EGF, 
but with much shorter kinetics. Under these conditions, Akt phosphorylation was attenuated 
more rapidly in cells over-expressing PI3KC2β-WT and it correlated with lower intracellular 
levels of PtdIns(3,4,5)P3 [84]. Analogously, HT-29 cells expressing PI3KC2β Y127/228F 
mutant or empty vector showed increased Akt phosphorylation in comparison to cells 
transfected with PI3KC2β-WT (Fig. 3-18 B and 3-21). Unfortunately, the intracellular levels of 
phosphoinositides were not investigated. The authors of the above studies point out the 
strong time contrast between FBS and EGF stimulation. They also emphasized decreased 
levels of PtdIns(3,4,5)P3 and increased levels of PTEN in HEK293 cells over-expressing 
PI3KC2β-WT suggesting that PI3KC2β might regulate class I PI3K signaling [84]. This 
interesting hypothesis is partially confirmed in my results. However, Akt/PKB directly binds to 
both PI3Ks products, namely PtdIns(3,4,5)P3 and PtdIns(3,4)P2 [25]. The main product of 
PI3KC2β activity in vitro is PtdIns(3)P, but under some circumstances (in the presence of 
Mg2+) it can potentially generate PtdIns(3,4)P2 [72]. Whether PI3KC2β-mediated regulation of 
Akt activity is due to class I PI3Ks activation or other factors, is an interesting question. 
Moreover, no difference in Akt phosphorylation at Ser473 was detected between A-431 cells 
over-expressing PI3KC2β-WT and parental A-431 cells. No Akt impact on cell proliferation or 
protection against anoikis was observed [103]. More studies would be therefore required to 
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find out how PI3KC2β regulates Akt signaling in HT-29 cells and whether it is through a direct 
or indirect mechanism. 
 
 
Mechanism of regulation PI3KC2β function by Y127 and Y228 phosphorylation in the N-
terminal domain 
 
 Here, I identified that phosphorylation of Y127 and Y228 in PI3KC2β negatively 
regulates HT-29 cell proliferation and cell-cell adhesions formation. This mode of action was 
reflected in the Akt/PKB signaling pathway activation upon stimulation with EGF, where Akt 
phosphorylation at Ser473 was found to be down-regulated in PI3KC2β-WT expressing cells 
when compared to HT-29 cells over-expressing PI3KC2β Y127/228F mutant, as well as an 
empty vector control. These results are in line with recently published reports, which identifiy 
PI3KC2β’s role in negative regulation of Akt phosphorylation in HeLa cells and primary 
human skeletal muscle myotubes [218]. PI3KC2β generates a pool of PtdIns(3)P, which 
becomes a substrate for myotubularin 1 (MTM1) phosphatase. This in turn has the ability to 
dephosphorylate PtdIns(3)P and to generate PtdIns, which seems to stimulate Akt/PKB 
pathway. Down-regulation of MTM1 results in the accumulation of PtdIns(3)P and inhibition 
of the EGF-induced Akt phosphorylation, as well as its downstream targets (4E-BP1, FoxO 
transcription factors, 70S6K), which leads to caspase-dependent cell death. These findings 
unveil PtdIns(3)P’s role as a direct negative regulator of Akt/PKB signaling pathway. Co-
silencing of PI3KC2β in MTM1 down-regulated HeLa cells reduced PtdIns(3)P level and 
restored EGF-mediated Akt phosphorylation clearly indicating an importance of PI3KC2β 
lipid product in negative regulation of Akt activation. MTM1 on the other hand acts as a 
positive reulator of Akt-dependent cell growth and survival by converting PtdIns(3)P to PtdIns  
[218]. A schematic representation of PI3KC2β and MTM1-mediated regulation of Akt/PKB 
pathway activation by modulation of PtdIns(3)P levels upon EGF stimlation can be found in 
Fig. 3-22 A-C. These data are consistent with my results, which show decreased Akt 
phosphorylation upon HT-29 cell transfection with PI3KC2β-WT when compared to PI3KC2β 
Y127/228F mutant and empty vector transfected cells (Fig. 3-21). It could therefore suggest 
that the PtdIns(3)P pool generated by PI3KC2β may negatively regulate Akt/PKB pathway 
activation in HT-29 cells. In cells transfected with PI3KC2β-WT there is still some level of 
endogenous protein, which additionally contributes to the observed effect. In HT-29 cells 
expressing an empty vector or un-functional PI3KC2β Y127/228F mutant, synthesis of 
additional pools of negative regulator PtdIns(3)P is missing, therefore Akt activation 
increases. This hypothesis could be also true for PI3KC2β-KD transfected cells. 
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Figure 3-22. PI3KC2β and MTM1 – mediated regulation of Akt/PKB pathway activation. (A) Upon 
EGF stimulation PI3KC2β generates PtdIns(3)P pool in HeLa cells, which becomes a substrate for 
MTM1 (myotubularin 1) phosphatase. As a result of PtdIns(3)P dephosphorylation, PtdIns is 
generated, which seem to stimulate Akt/PKB pathway activation. (B) Knock-down of MTM1 increases 
PI3KC2β-dependent PtdIns(3)P level, which neagtively regulates phosphorylation of Akt and its 
downstream targets leading to caspase-dependent cell death. (C) Co-silencing of PI3KC2β in MTM1 
down-regulated HeLa cells decreases PtdIns(3)P pool and restores EGF-mediated Akt activation. 
 
 
The tyrosine phosphorylation sites 127 and 228 may therefore directly control PI3KC2β 
activity, which leads to increased PtdIns(3)P synthesis. In other words, Y127 and Y228 
phosphorylation positively regulates PI3KC2β catalytic activity toward PtdIns leading to 
generation of PtdIns(3)P, which negatively regulate activation of Akt/PKB and associated 
signaling pathways (schematic representation of the hypothetic model, see Fig. 3-23).  
Most likely, N-terminal phosphorylation of Y127 and Y228 is necessary for appropriate 
regulation of PI3KC2β lipid kinase activity. Moreover, it has been proven that regulatory role 
of the N terminus in PI3KC2α and PI3KC2β strongly depends on the binding of additional 
molecular factors such as clathrin or intersectin [92, 93, 104]. Therefore, in HT-29 cells a 
non-receptor tyrosine kinase may exist, which interacts with the enzyme leading to its 
phosphorylation and activation. On the other hand, the possibility exists that phosphorylation 
of Y127 and Y228 indirectly controls PI3KC2β function through cross-talk with other signaling 
molecules and has nothing to do with enzyme’s kinase activity toward lipids in the 
membrane. Not only proline-rich motifs in the N-terminal portion of the kinase can play a role 
of docking sites, but also phospho-tyrosine residues themselves can act as binding motifs for 
multiple SH2 or PTB-containing proteins [18]. As already shown for other PI3Ks [219], 
PI3KC2β might be involved in protein-protein interactions that affect signaling independently 
of its kinase activity. Thus, it may play a role of scaffolding protein transmiting signals to 
other effector molecules and simultaneously it stays inactive as a kinase. However, since I 
observed similar cellular responses for HT-29 cells transfected with PI3KC2β-KD and with 
the PI3KC2β Y127/228F mutant (Fig. 3-19 A, B), it is more likely that phosphorylation of 127 
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and 228 tyrosine residues controls lipid kinase function of PI3KC2β and that PtdIns(3)P pools 
may play an important role in cell proliferation and cell-cell adhesions formation. 
 
 
 
 
Figure 3-23. Hypothetical model illustrating PI3KC2β negative regulation of Akt/PKB pathway in 
HT-29 cells. (A) Mutation of Y127 and Y228 in PI3KC2β-WT or inactivation of PI3KC2β catalytic 
domain leads to decrease in PtdIns(3)P levels at the plasma mebrane. Loss of PtdIns(3)P, Akt 
negative regulator, increases Akt/PKB activation. (B) Phosphorylation of Y127 and Y228 in N-terminal 
region of PI3KC2β regulates the enzyme’s kinase activity toward PtdIns leading to generation of 
PtdIns(3)P, which in turn suppress Akt phoshorylation. WT–wild-type, KD–kinase-dead. Stars indicate 
mutation. 
 
 
Production of specific phosphorylated lipids in the membranes of different cellular 
compartments is a dynamic process resulting from orchestrated action of lipid kinases and 
phosphatases. In comparison to PtdIns(3,4)P2 and PtdIns(3,4,5)P3, substantial quantities of 
PtdIns(3)P are present in the cells in the basal state and does not increase much upon 
stimulation [25], suggesting a general role of PtdIns(3)P in maintaining cellular homeostasis. 
Class II enzymes supported by the activation of lipid phosphatases may therefore be 
responsible for keeping cellular processes in balance. With respect to that, a possible role of 
MTM1 in PI3KC2β signaling in HT-29 stable cell lines could be verified too. It was shown in 
HeLa cells that knock-down of PI3KC2β, but not PI3KC2α or Vps34 counteracted the effect 
of MTM1-depletion on Akt phosphorylation and apoptotic pathway [218]. Moreover, it was 
previously demonstrated in Drosophila melanogaster that Pi3K68D, but not Vps34, acts in 
collaboration with endosomal Mtm-1 to coregulate the PI(3)P pool, which in turn promotes F-
actin reorganization and modulates protrusion formation in hemocytes and insect immune 
cells. Human Mtm genes present high functional conservation with the D. melanogaster MTM 
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family members, therefore it is not surprising that MTM/Class II PI3K pathway may be 
important for similar biological responses in mammalian cells [220]. 
The increase in cell proliferation and cell-cell adhesions formation in PI3KC2β 
Y127/228F and –KD mutants upon 72 hrs of culture in 10% serum is also an intriguing issue. 
E-cadherin was in fact associated with both anti-proliferative role, as well as increased cell 
proliferation depending on the cellular system, adhesive context and seeding density [221]. 
In colon carcinomas proliferation was linked with the localization of E-cadherin to the cell 
periphery [222]. The assembly of adherens junctions is promoted by PI3Ks, which in turn 
control Akt and p38 MAPK activation [209], but it also involves Rho GTPases [221]. 
Therefore, it would be interesting to investigate through which signaling pathways cell 
proliferation and cell-cell adhesions formation are regulated in HT-29 stably transfected with 
PI3KC2β Y127/228F and –KD mutants. 
 
 
PI3KC2B somatic mutations in cancer 
 
Amplifications and over-expression of PIK3C2B in different types of human cancer 
were identified, but the significance and consequences of these alterations have not been 
studied in detail. Even less information is available about PIK3C2B mutations in tumors, but 
some reports have started to appear due to increasing cancer cells genome sequencing 
data. Frequent PIK3C2B mutations were found recently in NSCLC adenocarcinomas and 
squamous cell carcinomas [127]. They were not found in previous sequencing studies, which 
determined already TP53, KRAS, EGFR, CDKN2A and RB1 to be the most common 
mutated genes in lung cancer. PIK3C2B alterations were detected in the exons and 
appeared to be missense mutations predicted to affect protein function [127]. However, how 
these mutations contrubute to the lung cancer progression has not been studied yet. The 
situation is different with the identification of SNPs in the PIK3C2β gene, whose function was 
significantly associated with prostate cancer risk, especially for men diagnosed before age of 
65 or for men with a family history of prostate cancer [142]. On the other hand, my results 
showed that mutation of the tyrosine phosphorylation sites in N-terminal region of PI3KC2β 
can lead to deregulation of cell-cell adhesion processes in epithelial colon cancer cells (Fig. 
3-20). Whether these types of PI3KC2β mutations are present in tumors during the process 
of mutation accumulation is not known. However, the increasing amount of cancer genomes 
sequencing data may still bring an answer to that question. While discussing the increased 
cell-cell adhesions formation and elevated cell proliferation induced by mutation of Y127 and 
Y228 in PI3KC2β-WT, it is good to remember that perturbation of intracellular adhesion is 
directly implicated in carcinogenesis and the onset of most solid tumors [148]. First, cancer 
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cells have to break cell-cell and cell-matrix adhesions to be able to proliferate or migrate to 
distinct tissues. Furthermore, they need to preserve their phenotypic plasticity to transit 
through the bloodstream or lymphatic vessels, and renew proliferation in secondary sites of 
the body [148]. The breaking and reassembling PI3KC2β-regulated E-cadherin cell-cell 
connections or cell-matrix adhesions might be therefore essential at each phase of 
metastasis. It is noteworthy that PI3KC2β expression was recently correlated with metastasis 
in oesophageal squamous cell carcinoma (ESCC) patients [141]. 68.2% of patients with 
PI3KC2β-positive ESCC tumors had metastasis compared with only 31.8% of PI3KC2β-
negative cases [141].  
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3.2.6. Conclusions and outlook 
 
 The aim of this project was to characterize the functional relevance of tyrosine 
phosphorylation sites identified within PI3KC2β isolated from human cancer cell lines, which 
were treated with or without pervanadate/calyculin, 10% serum or EGF. Mass spectrometry 
analysis of cell lysates revealed four new tyrosine phosphorylation sites, namely Y68, Y127, 
Y228 and Y1541, which were located at the regulatory N-terminal and C2 C-terminal 
domains of the kinase. All of them appeared to be conserved throughout evolution among 
different vertebrate species suggesting their functional importance. Indeed, loss of Y127 and 
Y228 phosphorylation due to site-directed mutagenesis within the N terminus of the 
PI3KC2β-WT construct induced increased proliferation and cell-cell junctions formation when 
compared to the wild-type form of PI3KC2β in HT-29 stably transfected colorectal carcinoma 
cells. Similar results were obtained for HT-29 cells expressing PI3KC2β-KD, which indicated 
an important role of the PI3KC2β catalytical activity in the investigated cellular responses. 
Additionally, a decrease in Akt phosphorylation at Ser473 was observed in HT-29 cells over-
expressing PI3KC2β Y127/228F or –KD mutant when comapred to PI3KC2β-WT expressing 
cells. Therefore, I propose that phosphorylation of Y127 and Y228 negatively regulates 
Akt/PKB pathway activation, and in turn cell proliferation and cell-cell junctions formation. 
The mechanism of this regulation remains unknown. However, I hypothesize that PtdIns(3)P, 
as PI3KC2β’s main lipid product, may play a function of negative regulator, as showed 
previously in HeLa cells [218]. In this context, phosphorylation of Y127 and Y228 in PI3KC2β 
may positively regulate kinase activity of the enzyme leading to generation of PtdIns(3)P, 
which in turn negatively regulates Akt and associated downstream signaling pathways, which 
further helps to maintain the balance in functioning of the cell. Whether the N-terminal 
tyrosine phosphorylation operates in concert with the kinase activity or act in complete 
autonomy from the catalytic function would be an interesting issue for further investigations.  
 To confirm the proposed hypothesis, the first and the most important thing to test 
would be to investigate PtdIns(3)P synthesis in HT-29 cells stably transfected with PI3KC2β 
Y127/228F or -KD mutants, -WT and empty vector. This would give an answer to the 
question of whether phosphorylation of Y127 and Y228 is essential for stimulation of 
PI3KC2β enzymatic function. Furthermore, PtdIns(3)P is not a direct ligand of the Akt PH-
domain, suggesting the involvement of other mediators in the Akt activation. Whether these 
are class I PI3Ks or other factors would be interesting to find out. Subsequently, more 
detailed studies of signaling pathways activated upon PI3KC2β mutations would be required. 
The possible involvement of Rho GTPases or MAPK pathways would have to be examined, 
as well as investigating whether cell proliferation and cell-cell adhesions formation are 
controlled by the same or different signaling pathways. Studying the possible physical 
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interaction of PI3KC2β with E-cadherin would help understand the mechanism of cell-cell 
contacts formation in PI3KC2β Y127/228F and –KD transfected cells. Last but not least, 
dissecting Y127 and Y228’s role in the described cellular responses would bring even more 
understanding into the process of PI3KC2β regulation in human cancer cells.  
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Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets 
Karolina Błajecka$, Anna Borgström$ and Alexandre Arcaro* 
University of Bern, Department of Clinical Research, Bern, Switzerland 
Abstract: Phosphatidylinositol 3-kinases (PI3Ks) are key molecules in the signal transduction pathways initiated by the 
binding of extracellular signals to their cell surface receptors. The PI3K family of enzymes comprises eight catalytic 
isoforms subdivided into three classes and control a variety of cellular processes including proliferation, growth, 
apoptosis, migration and metabolism. Deregulation of the PI3K pathway has been extensively investigated in connection 
to cancer, but is also involved in other commonly occurring diseases such as chronic inflammation, autoimmunity, 
allergy, atherosclerosis, cardiovascular and metabolic diseases. The fact that the PI3K pathway is deregulated in a large 
number of human diseases, and its importance for different cellular responses, makes it an attractive drug target. 
Pharmacological PI3K inhibitors have played a very important role in studying cellular responses involving these 
enzymes. Currently, a wide range of selective PI3K inhibitors have been tested in preclinical studies and some have 
entered clinical trials in oncology. However, due to the complexity of PI3K signaling pathways, developing an effective 
anti-cancer therapy may be difficult. The biggest challenge in curing cancer patients with various signaling pathway 
abnormalities is to target multiple components of different signal transduction pathways with mechanism-based 
combinatorial treatments. In this article we will give an overview of the complex role of PI3K isoforms in human diseases 
and discuss their potential as drug targets. In addition, we will describe the drugs currently used in clinical trials, as well 
as promising emerging candidates. 
Keywords: Phosphatidylinositol 3-kinases (PI3Ks), cancer, autoimmune and cardiovascular diseases, ATP-competitive small 
molecule inhibitors. 
1. INTRODUCTION 
 The involvement of phosphatidylinositol 3-kinases 
(PI3Ks) in human diseases has been known for over two 
decades, and the importance and knowledge concerning the 
PI3K/Akt signaling pathway complexity appears to increase 
each year. The PI3K/Akt pathway is deregulated in many 
human diseases and in the majority of human cancers, and is 
therefore an attractive target for therapeutic intervention. In 
this review we will highlight the importance of PI3Ks for 
normal cell signaling and its involvement in oncogenesis and 
other diseases, and finally discuss its potential as therapeutic 
target. Furthermore, we will review the data concerning the 
new and available pharmacological inhibitors targeting this 
key signaling pathway.  
1.1. The PI3K/Akt Pathway – An Overview 
 PI3Ks are a family of evolutionary conserved lipid 
kinases, playing a crucial role in controlling a wide variety 
of intracellular signaling events. Therefore PI3K signaling is 
often found deregulated in human diseases, not at least in 
cancer. Activation of the PI3K/Akt pathway leads to inc-
reased cell growth, increased proliferation, protection against 
apoptosis, cell migration, and controls vesicular transport 
and actin rearrangements [1].  
 The PI3Ks are activated in response to extracellular 
stimuli and receptor stimulation. Upon activation, the PI3Ks  
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phosphorylate plasma membrane lipid phosphatidylinositoles 
at the 3’ OH-group of the inositol ring, thereby producing 
distinct second messengers such as PtdIns(3)P, PtdIns(3,4)P2 
and PtdIns(3,4,5)P3 (PIP3). These lipid products are known to 
activate and recruit a diversity of target proteins involved in 
complex signaling cascades. The effector proteins are 
recruited to the plasma membrane by binding to the PtdIns 
via the pleckstrin homology domain (PH-domain), phox 
domain (PX) or FYVE zinc finger domains of the proteins 
[2, 3]. 
 One of the most important proteins activated by PIP3 is 
the enzyme phosphoinositide-dependent protein kinase-1 
(PDK1), which controls the activation of the key signal 
transducer protein kinase B (PKB)/Akt. These two PH 
domains-containing serine/threonine kinases, (PDK1 and 
Akt) are brought into close proximity at the cell membrane 
by PIP3, where PDK1 activates Akt by phosphorylation at 
threonine 308 [4, 5]. However, to become fully activated Akt 
additionally needs to become phosphorylated at serine 473 
by the mammalian target of rapamycin complex 2 
(mTORC2) [6]. Upon activation, Akt phosphorylates a wide 
range of target proteins which control apoptosis, cell 
survival, growth and proliferation (Fig. 1). Akt influences 
the cell cycle and glucose metabolism through glycogen 
synthase kinase-3 beta (GSK3β) [7] and modulates cell 
growth and survival, as well as controls the translational 
machinery through the mammalian target of rapamycin 
complex 1 (mTORC1) [8], the ribosomal protein S6 kinase 
(S6K) and the 4E-binding protein (4E-BP) [9, 10]. Addi-
tionally, Akt regulates cell survival by phosphorylating the 
forkhead human rhabdomyosarcoma transcription factor 
(FKHR), and thereby inhibiting the translation of pro-
apoptopic genes such as the Bcl-2-antagonist of cell death 
(BAD), Bcl-2-interacting mediator of cell death (BIM) and 
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Fas ligand (FasL) [11, 12]. Akt furthermore phosphorylates 
the murine double minute 2 protein (Mdm2), which antago-
nizes p53-mediated apoptosis. The PI3Ks can additionally be 
activated independently of upstream regulators when the 
tumor suppressor protein phosphatase and tensin homologue 
deleted on chromosome 10 (PTEN) is inactivated through 
mutation. PTEN is an antagonist of PI3Ks which can 
dephosphorylate the 3’ position of PIP3 and therefore acts as 
a brake for class I PI3Ks. PTEN is therefore not surprisingly 
often found mutated in cancer, leading to constitutive 
activation of the PI3K/Akt signaling axis [13-25]. 
2. PI3K CLASSIFICATION 
 The family of PI3Ks consists of 8 catalytic isoforms in 
human and is subdivided into three classes (class I, II and 
III) according to their sequence homologies and in vitro 
substrate preference (Box 1) [26]. Class I is further sub-
divided into class IA and class IB depending on the receptors 
they become activated by. Of the three classes, class I PI3Ks 
are the best characterized in human diseases, while the role 
of class II and III is less well defined. We will therefore 
focus our discussion mostly on the class I PI3Ks.  
2.1. Class IA PI3K Isoforms  
 Class IA PI3Ks comprises a group of catalytic (p110α, 
p110β, p110δ) and regulatory (p85α, p85β, p55δ, p55α, 
p50α) subunits which become activated through direct 
interaction with a broad variety of receptor tyrosine kinases 
(RTKs), such as the epidermal growth factor receptor 
(EGFR), platelet-derived growth factor receptor (PDGFR) 
and insulin-like growth factor-1 receptor (IGF-1R/IRS) [27-
31]. On the other hand, the p110β isoform of class IA 
together with p110γ from class IB is regulated by G-protein-
coupled receptor (GPCR) signaling [32-34]. Activated Ras is 
also known to stimulate PI3Ks by directly binding to the 
catalytic subunit p110 [35]. There is strong evidence for 
interaction and activation of p110γ by Ras [36]. Ras has also 
been shown to play a role in activating p110α and p110δ 
[36]. Both the regulatory and the catalytic class IA PI3K 
subunits in human are encoded by three genes respectively, 
but due to alternate splicing the three genes encoding the 
regulatory subunits can give rise to five different subunits 
[37-40]. Even though there are preferences, each p85 can 
form heterodimers with any of the catalytic p110 isoforms, 
although the exact role of the different p85 splicing variants 
is not well understood [41]. Together with the catalytic 
 
Fig. (1). The PI3K/Akt signaling cascade. Upon ligand stimulation, RTKs becomes autophosphorylated and recruits the p85-p110 
heterodimer to the plasma membrane. In consequence, the PI3K complex phosphorylates PtdIns(4,5)P2 located in the membrane, 
producing  PtdIns(3,4,5)P3 which acts as a docking site for PH-domain containing proteins, such as Akt and PDK1. Subsequenty, 
PDK1 together with mTORC2 phosphorylates Akt at Thr308 and Ser473, respectively. Activation of Akt induces a cascade of 
signaling events controlling glucose metabolism, cell cycle, apoptosis, protein synthesis and cell growth. Moreover, a negative 
feedback loop from mTORC1 and S6K to PI3K and Akt blocks pro-survival and proliferative signaling. The tumor suppressor PTEN 
antagonizes the action of PI3Ks by dephosphorylating PtdIns(3,4,5)P3. 
Akt
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PDK1
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isoforms, these five regulatory isoforms give rise to fifteen 
possible p85-p110 combinations in mammals [41]. 
 The PI3K heterodimers bind to activated RTKs via 
interaction of the Src homology-2 (SH2) domains of the p85 
subunit to specific phosphotyrosine residues in the cyto-
plasmic domains of RTKs [28, 41-45]. The p85 subunit 
furthermore contains two proline-rich sequences in its N-
terminal region, which can bind to Src homology-3 (SH3) 
domains, such as those present in Src family kinases (Box 1) 
 
Box 1. Classification and domain structure of PI3K family members 
 
A. Classification of PI3K family members 
 
 Isoforms Gene name Substrate 
speifity 
Regulator Cellular 
function 
Expression 
Class IA Regulatory 
p85α, p55α,  p50α  
p85 β  
p55γ 
 
Catalytic 
p110α 
p110β 
p110δ 
 
 
PIK3R1 
PIK3R2 
PIK3R3 
 
 
PIK3CA 
PIK3CB 
PIK3CD 
 
PtdIns 
PtdIns(4)P 
PtdIns(4,5)P2 
 
RTKs 
GPCRs (p110β) 
Ras 
 
-proliferation 
-metabolism 
-migration 
-survival 
 
-immunity   
(p110δ) 
 
ubiquitous 
 
 
 
 
p110δ mainly in 
leukocytes 
Class IB Regulatory 
p101 
p84/p87 
 
Catalytic 
p110γ 
 
 
PIK3R5 
PIK3R6 
 
 
PIK3CG 
 
PtdIns 
PtdIns(4)P 
PtdIns(4,5)P2 
 
GPCRs 
Ras 
 
-inflammation 
-platelet  
aggregation  
-immunity 
 
mainly in 
leukocytes 
Class II Catalytic 
PI3KC2α,  
PI3KC2β  
PI3KC2γ 
 
 
PIK3C2A  
PIK3C2B  
PIK3C2G 
 
 
PtdIns 
PtdIns(4)P 
 
 
RTKs 
Cytokine receptors 
Integrins 
GPCRs (LPA) 
 
-vesicular 
transport  
-cell migration 
-chemotaxis  
 
Broad expression, 
but not ubiquitous 
 
PI3KC2γ mainly 
in liver 
 
Class III Regulatory 
Vps15/p150 
 
Catalytic 
Vps34 
 
 
PIK3R4 
 
PIK3C3 
 
PtdIns 
 
 
GPCRs 
amino acids, glucose 
 
-autophagy 
-vesicular 
transport 
 
ubiquitous 
 
B..Domain structures of PI3K family 
 
Box 1. A. Classification of PI3K family members. The PI3K family of enzymes comprises eight catalytic isoforms divided into three classes 
according to their structural similarities and substrate specificity. B. Domain structures of the PI3K family. Class IA regulatory subunit consists of 
a p110-binding domain, two SH2 domains, which are responsible for binding tyrosine-phosphorylated residues on proteins, and for the p85α and 
p85β isoforms, additionally a SH3 domain and a BCR homology (BH) domain flanked by two proline rich regions (P). The shorter splicing 
variants of p85α lack the N-terminal BH- and SH3 domain. Class IA catalytic subunit consists of the PI3K core structure containing a kinase and 
helical domain, followed by a C2 domain. Additionally, the catalytic subunits have a p85 binding domain in the N-terminal for interaction with 
the p85 regulatory subunit, and a Ras binding domain. The catalytic p101γ isoform of class IB has the same domain structure as class IA apart 
from the lack of p85 binding domain. Class IB regulatory isoforms, p101 and p87 do not have any homology to other proteins and this far, none of 
their domains have been identified. Class II PI3Ks comprises only three catalytic isoforms and are characterized by an additional C2 and PX 
domain in the C-terminal and a proline rich region in the N-terminal, which differs between the three isoforms. The catalytic subunit of class III 
PI3Ks, Vps34, consists of the PI3K core structure with a helical and a catalytic domain as well as the N-terminal C2 domain. The regulatory 
isoform, Vps15 (also known as p150) contain a kinase domain, which is thought to be inactive, and several WD40 repeats and HEAT domains.  
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[46, 47]. The p85 regulatory subunit releases its inhibition on 
the p110 catalytic subunit upon binding of the heterodimer to 
RTKs. As a consequence of its relocation to the plasma 
membrane the heterodimer becomes activated. The PI3Ks 
becomes activated by at least three distinct mechanisms: I) 
close proximity to the lipid substrates, II) the loss of p85 
subunits regulatory effect caused by the SH2-phospho-
tyrosine docking to RTKs [30, 48], and III) activation 
through the interaction with Ras GTPase.  
 The promoter of p110α was recently shown to be under 
positive control of Forkhead box 03a (FOXO3a) [49] and 
Nuclear factor of kappa light polypeptide gene enhancer in 
B-cell 1 (NF-kB) [50] and to be negatively regulated by p53 
[51]. Since PI3K signaling inhibits FOXO3a, p110α is able 
to negatively regulate its own gene expression [52]. In 
addition to lipid kinase activity, the class I PI3K catalytic 
isoforms were shown to possess a protein kinase activity, 
which can phosphorylate the p85 adaptor subunit [53]. 
 The p110α and p110β isoforms are broadly expressed 
throughout the body. The p110α was recently reported to be 
enriched in non-proliferating tumor tissue of ovarian cancer 
in vivo, even though it is known to play a role in cellular 
proliferation [50]. On the other hand, fully differentiated, 
non-proliferative healthy tissue has been reported to be 
enriched in the regulatory subunits p85α, p55α and p50α of 
class IA [54]. p110δ, which is involved in immune functions 
and inflammation, is predominantly expressed in leukocytes 
[55-57]. However, it was unexpectedly also found expressed 
in the developing nervous system [58]. 
2.2. Class IB PI3K Isoforms 
 Class IB consists of the regulatory subunit p101, a p101 
homolog p84 (also called p87PIKAP) and the catalytic subunit 
p110γ [59-62], which like class IA form heterodimers. Since 
p110γ does not bind any SH2 domain-containing p85 regula-
tory subunit it is not regulated by RTKs. Instead this class is 
exclusively activated by GPCRs, through direct interaction 
with the Gβγ subunit [63]. Gβγ recruits p110γ  from the 
cytosol to the membrane by interaction with its p101 or p84 
subunit [64]. Accordingly, p101 was found to be required for 
G protein-mediated activation of p110γ in living cells [64]. 
Studies have confirmed a direct interaction between Gβγ and 
the N- or C-terminal of p110γ  [65]. However, for efficient 
stimulated phosphorylation of PtdIns(4,5)P2 in vitro, the 
binding of the regulatory p101 or p84 subunits are required 
[60, 66, 67]. Ras-GTPases can also regulate p110γ. Ras 
activates p110γ  at the level of the membrane, by allosteric 
modulation and/or reorientation of the p110γ, implying that 
Ras can activate p110γ without its membrane translocation 
[68].  
 The class IB PI3K pathway plays an important role in 
immune cells, such as mast cells, dendritic cells, B and T 
lymphocytes, and also in platelets, the endothelium and 
cardiac tissue (discussed in section 3). p110γ is highly 
enriched in leukocytes, whereas the two regulatory subunits, 
p101 and p84, are accordingly found preferently expressed 
in haematopoetic tissue [60].  
 
2.3. Class II PI3K Isoforms 
 The class II of PI3K consists of three distinct catalytic 
subunits (PI3KC2α, PI3KC2β, PI3KC2γ). This class of 
PI3Ks was first identified in Drosophila and mammalian 
cells by sequence similarities to the other PI3Ks, and is 
characterized by an additional C-terminal C2 domain [69, 
70]. Class II isoforms do not bind any regulatory subunit as 
do class I and III, but the PI3KC2β isoform has been shown 
to bind to activated EGFR via an interaction with the growth 
factor receptor-bound protein 2 (Grb2) through its proline-
rich motifs at the N-terminus [71]. Upon binding to the 
EGFR, the enzyme becomes activated. The three catalytic 
subunits of class II have a substrate specificity restricted to 
PtdInsP and PtdIns(4)P in vitro and can be activated by 
RTKs, cytokine receptors, integrins and lysophosphatidic 
acid (LPA) [69, 70, 72, 73]. 
 Class II members have been identified as playing a role 
in diverse cellular functions, but there are still few reports 
[73-76]. The PI3KC2α isoform has been reported to play a 
role in clathrin-mediated vesicular trafficking [77, 78]. 
Moreover, LPA has been shown to stimulate the production 
of PtdIns(3)P through activation of PI3KC2β [73], which has 
been linked to cell migration in human cancer cell lines [73]. 
Increased expression of class II PI3KC2β stimulated Rac 
activity in A-431 epidermoid carcinoma cells, resulting in 
enhanced membrane ruffling and migration speed of the cells 
[74]. Furthermore, PI3KC2β-overexpressing cells were 
protected from anoikis and displayed enhanced proliferation, 
independently of Rac function [74]. A recent study has 
shown PI3KC2γ to be involved in the regulation of stromal 
cell-derived factor α (SDF1α)-stimulated chemotaxis [79]. 
Yu et al. [79] suggested that down-regulation of PI3KC2γ 
might be the mechanism by which Bcr-Abl induces 
abnormal homing of leukemic cells. 
2.4. Class III PI3K 
 The class III of PI3K is composed of a regulatory subunit 
(Vps15, also called p150) and a catalytic subunit (Vps34). 
The class III catalytic subunit was first described in 
Saccharomyces cervesiae where it was identified as a com-
ponent of the vacuolar protein sorting system, and has since 
then been documented in all investigated eukaryotes. The 
human Vps34 was reported to associate with the trans-Golgi 
network, a key site for the formation of transport vesicles 
destined for different intracellular compartments [80]. 
Additionally, Vps34 and Vps15 are required for the 
induction of autophagy [81-85]. It was shown that Beclin co-
immunoprecipitates with Vps34, which is also required for 
autophagy suggesting that Beclin is a component of the 
Vps34 complex [86]. Similary to class I PI3Ks, Vps34 might 
be important for controlling cell growth, through the 
regulation of the mTOR/S6K1 pathway, which regulate 
protein synthesis in response to amino-acid availability [26, 
81, 82].  
 The lack of potent inhibitors targeting Vps34, resulting 
from a smaller adenosine triphosphate (ATP)-binding pocket 
compared to class I PI3K, has for a long time limited the 
studies of its function [87]. 3-methyladenine (3-MA) is today  
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most effective inhibitor of Vps34, but it has to be used at 
very high concentrations (10mM) in cells to inhibit 
autophagy [88]. However, the crystal structure of Vps34 was 
recently reported, giving important information which now 
may be used for the designing novel Vps34-selective 
inhibitors. There are yet no studies performed with Vps34 
knockout mouse models, but genetic studies of mutated 
Vps34 and Vps15 genes in Drosophila and C.elegans have 
given a greater insight into the function of class III PI3K 
isoforms. Introduction of the mutated gene irdl, (the 
Drosphila homologue of Vps34-related kinase Vps15), 
which additionally is presumed to also inhibit dVps34, 
resulted in a phenotype of starvation-induced activation of 
antimicrobial peptides, which suggests a role of Vps34 in the 
innate immune system [89]. In addition, genetic approaches 
targeting let-512 (Vps34 gene homologue in C.elegans) 
induced embryonic lethality and impaired membrane 
transport between the outer nuclear membrane and the 
periphery of the cell [90]. 
 The information about the involvement of class III PI3Ks 
in human diseases is rather limited. So far there are only two 
reports linking mutations in the Vps34 promotor region to 
schizophrenia [91, 92]. However, due to the importance of 
Vps34 for mTOR signaling [81, 82] inhibiting Vps34 may 
become useful in the treatment of insulin resistance in 
obesity (according to [93]). Furthermore, in the context of 
tumor suppression an up-regulation of Vps34 would lead to 
enhanced autophagy [94], which in turn also is needed for 
the clearance of pathological protein aggregations in diverse 
neurodegenerative diseases. Therefore, pharmacological up-
regulation of Vps34 could possibly become a new ther-
apeutic approach for treating these diseases.  
3. MOUSE MODELS 
 Mouse knock-out and knock-in models have greatly 
contributed to our understanding of the function of class I 
PI3Ks in normal tissue and cells, and additionally helped 
confirming their role in diseases [95]. Furthermore, these 
mouse models, in combination with gene targeting methods, 
have been useful and facilitated the design of inhibitors 
targeting the PI3K/Akt pathway for treatment of diseases. 
But since the different isoforms seem to have the potential to 
compensate for each other, there have been difficulties in 
elucidating the exact function of the single isoforms of the 
PI3K family. Additionally, homozygous knock-outs of the 
majority of class I catalytic subunits were found to be lethal, 
a fact which further hindered the investigations of their 
functional relevance [96]. 
 Homozygous knock-out of either PIK3CA or PIK3CB 
yielded an early embryonic lethal phenotype [97, 98], while 
mice deficient in PIK3CG or PIK3CD isoform survived to 
adulthood (Table 1) [55, 99-101]. However, double hetero-
zygous mice of PIK3CA(+/-) PIK3CB(+/-) survived, but with 
impaired insulin responses [102]. Furthermore, knock-in 
studies resulting in kinase-dead p110α phenotype gave 
similar result, suggesting an important kinase-dependent role 
for p110α in insulin signaling [102, 103]. These findings 
have subsequently been confirmed with pharmacological 
inhibitor studies [103, 104].  
 While p110α was found to play an important role in 
short-term insulin receptor signaling, p110β was described to 
be important to sustain long-term insulin signaling [105]. It 
was reported that mice carrying a kinase-dead p110β mutant 
survive to adulthood, but develop mild insulin resistance at 
Table 1. Mouse Models of PI3K Signaling Pathway 
 
Target Viability Phenotype Alteration in PI3K Subunit Expression Refs. 
p110α -/- : embryonic lethal 
*KD/KD : viable 
KD/+ : viable 
- 
impaired insulin signaling 
decreased growth factor/metabolic signaling 
 
No alterations  in 
p110α, p110β, p110δ 
or  p85 
[98] 
[103] 
p110β -/- : embryonic lethal 
KD/KD : viable 
- 
retarded growth, 
Impaired insulin signaling 
 [97] 
 
[105] 
p110δ -/- : viable 
KD/KD : viable 
Impaired B-and T-cell function, attenuated immunresponse  
Impaired B-and T-cell antigen receptor signaling, attenuated 
immune response, developed inflammatory bowel disease 
 [95, 101, 107] 
[101] 
p110γ -/- : viable impaired T-cell survival, increased NF-κB activation  [113, 115] 
p85α -/- : viable 
 
+/- : viable 
Increased insulin signalling, impaired B-cell development, no T-
cell independent antibody production 
Increased Akt activity, increased apoptosis 
↑ p55α ↑ p50α [117-120, 122, 
128, 129] 
[120] 
p85α/p55α/p50α 
pan 
-/- : perinatal lethal 
 
+/- :  viable 
Hypoglycemia, hypoinsulinaemia 
 
Increased insulin sensitivity, reduced number of mature B-cells, 
decreased serum immunoglobin 
↑p85β ↓p110α 
↓p110β 
↑p85β, p110α and 
p110β not affected 
[118-120, 122] 
 
[120, 130] 
p55α/p50α -/- : viable Increased insulin sensitivity In muscles ↓p85α [131] 
p85β -/- : viable Increased insulin sensitivity  No alteration 
reported [122] 
*KD - kinase-dead. 
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the age of 6 months, in addition to suffering from a retarded 
growth rate [105]. Furthermore, mice carrying a conditional 
knock-out PIK3CB allele, with liver-specific deletion, 
showed higher levels of insulin in the blood, compared to the 
wild type animals, but without significant changes in Akt 
phosphorylation [105]. Additionally, mouse embryonic 
fibroblasts (MEFs) lacking p110β proliferated slower than 
wild type cells and showed impaired insulin sensitivity, 
without changes in Akt phosphorylation status [105, 106]. 
The catalytic function of p110β was not needed for phos-
phorylation of Akt upon stimulation with EGF, IGF-1 or 
PDGF, but its function was however required for activation 
of Akt upon LPA and sphingosine-1-phosphate (S1P) stimu-
lation [105]. Taken together, these results show that p110β 
posseses both a kinase- dependent and a kinase-independent 
function. Low levels of p110β led to embryonic lethality, 
while the presence of catalytically inactive p110β was 
sufficient to proceed through development and led to 
survival into adulthood [105]. The p110β catalytic function 
is required for development, while insulin signaling is a 
kinase-independent function of p110β. Additionally, the 
abovementioned results provide an evidence for the 
involvement of the p110β isoform in GPCR signaling.  
 Mice deficient in p110δ were viable, but had severely 
impaired T and B cell function [101, 107]. In mice expres-
sing a catalytically inactive form of p110δ (p110δ(D910A)), the 
antigen receptor signaling in B and T cells was impaired and 
immune responses in vivo were attenuated [101]. Resting B 
cells with catalytically inactive p110δ failed to enter the cell 
cycle and p110δ activity was also critical for interleukin 4 
(IL-4)-signaling and protection from apoptosis [108]. 
Inactivation of p110δ significantly impaired the ability of B 
cells to activate T cells in a BCR-mediated antigen uptake 
and presentation model [109]. Additionally, the transgenic 
mice developed inflammatory bowel diseases [101]. These 
results revealed a selective role for p110δ in immunity [101, 
110, 111].  
 Mice deficient in both PIK3CG and PIK3CD were 
generated and shown to have a profound block in T cell 
development that occurs at the β-selection checkpoint [112]. 
Mice lacking the GPCR-coupled p110γ were viable and had 
fully differentiated neutrophils and macrophages [113, 114]. 
Chemoattractant-stimulated PIK3CG (-/-) neutrophils failed to 
produce PtdIns(3,4,5)P3, did not activate Akt, and displayed 
impaired respiratory burst and motility [55, 113, 115, 116].  
 Deletion of the gene encoding the regulatory subunit p85 
alone was shown to change the expression and activity of 
other regulatory and catalytic subunits of class I PI3K (Table 
1). Mice deficient in p85α showed increased insulin signal-
ing and displayed up-regulation of the p55α and p50α 
regulatory subunit [117]. Total knock-out of PIK3R1 (p85α 
and its splicing variants p55α, p50α) resulted in prenatal 
lethality [118, 119]. The mice died due to the reduction in 
class IA PI3K catalytic function which led to abnormalities in 
multiple tissues, such as extensive hepatocyte necrosis, 
hypoglycemia and hypoinsulinaemia [119]. The animals 
furthermore displayed reduced numbers of peripheral mature 
B cells and decreased serum immunoglobulins [118]. Hete-
rozygous disruption of PIK3R1 resulted in increased Akt 
activity and decreased apoptosis by IGF-1 through up-
regulated PtdIns(3,4,5)P3 production [120]. Complete deple-
tion of p85α, on the other hand, resulted in significantly 
increased apoptosis due to reduced PI3K-dependent signal-
ing [120]. These findings revealed that p55α and/or p50α are 
required for survival, but not for development of hypo-
glycaemia in mice lacking p85α  [119].  
 As with the homozogous knock-out of p85α, homozy-
gous knock-out of p85β yieled mice with hypoinsuline- 
mia, hypoglycemia, and improved insulin sensitivity [121].  
p85β(-/-) cells however, exhibited significantly increased 
insulin-induced Akt activation, despite the reduction in 
regulatory subunits, leading to increased anti-apoptotic 
signaling [122]. Thus, p85α and p85β modulate PI3K-
dependent signaling by multiple mechanisms and transmit 
signals independently of PI3K activation [122]. The 
observation that depletion of the regulatory subunits can 
enhance insulin signaling has been explained in two ways: i) 
deletion of monomeric p85 gives the chance for p110/p85 
heterodimers to signal without competition, ii) p85 mono-
mers are unstable [122]. Deletion of p110α or p110β reduced 
the overall p85 levels, and additionally it was shown that 
introduction monomeric p85α into adipocytes lacking p85α, 
p55α and p50α was not sufficient to restore PI3K activity 
[102, 122-124]. These results indicate that, in addition to 
their roles in recruiting the catalytic subunit of PI3K to the 
insulin receptor substrate proteins, both p85α and p85β play 
negative roles in insulin signaling [121]. 
 p101-null mouse neutrophils demonstrated impaired 
GPCR ligand-triggered induction of chemotactic responses 
[125]. However, even though both the induction of neutron-
phil NADPH oxidase and the GPCR-ligand induction are 
dependent on p110γ, only GPCR induction was affected by 
the depletion of p101 [113, 125].  
 The investigation of the function of PI3K family mem-
bers has additionally been carried out by constructing mouse 
strains with a constitutively activated PI3K pathway. Over-
expression of mutated proteins or other alterations in the 
signaling pathway have provided evidence for the impor-
tance of genetic alterations for the development of different 
cancer phenotypes. PI3K/Akt signaling can be triggered by 
activating mutations, amplifications or deletion of PTEN. 
However, overexpression of any of the PI3K pathway com-
ponents alone is not enough to cause cancer. It has to be 
expressed in combination with other oncoproteins from a 
second pathway. For example, mice expressing the activated 
p85 allele, p65pi3k were reported to develop lymphoprolife-
rative disorders, but did not develop lymphoma until crossed 
with p53-/- mice [126]. Additionally, mouse brain progenitor 
cells co-transfected with activated alleles of Ras and Akt 
developed glioblastoma, whereas single transfection of either 
gene alone did not induce tumorigenesis [127]. 
4. PI3K IN HUMAN DISEASES  
 Studies of mouse models have been of great importance 
for elucidating the biological functions of the PI3K family, 
and have furthermore given valuable information about the 
involvement of these enzymes in human diseases. Most 
studies have been focused on PI3Ks connection to cancer, 
but the list of human diseases in which PI3K signaling is 
involved is much longer than that. In the next section, we 
will describe human diseases with existing mouse models, 
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showing the involvement of PI3Ks and their central role in 
disease evolvement and progression. 
4.1. PI3K Deregulation in Cancer 
 Tumorigenesis is a multistep process involving genetic 
alterations in a large number of genes controlling processes 
such as cell proliferation, growth, apoptosis, migration and 
metabolism. It is therefore not surprising that PI3K family 
members are frequently mutated in cancer at different stages 
of tumor progression starting at the initiation phase up to the 
stage of metastasis. The PI3K/Akt pathway can be activated 
through various mechanisms, including gene amplification, 
mutations and loss-of-function of the PI3K antagonist PTEN. 
The observation that the tumor suppressor PTEN functions 
as an antagonist of PI3K gave the first firm link between 
PI3K activity and cancer [132]. In addition, PI3Ks were 
previously found associated with the activity of the Rous 
sarcoma pp60v-src protein and the polyoma middle T antigen 
oncogenes [133-135], which further supported the impor-
tance of the PI3K family in tumorigenesis.  
 The PI3K pathway is, after the p53 tumor suppressor 
pathway, the most highly mutated pathway in human cancer 
[136]. Most mutations were reported in PIK3CA and PTEN 
so far. Somatic mutations in PIK3CA, encoding the class IA 
p110α, and PIK3RI, encoding p85, promote the activation of 
the PI3K/Akt pathway [137-140]. Activating mutations in 
PIK3CA have been reported in many cancer types including 
breast, colon, endometrial, glioblastoma, ovarian and hepato-
cellular cancers (references see Table 2). Additionally, 
PIK3CA gene amplification is most frequently encountered 
in cervical, lung, gastric, ovarian and head and neck cancers 
[141, 143, 145, 148, 177]. Interestingly, most of the muta-
tions in PIK3CA are clustered in two “hot spot” regions in 
exon 9 and 20 which encode the helical and kinase domain 
respectively (Box 1) [139, 147]. Mutations in the kinase 
domain result in enhanced enzymatic activity, while muta-
tions in the helical domain de-repress the inhibitory effect of 
p85 on the p110α catalytic subunit [149, 150]. In addition to 
the “hot spot” mutations, up to 100 rare PIK3CA mutations 
have been reported in various cancers [151]. Fifteen of these 
rare mutations were further characterized and all but one 
showed increased oncogenic function [152].  
 Although activating mutations in PIK3CA frequently 
occur, there is so far no evidence of activating oncogenic 
mutations in the other class IA or IB catalytic subunits. 
Overexpression of p110β was reported in several tumor 
types [153, 154], as well as rare cases of somatic single-
residue substitution in p110β and in p110γ, but the effect of 
these substitutions remains to be studied [155]. However, 
over-expression of wild-type p110β, p110δ or p110γ was 
found to be transforming in cell culture unlike the p110α 
isoform [31]. A recent study showed an important role for 
p110β in PTEN-deficient tumors. PIK3CB depletion in a 
mouse model of prostate cancer induced by PTEN knock-
out, led to decreased PI3K signaling and prevented prostate 
tumorigenesis [106]. Double knock-down of PTEN and 
PIK3CA on the other hand, had no significant effect on 
tumorigenesis, suggesting that it could be worth considering 
treating PTEN-deficient tumors by targeting the p110β 
isoform even if it is a PIK3CA-mutation driven tumour 
(suggested by [155]). Furthermore, studies in mice using an 
HER2/ErbB-2 triggered breast cancer model showed that the 
expression of kinase-dead p110β delayed tumor development 
compared to control mice [105]. This result was confirmed 
by inhibitor studies, demonstrating the involvement of p110β 
catalytic function in HER2-driven tumors [105]. 
 p110δ expression is normally restricted to leukocytes, but 
there are reports showing that the p110δ isoform is over-
Table 2. Genetic Alterations of the PI3K Pathway 
 
Genetic 
Mutations 
Affected PI3K 
Isoforms Most Common Cancer Types Refs. 
PIK3CA p110α Breast, colon, gastric,, glioma, endometrial carcinoma, hepatocellular carcinoma 
[141, 142, 144, 146-148, 
159] 
PIK3R1 p85α Colon, ovarian, breast cancer [137, 160] 
PIK3R5 p101 Colon cancer [160] 
PIK3R4 Vps15/p150 Breast cancer [160] 
AKT1 (E17K)  Breast, ovarian, colorectal, sqamous cell lung carcinoma, acute leukemia [163, 164, 170] 
AKT2  Colorectal, gastric, lung [167, 176] 
AKT3  Melanoma [168] 
PTEN  Glioblastoma, melanoma, breast, prostate, ovarian, thyroid, lymphoma, hepatocellular carcinoma endometrial carcinoma, renal-cell carcinoma [13-25] 
  
Genetic 
Amplification 
Affected PI3K 
Isoforms Most Common Cancer Types Refs. 
PIK3CA p110α Cervical, ovarian, lung, thyroid, gastric, head and neck sqamous cell carcinoma [141, 143, 145, 177-179] 
AKT1  Gastric cancer [169] 
AKT2  Head and neck, pancreatic, ovary, breast cancer [169, 170] 
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expressed in colon and bladder cancer [153], as well as in 
neuroblastoma [156], and acute myeloid leukemia [157, 
158]. Additionally, elevated mRNA levels of p110δ have 
been reported in glioblastoma [159]. Inhibitor studies have 
furthermore shown p110δ to be critical for the proliferation 
of acute myeloid leukemia blast cells [158]. 
 The class IA regulatory subunit p85 (PIK3R1) was 
reported to be mutated with a low frequency in breast, colon, 
and ovarian cancer [137, 160]. Alterations in PIK3R1 are 
known to cause impaired binding of the p85α subunit to the 
p110 isoforms, caused by alterations in the SH2 domain of 
p85α. This mutation leads to loss of p85α negative regulation 
of the p110 isoform catalytic activity [149]. As a cones-
quence, the p110 isoform is now able to initiate a down-
stream cascade of antiapoptopic and cell growth signaling 
through increased phosphorylation of Akt [161].  
 The familiy of Akt isoforms (Akt1, Akt2 and Akt3) were 
also found to be mutated in human cancers. Somatic 
mutations in AKT1 were discovered in breast, colorectal, 
ovarian and lung cancers as well as in leukemia [162-164, 
170]. The most common mutation (E17K) alters the lipid 
binding site of Akt1 (PH domain), causing constant mem-
brane localization, even in the absence of PtdIns(3,4,5)P3 
[162]. On the other hand, there are a few reports available 
which demonstrate the lack of involvement of AKT1 PH-
domain mutation in the development of hematologic malign-
nancies, such as acute myeloid leukaemia (AML), acute 
lymphoblastic leukaemia (ALL), chronic lymphocytic leu-
kaemia (CLL), prolymphocytic leukaemia (PLL) [165, 166]. 
Somatic mutations of AKT2 and AKT3 were also reported in 
different tumor types [167, 168]. AKT1 and AKT2 are 
furthermore often found amplified in human cancer (Table 2) 
[169, 170].  
 One of the most common genetic alterations in the PI3K 
pathway is inactivation of the PTEN gene. The expression of 
PTEN can be altered through several mechanisms: loss of 
heterozygoty (LOH), point mutations, homozygous deletion 
and epigenetic silencing via promoter methylation. Altera-
tions in PTEN expression are responsible for clinical syn-
dromes such as Cowden’s disease, Lhermitte-Doclos disease, 
Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome 
and Proteus-like syndrome [174], with predisposition to 
cancer. Loss-of-function mutations in the PTEN gene are 
also extremely common in giloblastoma, melanoma, pros-
tate, breast, ovarian, endometrial, thyroid, lymphoid, and 
colorectal cancer, and in hepatocellular and renal-cell 
carcinoma (references see Table 2).  
 In normal cells, PI3K signaling is under the regulation of 
RTKs, but in cancer RTKs are often mutated, amplified or 
over-expressed, causing constant PI3K signal activation. 
Therefore, inhibitors targeting the upstream RTKs may 
represent promising therapeutics for cancer patients whose 
tumors have a deregulated PI3K/Akt pathway. However, 
activating mutations downstream of RTKs cause constitutive 
activation of the pathway and are therefore believed to also 
cause resistance towards therapies targeting RTKs [175].  
4.2. Autoimmune and Inflammatory Diseases 
 Inflammation is a physiological reaction of an immune 
system in response to injuries or exposure to pathogens. 
During this “state of emergency”, different kinds of immune 
cells (leukocytes) are mobilized to overcome the threat for 
the organism. PI3Ks are known to be expressed in leuko-
cytes and to be involved in the development, migration and 
function of these cells (reviewed in [110, 180, 181]). Conse-
quently, these enzymes control different kinds of immune 
responses: the innate response, which induce neutrophils, 
eosinophils, macrophages and mast cells, and the adaptive 
response, which engages T- and B-lymphocytes (reviewed in 
[180, 181]). Since PIK3CA and PIK3CB mouse knock-out 
models are lethal at the early embryonic stage, their function 
in the immune system has not been studied exhaustively. The 
class IA p110δ and class IB p110γ are considered to be key 
players in inflammation. Loss-of-expression of PIK3CD or 
PIK3CG is not lethal, but it causes severe malfunctions in 
immune responses of animal models [95]. The data derived 
from animal studies support the model that the p110δ and 
p110γ isoforms play non-redundant functions in immunity, 
but also cooperate with each other to regulate immune 
system responses [95]. Inactivation of p110δ reduced B- and 
T-cell receptors signaling [101], whereas p110γ-deficient 
mice, beside impaired T-cells activation, also displayed 
impaired neutrophil and macrophage migration [113, 115]. It 
was demonstrated in double mutant p110δ/γ-/- mice that the 
combined functions of these two isoforms are required for 
critical steps in T-cell development [112]. Moreover, both 
p110δ and p110γ contribute to PtdIns(3,4,5)P3 accumulation 
in tumor necrosis factor α (TNFα)-primed human neutro-
phils after formyl-methionyl-leucyl-phenylalanine (fMLP) 
stimulation. p110γ is responsible for a first phase of 
PtdIns(3,4,5)P3 synthesis, whereas a second phase depends 
on p110δ action and requires TNFα-pretreatment [182]. On 
the other hand, it has been recently shown that p110δ, but 
not p110γ, mediates optimal IgE/Ag-dependent allergic 
response in vivo [183]. Deregulation of any p110δ and 
p110γ-driven signaling pathways in inflammation leads to 
development of various autoimmune, respiratory and 
cardiovascular diseases. 
4.2.1. Autoimmune Diseases 
 Systemic lupus erythematosus (SLE) is a chronic inflam-
matory disorder occuring mostly in females from African or 
Asian countries. The risk of SLE development strongly 
depends on genetic predispositions which drive the loss of 
the tolerance of the immune system to nuclear antigens, an 
increase in B-cell activation and dysregulate T-cells 
(reviewed in [184, 185]). When the CD4+ memory T cells 
are deregulated, B-cell activation is prompted, which in turn 
leads to hypergammaglobulinemia and elevated production 
of DNA-specific autoantibodies. These anti-DNA antibodies 
contribute to tissue damage by binding to native double-
stranded DNA of host cells, especially kidney cells, where 
they form deposits, settle and promote local inflammation 
followed by glomerulonephritis and, in the worst case, renal 
failure (reviewed in [184, 186]). p110γ was shown to play an 
important role in SLE progression. Pharmacological inhibit-
tion of this isoform with the AS605240 compound was 
investigated in the SLE-susceptible MRL-lpr mouse model 
exhibiting increased activation of CD4+ T cells and 
PI3K/Akt pathway. Inhibition of p110γ extended the lifespan 
of the animals, reduced anti-DNA antibody levels and the 
absolute number of pathogenic CD4+ memory cells, and 
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prevented glomerulonephritis and proteinuria progression 
[187]. A similar decline in SLE symptoms was obtained in 
p110γ-deficient mice constitutively expressing p65PI3K, 
which is a truncated form of p85 regulatory subunit. When 
p65PI3K is expressed alone it causes up-regulation of the 
PI3K pathway and induces SLE development [126, 188]. 
Moreover, inactivation of PTEN also triggers the SLE 
phenotype, further emphasizing an important role of PI3Ks 
in progression of this disease [126]. 
 Rheumatoid arthritis (RA) is another chronic inflamma-
tory disease that affects synovial joints and results in serious 
problems with mobility (explained in [189, 190]). Degra-
dation of cartilage and bone in the joints is driven by 
infiltration of macrophages, neutrophils, synovial fibroblasts, 
as well as B- and T-cells, but the exact causes and patho-
genesis of the disease are not completely understood 
(reviewed in [189, 190]). Since it was shown that p110γ 
mediates leukocytes migration [113, 115], it was suggested 
that the enzyme may be involved in RA pathogenesis. 
Passive type II collagen-specific antibody-induced arthritis 
(αCII-IA) mouse model (T- and B-cells independent) lacking 
p110γ (p110γ-/-) showed defective neutrophil migration when 
compared to p110γ+/+ mice and, as a consequence, did not 
developed severe RA symptoms [191]. Pharmacological 
blockade of p110γ with AS-605240 inhibitor in the wild type 
αCII-IA model, and in the distinct collagen-induced arthritis 
(CIA) mouse model (T- and B-cells dependent) also inhi-
bited neutrophil migration and accumulation in the joints, 
preventing disease progression [191]. p110γ-deficient mice 
were therefore protected from RA dvelopment, indepen-
dently of the model used. Recently, an alternative human 
tumor necrosis factor (TNF)-dependent transgenic mouse 
model (hTNFtg) for studying the chronic, destructive phase 
of RA was used [192]. p110γ-lacking hTNFtg mice showed 
less severe inflammatory arthritis. This phenotype did not 
result from decreased invasion of immune cells, but was 
rather due to impaired expression of matrix metallopro-
teinases in fibroblasts and chondrocytes, driven by reduced 
phosphorylation of Akt and extracellular signal-regulated 
kinase (ERK). As a consequence, cartilage damage and joint 
destruction was stopped confirming the therapeutic potential 
of p110γ inhibition in RA [192]. Interestingly, a similar 
decrease in joint and cartilage erosion was obtained in vivo 
as a result of PIK3CD gene deletion or selective, pharmaco-
logical inhibition of p110δ enzymatic activity obtained with 
IC87114 [193]. Importantly, inactivation of both p110δ and 
p110γ enzymes in vivo through IC87114 administration to 
p110γ-/- animals, almost completely abolished joint injury 
caused by leukotriene B4 (LTB4)-mediated neutrophil influx 
into inflamed tissue. These findings indicate that in response 
to the chemoattractant LTB4, which stimulates autoanti-
body-mediated arthritis in mice, p110δ collaborates with 
p110γ to induce maximal neutrophil migration [193]. Taken 
together, targeting p110δ and p110γ can result in significant 
therapeutical benefits in blocking RA progression.  
4.2.2. Respiratory Diseases 
 Allergic asthma is a chronic disease of the respiratory 
system characterized by airway hyper-responsiveness 
(AHR), inflammation and reversible obstruction, as well as 
mucus secretion in response to allergen [194]. The pathogen-
nesis of asthma strongly depends on elevated levels of IgE 
antibodies and activation of immune cells such as T helper 
type 2 (Th2) cells, mast cells, neutrophils, B cells and eosino-
phils, which produce a number of cytokines, chemokines, 
adhesion molecules, growth factors and enzymes contribut-
ing to disease progression (reviewed in [194]). PI3Ks are 
part of the complex signaling network involved in asthma 
development (reviewed in [195, 196]). Genetic inactivation 
of p110δ in ovalbumin (OVA)-challenged mice decreased 
Th2 cytokine-dependent airway inflammation, mucus pro-
duction and reduced eosinophil recruitment [197]. Similar 
findings were reported with the use of a pharmacological 
approach, the p110δ-selective inhibitor IC-87114, in the 
mouse asthma model sensitized with OVA [198]. Further-
more, depletion of p110δ protected mice against anaphy-
lactic responses [199]. For these reasons, p110δ was pro-
posed as a new target for the treatment of allergy and mast-
cell-related pathologies. Additionally, two separate studies 
reported that, in contrast to wild type animals, OVA-induced 
p110γ-deficient asthma mouse models stimulated with the 
allergen exhibited a significant reduction in Th2 cytokine 
production, decreased airway remodelling, inflammation and 
hyper-responsiveness [200, 201]. Taken together, these 
findings indicate a role for p110δ and p110γ in the 
development of allergic asthma and emphasize their potential 
as targets for therapeutical intervention.  
 Chronic obstructive pulmonary disease (COPD) is 
another common airway dysfunction which is characterized 
by airflow limitation, but in contrast to asthma, is poorly 
reversible and progressive [202]. Administration of a 
p110δ/p110γ selective pharmacological inhibitor TG100-115 
to mouse models of COPD reduced lipopolysaccharide 
(LPS) and smoke-induced pulmonary inflammation, suggest-
ing the therapeutic potential of p110δ and p110γ inhibitors 
for the COPD treatment [203]. 
 In addition to all these reports documenting the ther-
apeutic potential of the PI3K isoforms in diverse auto-
immune human disorders, we can add that inflammation, 
which is partially driven by the PI3K/Akt pathway, may also 
lead to the development of cancer [204]. 
4.3. Cardiovascular Diseases (CVDs) 
 The term CVDs encompasses all disorders of the heart 
and blood vessels, including those arising on the basis of 
inflammatory defects such as atherosclerosis.  
 Atherosclerosis is a chronic inflammatory disease affect-
ing large arteries, culminating with cardiovascular disorders 
such as myocardial infarction and heart failure, stroke, renal 
damage or acute limb ischaemia (reviewed in [205] and 
[206]). Inflammation processes are involved in all phases of 
atherosclerosis, starting from atherosclerotic plaque forma-
tion, up to its disruption. All types of immune cells migrate 
to atherosclerotic plaques, but the crucial step for the onset 
of the disease, the transformation of oxidized low density 
lipoprotein (Ox-LDL) to foam cells, is driven by macro-
phages (reviewed in [205, 207]). It is known that Ox-LDL 
triggers PI3K signaling in macrophages/foam cells, which 
produce growth factors and cytokines for PI3K pathway 
stimulation (reviewed in [205, 207, 208]). p110γ plays an 
important role in the activation of macrophages induced by 
Ox-LDL, angiotensin II (AngII) and chemokines [209]. 
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ApoE-/- mouse models of acute atherosclerosis lacking p110γ 
(p110γ-/-) demonstrated a reduced size of the plaque in 
comprison to ApoE-/-p110γ+/+ or ApoE-/-p110γ+/- mice [209]. 
Furthermore, p110γ expression in atherosclerotic lesions was 
shown to be elevated in murine model, whereas loss of the 
isoform impaired the macrophage and T-cell infiltration, 
which was associated with increased plaque stabilization 
[210]. Taken together, these results indicate that p110γ can 
serve as a potential therapeutic target for atherosclerosis 
treatment. 
 When not cured, atherosclerosis usually causes an inter-
ruption in the blood and oxygen supply to the heart, which 
leads to cardiomyocyte death and results in myocardial 
infarction (MI) (heart attack). Following cardiomyocyte 
death an immune response is promoted to activate reparation 
processes of damaged tissue (reviewed elsewhere: [211] and 
[212]). The contribution of p110δ and p110γ to the 
inflammation process after ischemic damage was confirmed 
in pharmacological inhibition studies with the use of a dual 
p110δ/p110γ inhibitor TG100-115 (described later in section 
5.2) [213].  
 All members of class I PI3Ks, comprising of p110α, 
p110β, p110δ and p110γ are expressed in the heart, where 
they mediate distinct cellular functions such as cell survival, 
metabolism, hypertrophy, contractility and mechanotrans-
duction. p110α and p110γ activation in the heart is the most 
intensively studied. Together with the PTEN phosphatase, 
which antagonizes PI3K action, the enzymes are expressed 
in the cardiomyocytes, fibroblasts, endothelial cells, and 
vascular smooth muscle cells (VSMCs) (reviewed in [214]). 
Thus, in concert with PTEN, ubiquitously expressed PI3K 
isoforms are involved in both physiological and pathological 
processes occuring in the heart (reviewed in [214-216]). 
While p110α mainly regulates heart size (hypertrophy), 
p110γ influences heart contractility [217]. Constitutive 
activation of p110α in mice resulted in the development of 
larger hearts due to an increase in myocyte size, whereas 
dominant negative mutants developed smaller hearts consist-
ing of smaller myocytes [218]. Analogous results were also 
obtained by constitutive expression of Akt or inactivation of 
PTEN, which caused pronounced elevation of Akt and S6K 
phosphorylation levels [217, 219]. Rapamycin treatment of 
mice expressing constitutively active Akt caused a reduction 
in heart size, demonstrating that mTOR and/or its effectors 
are involved in controlling physiological heart hypertrophy 
[219]. The fact that cardiac deletion of PIK3R1 encoding 
regulatory subunits also leads to a decrease in heart size 
provides a proof-of-concept for the hypothesis that class IA 
PI3K, especially p110α, are necessary and sufficient to 
regulate cardiac hypertrophy [220]. 
 In the physiological context of heart hypertrophy, which 
is an adaptive process stimulated for example by physical 
exercise, p110α is activated upon insulin growth factor (IGF-
1) binding to RTKs, in particular to the IGF-1R [221]. In 
contrast, pathological hypertrophy, resulting from pressure 
overload on cardiac walls (hypertension) and showing 
defective adaptation, involves activation of p110γ down-
stream of GPCRs [222]. Stimulation of GPCRs with differ-
rent ligands such as AngII, endothelin-1 (ET-1) hormones 
and catecholamines induces signal transmission to down-
stream effectors such as mitogen-activated protein kinases 
(MAPKs), c-Jun N-terminal kinase (JNK) and p38 MAPK 
(see [223, 224]). 
 Unlike p110α, p110γ-deficient mice displayed hyper-
contractility of the heart muscle associated with increased 
levels of cAMP [217]. Loss of PTEN in the heart of mice 
decreased the organ contractility, whereas targeting of p110γ 
function in PTEN-depleted mice completely reverted this 
phenotype [217]. Importantly, p110γ was shown to control 
cAMP levels and heart contractility independently from its 
enzymatic activity, but dependent on its scaffolding role for 
phosphodiesterase 3B (PDE3B) [216, 225]. Apart from the 
scaffolding function of p110γ, the enzyme also utilizes its 
kinase activity for the regulation of β-adrenergic receptors 
(β-AR) [226]. By interacting with G protein-coupled 
receptor kinase-2 (GRK-2), p110γ turns off β2-AR signaling, 
downregulates cell surface expression of β2-AR and 
promotes receptor internalization, which is associated with 
the development of heart failure (HF) [216, 227, 228]. 
Accordingly, p110γ is considered to play negative role in 
heart failure, whereas p110α is associated with a positive 
function.  
 In addition to CVDs directly associated with the heart, 
there are some blood vessel disorders which involve the 
action of PI3Ks. Platelets express all class I PI3K catalytic 
isoforms, including p110α, p110β, p110δ, and p110γ, but 
only the role of p110γ and p110β in platelet function has 
been studied so far [229]. Low expression levels of p110δ 
and a lack of information concerning the role of p110α in 
platelets have caused a lack of interest in the investigation of 
the function of these two isoforms in the context of blood 
vessel diseases. In contrast, platelets from p110γ-null mice 
showed impaired aggregation after stimulation with 
adenosine diphosphate (ADP) which acts via GPCRs [230, 
231]. Arterial thrombosis modified ‘Folts-type’ rat and 
rabbit models and rat cartoid artery electrolytic injury model 
treated with a selective TGX-221 inhibitor of p110β 
exhibited defects in arterial thrombus formation without a 
corresponding increase in bleeding time [232]. These results 
suggest that both p110γ and p110β can play an important 
role in the physiological process of platelet adhesion and 
aggregation at the sites of vascular injury, as well as in the 
pathological conditions of thrombus formation. If not cured, 
arterial thrombosis leads to the development of myocardial 
infarction and ischemic stroke. The major cause of these 
disorders is assigned to platelets, which get activated by high 
shear stress conditions. High shear stress conditions usually 
occur in the blood vessels after sudden disruption of 
atherosclerotic plaques which normally stimulate excessive 
platelet accumulation, and as a consequence, changes in 
blood flow velocity. Rapid blood flow associated with an 
increase in high shear forces promotes blood clot (thrombus) 
growth and diseases progression [229, 233]. PI3Ks act 
downstream of the main platelet receptors involved in shear-
induced platelet activation, such as glycoprotein Ib/V/IX and 
integrin αIIbβ3 [234]. Platelets aggregation depends on 
signals triggered by multiple adhesive ligands (e.g. von 
Willebrand factor, fibrynogen, collagen, vitronectin and 
soluble agonists like thrombin or ADP) and transduced to a 
major platelet integrin αIIbβ3, which mediates platelet–vessel 
wall and platelet-platelet adhesive interactions. Maintaining 
platelet adhesion under rapid flow conditions depends on 
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integrin αIIbβ3-driven calcium flux combined with ADP 
release [235]. 
4.4. Metabolic Diseases 
 The development of metabolic disorders such as obesity 
or diabetes mellitus results from perturbances in glucose 
homeostasis, which crucially depends on the action of 
insulin. The major role of insulin is to stimulate glucose up-
take from the blood and its metabolization in peripheral 
tissues, e.g. muscles [236]. The impaired ability of muscle 
tissue to respond to changing concentrations of insulin is 
called insulin resistance. It develops as an effect of abnor-
malities in insulin signaling and leads to serious health 
problems, such as hyperglycemia, diabetes mellitus type 2, 
obesity, cardiovascular disease, hypertension, heart failure, 
heart attack, stroke, increased incidence of cancer and 
psychosocial problems [237, 238].  
 The main signaling event which accounts for insulin 
resistance involves the translocation of the main glucose 
transporter (GLUT-4) to the plasma membrane [239]. PI3Ks 
and their downstream effectors are involved in the insulin 
signaling cascade controlling GLUT-4 translocation and gly-
cogen synthesis. Binding of insulin to its receptor stimulates 
the intrinsic kinase activity of the receptor, which results in 
receptor autophosphorylation and phosphorylation of insulin 
receptor substrates (IRSs), including IRS1-4, Gab1 and Shc 
(reviewed in [240]). These in turn, interact with p85 
regulatory subunits of PI3Ks, which is followed by PI3K 
activation and phosphorylation of PtdIns(4,5)P2 at the 
plasma membrane. PtdIns(3,4,5)P3 act as a docking site for 
Akt which subsequently is activated by the concerted action 
of PDK1 and mTORC2. As a result, both atypical protein 
kinase Cλ and ζ, (PKCλ/ζ) and the Akt substrate of 160 kDA 
(AS160) get activated. As a consequence, insulin-mediated 
GLUT-4 translocation from intracellular vesicles to the 
membrane is stimulated [241, 242]. Deregulation of GLUT-4 
translocation prevents the uptake of glucose from the blood 
and contributes to insulin resistance [243]. 
 Among all class I PI3Ks, the most prominent role in 
controlling glucose homeostasis was attributed so far to 
p110α [104]. Pharmacological inhibition of this isoform with 
a panel of chemically diverse agents (PIK-75, PIK-90, PI-
103) blocked insulin-stimulated phosphorylation of Akt in 
adipocytes and myotubes in vitro, as well as glucose uptake 
in vivo. Moreover, mice heterozygous for a kinase-dead 
p110α mutation displayed impaired insulin, IGF-1 and leptin 
signaling via IRS proteins. As a consequence, the animals 
suffered from hyperinsulinaemia, glucose intolerance, 
hyperphagia and increased adiposity and presented reduced 
somatic growth [103]. Although p110β is also involved in 
insulin signaling, its role appears to be less significant. It was 
demonstrated that p110β associates with IRS-1 and generates 
a basal pool of PtdIns(3,4,5)P3 which is not sufficient for 
complete activation of Akt. Instead, this pool of p110β-
generated PtdIns(3,4,5)P3 defines the amount of p110α 
activity required for Akt phosphorylation [104]. This data 
goes in line with results observed in the liver of PIK3CB 
knockout mice, which showed that decreased insulin 
sensitivity and glucose metabolism correlate with small 
effect on Akt phosphorylation in response to insulin [106]. 
 Despite the positive function of the p85 regulatory 
subunit in the complex with class I PI3K, p85 has been also 
described to play a negative role in the regulation of insulin 
responses [102, 121]. Different models to explain this dual 
function were proposed. One of them suggests that p85 can 
exist in vivo in two forms, as a dimer associated with p110 
(PI3K), but also as a monomeric form [102]. While p110-
p85 duplexes positively regulate insulin signaling by 
producing PtdIns(3,4,5)P3 second messengers at the plasma 
membrane, free p85 acts as a negative regulator. Therefore, 
insulin sensitivity depends on a balance between the p85 and 
p110 subunits. When not protected by p110, the monomeric 
p85 form is much less stable than the complexed form. 
Therefore, in p85+/- and p85-/- mouse models the balance is 
shifted towards the p110-p85 complex, which results in 
increased insulin sensitivity [102, 121]. Interestingly, it was 
demonstrated that p85α inhibits insulin signaling via positive 
regulation of PTEN [244]. Liver PIK3R1 knock-out mice 
showed enhanced insulin signaling and activation of Akt, 
although the exact mechanism of p85α-dependent regulation 
of PTEN activity is not known. Since PTEN protein levels in 
the liver of PIK3R1 knock-out mice were not changed, the 
mechanism of regulation is probably not linked to 
modulations of PTEN expression [244]. In addition to these 
observations, polymorphism in the human PIK3R1 gene 
encoding p85 regulatory subunit is classified as one of the 
risk factors for developing type 2 diabetes [245]. 
5. PI3K ISOFORMS AS TARGETS FOR SPECIFIC 
SMALL MOLECULE INHIBITORS 
5.1. PI3K Inhibitors in Cancer Treatment 
 The involvement of PI3K family members in many 
human diseases, the gene mutations of PI3K enzymes in 
different types of cancer and their contribution to major 
mechanisms of resistance to anti-tumor therapies have 
stimulated a great interest in the development of PI3K/Akt 
pathway-targeting strategies. Uncovering the complicated 
molecular mechanisms governing human disease progression 
promoted the development of genetic (e.g. RNAi techno-
logy) and biochemical tools (e.g. small molecule inhibitors, 
monoclonal antibodies) which can disrupt the function of 
particular PI3Ks in both physiological and pathological 
states. Small-molecule PI3K inhibitors have turned out to be 
the most successful technology in preclinical settings so far. 
Here, we will discuss the most significant advances that have 
taken place during the last years in the area of PI3K inhibi-
tors, which has progressed dramatically. Small-molecule 
inhibitors became both powerful chemical tools used in 
research to understand the biological roles of PI3Ks, and 
potential drugs to be used in the clinics to treat patients 
suffering from many diseases, especially from cancer. 
 The natural compound wortmannin and the synthetic 
flavone LY294002 (Table 3), represent the earliest genera-
tion of PI3K inhibitors. Due to their significant limitations 
they have never been employed in the clinics, but their role 
in shaping our current knowledge about PI3K biology is 
unquestionable. The lack of selectivity and ability to dis-
criminate between different PI3K isoforms together with 
high in vivo toxicity of both compounds (dermal and liver 
side effects) created a need for the development of new PI3K 
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inhibitors [246, 247]. As a result, SF1126 and PI-103 as 
inhibitors with increased stability and potency were 
developed. 
 SF1126 was designed as a derivative of LY294002 
(Table 3) [248]. It is conjugated to an RGD integrin-binding 
peptide (ανβ3/α5β1) which targets the compound to the 
tumor vasculature and to tumor cells [248, 249]. This potent 
pan-PI3K prodrug overcomes the poor water solubility, and 
undesirable toxicity of LY294002, which makes it a good 
candidate for clinical applications. As LY294002, it inhibits 
other kinases including mTOR, DNA-dependent protein 
kinase (DNA-PK), Pim-1 oncogene (PIM1), polo-like kinase 
1 (PLK1), and casein kinase 2 (CK2) [250]. Its potent 
antitumor activity was shown in vitro and in vivo in various 
cancer? cell lines, as well as glioma, prostate and breast 
cancer xenografts [249]. The compound turned out to be an 
effective anti-angiogenic agent in six different xenograft 
models. Sustained inhibition of tumor growth as well as 
suppression of Akt and ribosomal S6 protein kinase 
phosphorylation was observed in SF1126-treated tumors up 
to several hours after cessation of drug administration [249]. 
Safety and tolerability of SF1126 in patients with advanced 
or metastatic tumors is currently being tested in a phase I 
clinical trial [251]. Initial reports from clinical trials 
demonstrated good tolerability and activity of the drug, 
which led to disease stabilization in patients with refractory 
tumors [248, 250]. 
 PI-103 was developed as a novel, very selective, dual 
PI3K (class I)/mTOR inhibitor (Table 3) [252]. The drug 
showed significant in vivo anti-tumor activity with no 
observable toxicity. It inhibited tumor cell invasion, 
metastasis and angiogenesis in breast and ovarian cancer 
xenograft models. Moreover, it induced a proliferative arrest 
in glioma cells regardless of alterations in the PI3K pathway 
(PTEN, EGFR) and inhibited the growth of glioma 
xenografts [253]. In mouse models of ALL the inhibitor 
significantly enhanced cell-cycle arrest and death of cancer 
cells [254]. Furtermore, treatment of PTEN-null PC3 
prostate and PIK3CA-mutated HCT116 colon cancer cells 
revealed a significant decrease in phosphocholine (PC) and 
total choline (tCh) levels, the increase of which normally 
serves as a biomarker of tumor progression [255]. Despite 
the many advantages of PI-103, this inhibitor could not be 
used for clinical development mainly due to its limited 
aqueous solubility and extensive metabolism [252]. These 
two pharmaceutical properties were substantially improved 
in the next generation inhibitor, a structural modification of 
PI-103, termed GDC-0941 (Table 3) [256, 257]. It is a 
potent, orally bioavailable, ATP-competitive inhibitor of 
class I PI3K which exhibits a higher selectivity towards 
p110α and p110δ than towards p110β and p110γ, and a 
much higher activity against class I PI3Ks versus classes II 
and III (including PI3KC2β and Vps34), as well as DNA-PK 
and mTOR [256]. Its activity in vitro is comparable to that of 
PI-103. Although GDC-0941 is much less active against 
mTOR and DNA-PK, it led to an anti-proliferative response 
and presented an anti-angiogenic potential in human cancer 
cells [257]. In vivo antitumor activity was observed when the 
compound was administrated orally to PTEN-null U87MG 
glioblastoma, as well as PTEN- and PIK3CA-mutant 
IGROV-1 ovarian cancer xenografts in athymic mice. 
Inhibition of tumor growth, prolonged inhibition of the PI3K 
pathway, including a significant reduction in Akt, GSK3β 
and S6K phosphorylation were observed [257]. Recent 
pharmacogenomic studies aiming at the identification of 
predictive biomarkers of GDC-0941 response in tumors, 
reported that breast cancer cell lines and tumor xenografts 
harboring mutations in PIK3CA or HER2 amplification were 
much more sensitive to the drug treatment than models 
without these alterations [258]. Similar susceptibilities were 
observed when two concomitant abnormalities were present 
(e.g., PIK3CA mutation and HER2 amplification, PIK3CA 
mutation and PTEN loss, or HER2 amplification and PTEN 
loss). In contrast, not all PTEN-null models responded as 
well as PIK3CA- or HER2-altered ones, suggesting that other 
factors are required for GDC-0941 sensitization. In addition, 
pS6K1, pS6, and p4EB-P1 significantly decreased in 
response to inhibitor treatment indicating their potential as 
pharmacodynamic biomarkers of GDC-0941 activity [258]. 
Due to its outstanding therapeutical and pharmacological 
profile, GDC-0941 was subjected to clinical development. A 
series of phase I clinical trials are currently being conducted 
[259]. Initial results from a phase I study evaluating the 
pharmacokinetics (PK) and pharmacodynamics (PD) of the 
drug showed that GDC-0941 is generally well tolerated and 
presents signs of antitumor activity. Additionaly, a bio-
marker analysis of target modulation consisting of a decline 
in pAkt levels in platelet-rich plasma and a decrease in pS6 
staining in tumor tissue was positive [260, 261]. 
 BEZ235 it is a novel and potent inhibitor belonging to 
the class of imidazoquinolines, which was designed based on 
the structure of previously identified dual PDK1/PI3K lead 
compounds (Table 3) [262]. It reversibly binds to class I 
PI3Ks and mTOR by competing at their ATP-binding site. 
The reduced phosphorylation of Akt and mTOR downstream 
effectors, such as GSK3β, forkhead in human rhabdomyo-
sarcoma-like 1 (FKHRL1) and S6K observed in response to 
BEZ235, as well as the lack of other protein kinase targets 
confirmed the high selectivity and specificity of the inhibitor 
[263]. In terms of cellular responses, it was shown that 
BEZ235 was able to block proliferation and induce a G1 cell 
cycle arrest in a panel of cancer cell lines of different origins 
[263]. The cell lines investigated displayed various 
alterations in the PI3K/Akt pathway: U87MG glioblastoma, 
PC3M prostate tumor cell lines exhibited loss-of-function of 
the PTEN tumor suppressor gene, whereas breast cancer cells 
showed mutated PIK3CA (E545K, H1047R) expression, loss 
of PTEN, or amplification of HER2. BEZ235 was able to 
overcome all these oncogenic mutations, which was also 
documented by inhibition of Akt, S6 protein and 4E-BP1 
phosphorylation. In breast cancer cell lines, observable mar-
kers of apoptosis such as caspase-3 and poly (ADP-ribose) 
polymerase (PARP) cleavage products were described after 
BEZ235 administration [264], although in some other types 
of tumors, an apoptotic response was not induced [265]. It 
was recently reported that BEZ235 treatment did not trigger 
cell death in breast cancer cells presenting loss of PTEN 
function or KRAS mutations, which was attributed to ERK 
pathway activation, but induced apoptosis in cells harbouring 
HER2 and/or PIK3CA mutations [266]. The anti-proliferat-
ive activity of the compound translated very well in in vivo 
PTEN-null U87MG and PC3M tumor xenografts, which 
displayed suppression of tumor growth after oral adminis-
tration of the drug [263]. The same response was observed in 
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a xenograft mouse model of BT474 breast cancer cells 
harbouring either the H1047R hotspot mutation in PIK3CA 
or the empty vector, where H1047R-expressing tumors 
responded even better then mock control [264]. BEZ235 was 
also described as a potent anti-angiogenic drug. It inhibited 
VEGF-induced endothelial cell proliferation in vitro and in 
vivo. In nude mouse models the compound caused an 
efficient elimination of VEGF-induced vasculature leakage 
in the normal and tumor tissue environment and led to a 
strong reduction in Akt and S6 protein phosphorylation 
levels [267]. Additional reports showed that BEZ235 affects 
cell proliferation, tumor growth, adhesion, migration and 
metastasis in the most common musculoskeletal sarcomas 
such as Ewing's sarcoma, osteosarcoma, and rhabdomyo-
sarcoma [265]. The drug’s antitumor activity against multi-
ple myeloma (MM) was also reported [268, 269]. Recent 
studies presented BEZ235-dependent inhibition of tumor 
growth in orthotopic mouse models of pancreatic cancers 
which is considered as a type of cancer that is rather aggres-
sive and highly resistant to chemotherapeutics and radiation 
[270]. In addition, BEZ235 was much more efficient in 
suppressing tumor growth in renal cell carcinoma (RCC) 
xenografts than was rapamycin [271]. Due to its high effi-
cacy in cancer treatment and all necessary properties 
required for clinical development, BEZ235 is currently being 
investigated in phase I/II clinical trials in patients with solid 
tumors enriched for patients with advanced breast cancer 
[272]. The first reports from clinical trials conducted in 
patients with solid tumors showed promising drug safety and 
tolerability, and a high activity, especially in tumors bearing 
PI3K pathway alterations [273]. 
 At the same time as the BEZ235 inhibitor was described, 
a similar oral PI3K/mTOR inhibitor BGT226 and a class I 
pan-PI3K BKM120 inhibitor were tested in preclinical 
Table 3. Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Preclinical and Clinical Development, their Targets and Therapeutical 
Application 
 
Inhibitor Targets Developmental Stage Therapeutic Application Refs. 
Pan-PI3K inhibitors 
Wortmannin Class I PI3K, mTOR, DNA-PK, PLK1 Preclinical Cancer [307-311] 
LY294002 Class I PI3K, mTOR, DNA-PK, ATM, ATR, p97/VCP, PXDK, CK2 Preclinical Cancer [309, 312-314] 
SF1126 Class I PI3K, mTOR, DNA-PK, PIM1, PLK1, CK2 Phase I Cancer [248-251] 
GDC-0941 Class I PI3K Phase I trial Cancer [256-261] 
BKM120 Class I PI3K Phase I/II trial Cancer [274, 276, 277] 
XL147 Class I PI3K Phase I/II trial Cancer [278-280, 283, 284] 
ZSTK474 Class I PI3K Preclinical Cancer [294-298] 
PX-866 Class I PI3K Phase I trial Cancer [247, 315] 
Dual pan-PI3K/mTOR inhibitors 
PI-103 Class I PI3K, mTOR, DNA-PK Preclinical Cancer [252-255] 
BEZ235 Class I PI3K, mTOR Phase I/II trial Cancer [262-273] 
BGT226 Class I PI3K, mTOR Phase I/II trial Cancer [274, 275] 
XL765 Class I PI3K, mTOR, DNA-PK Phase I/II trial Cancer [281, 282, 285] 
Isoform-specific PI3K inhibitors 
CAL-101 p110δ Phase I Cancer, allergic rhinitis [286-291] 
IC87114 p110δ Preclinical Cancer, allergic asthma, RA [193, 198, 292, 293, 316, 317] 
TG100-115 
p110δ 
p110γ 
Phase I/II trial MI ischemic damage, asthma, COPD [203, 213, 318] 
AS-605240 p110γ Preclinical RA, SLE, glomerulonephritis, atherosclerosis [187], [191], [209] 
TGX-221 p110β Preclinical Arterial thrombosis [232] 
PtdIns(3,4,5)P3 analogues 
2-O-Bn-
InsP5 PH-domain bearing proteins (e.g. Akt, PDK1) Preclinical Cancer [305] 
Information about clinical trials status was retrieved from [306]. 
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studies [274]. They both demonstrated equally good anti-
proliferative activity against tumor cell lines in animal 
models of cancer, as did BEZ235. Currently they are being 
investigated in phase I/II clinical trials in solid tumors [275, 
276]. Initial reports from a phase I study of BKM120 in 
patients with advanced solid tumors showed anti-tumor 
activity [277]. There are no informations available so far 
concerning the clinical evaluation of BGT226. 
 XL147 and XL765 are two ATP-competitive PI3K inhi-
bitors which have entered phase I/II clinical trials in recent 
years (Table 3). In addition, XL147 inhibits the extracellular 
signal-regulated kinase (ERK) pathway by inducing a 
reduction in pERK and pMEK [278], but does not affect the 
kinase activity of Vps34, DNA-PK or mTOR [279, 280]. In 
contrast, XL765 is also active against mTOR [281, 282]. 
Both orally administrated agents inhibited tumor growth and 
proliferation, as well as angiogenesis, and induced apoptosis 
in various xenograft models bearing PI3K pathway-activat-
ing mutations [278-282]. Moreover, in cellular settings, 
XL147 blocked hepatocyte growth factor (HGF)-stimulated 
cell migration [279]. Several clinical trials are currently 
being conducted for both inhibitors [283-285]. 
 CAL-101 is a new, potent p110δ-specific inhibitor which 
exhibits 40- to 300-fold selectivity for the p110δ isoform, as 
compared to other PI3K enzymes [286]. Since p110δ is 
primarily expressed in hematopoietic lineages preclinical 
evaluation of the drug in MM and CLL resulted in very 
encouraging results, which gave a strong basis for clinical 
studies [287, 288]. Treatment of p110δ-positive MM cell 
lines and patients samples with the inhibitor induced 
cytotoxic effects and cleavage of caspase-3, 8, 9 and PARP, 
suggesting that CAL-101-dependent cytotoxicity is driven 
through both the intrinsic and the extrinsic apoptotic 
pathways [287]. The cytotoxic response after drug treatment 
was not triggered in peripherial blood minonuclear cells 
originating from healthy donors. CAL-101-mediated conco-
mitant suppression of Akt and Erk1/2 as well as PDK1 
phosphorylation, which correlated with the induction of 
autophagy at earlier time point than the initiation of 
apoptosis. The inhibitor also turned out to be effective in 
overcoming drug-resistance in MM, as well as proliferative 
and anti-apoptotic signals mediated by IL-6 and IGF-1, 
which are secreted by co-cultured bone marrow stem cells 
(BMSCs). Moreover, capillary-like tubule formation, as well 
as phosphorylation and expression of Akt and Erk were also 
suppressed in HuVEC cells [287]. In other recently 
published studies on CLL cell lines and patient samples 
CAL-101 showed an equally good efficacy. It demonstrated 
an ability to act independently of CLL mutational prognostic 
markers (del (17p.13.1 and IgVH) and, in contrast to other 
CLL agents, showed a lack of off-target toxic effects in non-
hematopoetic cells [288]. Due to these very promising 
results, CAL-101 has been proposed for clinical studies in 
hematologic malignancies. A phase I trial on relapsed or 
refractory hematological malignancies is currently ongoing 
in CLL, AML, MM and non-hodgkin lymphoma (NHL) 
patients [289]. First interim reports from phase I trials with 
CAL-101 showed promising drug activity and a lack of 
severe toxicity in hematological cancer patients [286, 290]. 
Taking into account that p110δ is involved in the immune 
response, CAL-101 was also tested in subjects with allergic 
rhinitis [291]. 
 In addition to the second generation inhibitors which 
have successfully entered clinical development there are 
other compounds, which have shown very good results in 
preclinical studies of cancer treatment, but were not 
considered for clinical trials.  
 IC87114 is one of the first generation inhibitors 
descriminating among class I isoforms. The drug selectively 
targets the p110δ enzyme and was identified in a chemical 
library screen for the determination of PI3K involved in 
leukocyte migration. It exhibits 58-fold selectivity for p110δ 
over p110γ and over 100-fold selectivity towards p110α and 
p110β. In addition, IC87114 did not inhibit the activity of 
other protein kinases, which supports its specificity [292]. In 
terms of biological responses, IC87114 was originally 
presented as an inhibitor of fMLP-stimulated PtdIns(3,4,5)P3 
production and neutrophil chemotaxis. It especially affected 
neutrophil polarization and directional migration, which 
emphasized a significant and selective role of p110δ in 
chemotaxis [292]. In the context of human cancer, IC87114 
was shown to be effective in primary AML cells, which 
present much higher expression levels of p110δ isoform than 
other enzymes of class I PI3K. The drug inhibited p110δ-
regulated phosphorylation of Akt and in turn AML cell 
proliferation [293]. IC87114 treatment of normal haemato-
poietic CD34+ progenitor cells did not induce cytotoxic 
effects, which is of great advantage for normal haemato-
poiesis in vivo [293]. These studies not only shed light on the 
importance of p110δ in AML pathogenesis, but also 
underlined the therapeutic potential of selective inhibition of 
single PI3K isoform in contrast to blockade of all class I 
PI3Ks. 
 ZSTK474 was identified based on its strong anti-
proliferative activity in a chemical library screen of s-triazine 
derivatives [294]. In contrast to other well-known PI3K 
inhibitors, the drug presented higher specificity and potency 
for PI3K and no activity against other tested protein kinases 
such as mTOR [295] and DNA-PK [296]. Although it is 
considered as an ATP-competitive pan-PI3K inhibitor, 
ZSTK474 demonstrated a slightly higher potency towards 
the p110δ isoform [295]. It inhibited the phosphorylation of 
Akt in vitro and in vivo, as well as the phosphorylation of its 
downstream effectors such as GSK-3β, FKHRL1, FKHR, 
Tuberous sclerosis 2 protein (TSC-2), mTOR and S6K. 
However, the Ras/Erk pathway was not affected by inhibitor 
treatment. When orally administrated, the compound caused 
a strong suppression of tumor growth in vivo without 
induction of severe toxicity [294]. Instead of promoting 
apoptosis in cancer cells, ZSTK474 induced a strong G0/G1 
arrest and impaired proliferation through a reduction of 
proliferation marker expression, such as nuclear cyclin D1 
and Ki67 [294, 297]. Moreover, its anti-angiogenic activity 
in vivo was demonstrated [298]. 
 Beside applying isoform-specific or pan-PI3K inhibitors 
an alternative approach employing inositol polyphosphates 
(IPPs) has been proposed to interfere with PI3K/Akt path-
way in cancer [299]. An exogenous inositol 1,3,4,5,6-penta-
kisphosphate (InsP5) was used to block Akt phosphorylation 
and in turn promote apoptosis in human cancer cells [300], 
as well as to prevent tumor progression and angiogenesis in 
in vitro and in vivo settings [301, 302]. InsP5 is a water-
soluble compound, naturally occuring in mammalian cells 
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[303] and in some types of beans and nuts [304]. It is quickly 
absorbed by the cells and very stable in the intracellular 
environment [302]. Similarly to PtdIns(3,4,5)P3 in the 
plasma membrane, InsP5 recruits and binds to PH-domains 
of different effector molecules such as Akt and prevents their 
activation by blocking translocation to the plasma membrane 
[301, 302]. Recently, an improved version of InsP5 was 
synthesised by addition of a benzyl group to InsP5 [305]. 2-
O-benzyl-myo-inositol 1,3,4,5,6-pentakisphosphate (2-O-
Bn-InsP5) not only blocked Akt translocation to the 
membrane, but also selectively inhibited PDK-1-dependent 
phosphorylation of Akt. It showed much higher potency 
against PDK-1 than its precursor InsP5, and additionally it 
specifically suppressed mTOR in vitro [305]. Moreover, 2-
O-Bn-InsP5 displayed an enhanced pro-apoptotic activity in 
cancer cell lines and an augmented ability to reduce tumor 
growth in xenograft models which were resistant to InsP5 
treatment. Furthermore, 2-O-Bn-InsP5 was able to induce 
cell death even in usually chemotherapy-resistant pancreatic 
cancer cells [305]. Although 2-O-Bn-InsP5 does not directly 
inhibit any of the PI3K isoforms, it mimics the signaling 
function of PtdIns(3,4,5)P3 and blocks signal transduction 
through the PI3K/Akt pathway. Exploiting the ability of 2-
O-Bn-InsP5 to recruit PH-domains-bearing proteins is an 
interesting example of a potential novel anti-cancer 
approach. 
5.2. PI3K Inhibitors in other Diseases 
 While p110α plays an important function in oncogenesis, 
p110β, p110δ, and p110γ are essential for thrombosis, 
immune system function, and inflammation, respectively. 
The involvement of PI3K enzymes in the pathogenesis of 
other human diseases, such as atherosclerosis, chronic 
inflammation, allergy, autoimmunity, cardiovascular and 
metabolic disorders, opened an area for the development of 
additional PI3Ks inhibitors. An example of such a drug 
exhibiting broad anti-inflammatory activities? is TG100-115 
(Table 3) [213]. It was shown to potently inhibit vascular 
endothelial growth factor (VEGF) signaling which triggers 
edema and the inflammatory response which can also be 
induced by a wide number of other ligands upstream of 
RTKs and GPCRs. Importantly, TG100-115 did not block 
VEGF-driven angiogenesis in vivo and VEGF-stimulated 
ERK activation, which is a signaling event responsible for 
the mitogenic response to this growth factor [213]. As a 
result, the mitogenesis of endothelial cell was not perturbed, 
and a tissue repair process, which is critical for tissue 
survival after ischemic damage in MI could arise. Two 
known proinflamatory mediators, namely p110δ and p110γ, 
turned out to be the targets of TG100-115 in the context of 
inflammation-associated aspects of VEGF signaling. These 
enzymes were both inhibited with a much higher potency 
than other members of class I PI3Ks and a wide range of 
other protein kinases. The excellent specificity of the 
inhibitor was proven by conformational rotation studies. It 
turned out that the greater the barrier to rotation an inhibitor 
has, the more isoform-selective it is. This was the case for 
TG100-115 in comparison to other pan-PI3K agents [213]. 
Its prominent selectivity was accompanied by extreme 
effectiveness in vivo. The compound reduced infarct deve-
lopment and improved myocardial function in aggressive 
rodent and porcine MI models. Cardioprotection was 
achieved after delivering the drug at the time period when 
MI patients are most accessible for therapeutic intervention 
(up to 3 hours). This and other criteria such as a high 
efficacy at relatively low doses and single administration, 
long-lasting effects of p110δ/γ inhibition and the intravenous 
route of drug delivery appeared to be very beneficial for 
clinical use. TG100-115 is the first small-molecule kinase 
inhibitor which was studied in acute MI patients when 
delivered after ischemic damage and also one of the first 
isoform-specific?PI3K inhibitors which has entered clinical 
trials? [213]. Phase I and II clinical trials, aiming at an 
evaluation of TG100-115 safety and potential efficacy in the 
restoration of blood flow and the reduction of heart muscle 
damage after heart attack in MI patients was completed in 
2008 [318]. The anti-inflammatory potential of TG100-115 
was also tested for asthma and chronic obstructive pulmo-
nary disease (COPD) [203]. The favorable pharmacokinetics, 
safety, and biological activity of TG100-115 were shown 
with the use of mouse models of these respiratory diseases 
[203]. 
 Another specific PI3K inhibitor which is considered as a 
promising candidate for the treatment of inflammatory and 
autoimmune disorders is termed AS-605240. It blocks p110γ?
catalytic activity downstream of GPCRs, in an ATP-
competitive manner and is active in RA [191]. p110γ-/- 
mouse models displayed defects in neutrophil migration and 
were protected against RA. Oral administration of the drug 
to wild type mice (p110γ+/+) mimicked the effect of p110γ 
deficiency and minimized the progression of joint 
inflammation [191]. Furthermore, AS-605240 was able to 
overcome SLE development in SLE-prone MRL-lpr mice 
without inducing toxic effects during the treatment period 
(see section 4.2.1) [187]. In addition, different stages of 
atherosclerosis progression in mouse models were also 
affected by the inhibitor treatment [209]. Thus, targeting 
p110γ with this inhibitor seems to be very promising for the 
treatment of chronic inflammatory disorders. 
 Inhibition of p110δ with the use of IC87114 appeared to 
be very effective in reducing the symptoms of allergic 
asthma [198, 317]. Administration of the drug to the OVA-
induced mouse models of asthma substantially repressed 
airway inflammation, airway hyperresponsiveness and Th2 
cytokine levels. This effect was achieved due to p110δ-
dependent suppression of intereukin-17 (IL-17) expression, 
which was mediated by changes in Akt-induced NF-κB 
activation [198]. Besides asthma, the p110δ-selctive 
IC87114 agent was also shown to significantly suppress the 
bone and cartilage destruction typical for RA in wild type 
mice (see section 4.2.1) [193]. However, bone and cartilage 
damage was completely absent when IC87114 was 
administrated to p110γ-/- mice, suggesting the therapeutic 
potential of IC87114 as an adjuvant therapy for RA. 
 The fact that all class I PI3K isoforms are expressed in 
platelets has caused an increased interest in understanding 
the possible role of the enzymes in the progression of 
cardiovascular diseases. In turn, this area of human medicine 
has also benefited from the development of PI3K-targeting 
therapeutic strategies. The discovery that p110β is involved 
in the process of pathological thrombosis resulted in the 
identification of the TGX-221 inhibitor, which protected 
mouse models against occlusive thrombus formation [232]. 
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In contrast to other antithrombotic drugs (e.g. aspirin, 
clopidogrel), TGX-221 did not affect platelet homeostasis 
and thus did not induce bleeding complications. Animal 
models of arterial thrombosis showed normal tail bleeding 
time. This feature is undoubtedly of big advantage in terms 
of a possible utilization of the drug in the clinic. TGX-221 is 
a cell-permeable analogue of LY294002, exhibiting a high 
potency in the low nanomolar range and a specificity for 
p110β. It exhibits ~ 1000-fold selectivity for p110β over 
p110α and p110γ, and > 1000-fold selectivity over a broad 
range of protein kinases [232]. By inhibiting p110β under 
high shear stress conditions, TGX-221 abolished the cyto-
solic calcium flux and integrin αIIbβ3 activation in response 
to ADP and treshold doses of other soluble agonists 
(triiodothyronine receptor auxiliary protein, epinephrine). 
Thus, shear stress-induced PtdIns(3,4)P2 generation and 
integrin αIIbβ3-mediated stable adhesion contacts in platelets 
were blocked. Beside defining a new role for p110β in 
integrin αIIbβ3-dependent stable platelet adhesion and 
aggregation, these studies identified a new isoform-selective 
PI3K inhibitor which appears to exhibit antithrombotic 
potential [232]. 
5.3. Perspectives for PI3K-Targeting Agents in 
Overcoming the Problem of Drug Resistance in the 
PI3K/Akt/mTOR Pathway 
 Drug resistance is a complicated concept which involves 
many aspects of human biology. First of all, it is differentia-
ted into primary and acquired resistance mechanisms. In 
addition, multiple crosstalks between signal transduction 
pathways, feedback loops, multiple genetic alterations, such 
as secondary mutations in the drug target or in parallel 
pathways, and recently reported dynamic chromatin modifi-
cations make it difficult to unravel and translate new 
discoveries to the clinic [319, 320]. However, there are some 
facts about drug resistance mechanisms which are already 
known, especially in human cancer treatment. The PI3K 
family of enzymes represents one of the pieces of the puzzle 
of drug resistance. 
5.3.1. Oncogenic Mutations 
 Continuous PI3K/Akt signaling is a major cause of resist-
ance to anticancer drugs. Enhanced activation of the pathway 
is induced through genetic alterations such as PIK3CA, 
PIK3R1 and AKT-activating mutations, amplifications of 
PIK3CA, RTKs (e.g. EGFR family) and AKT, or PTEN loss-
of-function (Table 2). The coexistence of these oncogenic 
abnormalities [171], or point mutations in the drug affinity 
pocket of PI3K, which diminish effective drug interaction 
and block the enzymes [172] also contribute to drug 
resistance. It is known that mutations in the most important 
components of the PI3K/Akt axis (e.g. PIK3CA, PTEN, 
PIK3R1) lead to oncogenic activity of the enzymes and 
result in resistance to chemotherapeutics, as well as ther-
apeutic agents directed against other components of the path-
way (e.g. EGFR family) [171, 173]. Breast cancer patients 
subjected to therapy with the anti-HER2 antibody tras-
tuzumab developed resistance and were characterized as 
patients with poor prognosis due to hyperactivation of the 
PI3K pathway [171, 173]. It was described that in breast 
cancer cells carrying amplified HER2 receptor, p110α-
activating mutations (E545K, H1047R) confer resistance to 
trastuzumab [264]. Treatment of these cell lines with BEZ-
235 inhibited proliferation and hyperactivation of the 
PI3K/mTOR pathway induced by PIK3CA mutations, which 
was reflected by reductions in Akt, S6 and 4EPB1 phos-
phorylation. The tumor growth in trastuzumab-resistant 
breast cancer xenograft models was also suppressed [264]. 
 A different example of an inhibitor overcoming drug 
resistance is PX-866, an analogue of wortmannin. It acts on 
the p110α, γ and δ isoforms of class I PI3K and shows 
decreased potency against p110β and mTOR [247, 315]. The 
majority of non–small cell lung cancer (NSCLC) patients 
bearing EGFR mutations respond well to EGFR inhibitors, 
such as gefitinib. Furthermore, gefitinib inhibits activation of 
the PI3K signaling pathway due to the blockade of EGFR 
and ErbB-3 receptor dimerization after stimulation with 
ligand. A-549 NSCLC tumor xenografts, which do not 
express ErbB-3, turned out to be resistant to gefitinib. 
Treatment of these tumors with low doses of PX-866 prior to 
gefitinib administration potentiated the antitumor activity of 
the latter compound and overcame resistance. Full growth 
control and a reduction in Akt phosphorylation was 
achieved, which was not observed when xenografts were 
treated with gefitinib alone [315]. Although PX-866 showed 
some toxic effects, such as decreased glucose tolerance and 
increased neutrophil counts after prolonged administration, 
this did not disqualify it as a candidate for clinical use. 
Decreased glucose tolerance was abolished upon treatment 
cessation or reversed by insulin and by the peroxisome proli-
ferator-activated receptor-γ (PPAR-γ) activator pioglitazone. 
PX-866 is the only irreversible PI3K inhibitor which has 
entered the clinical stage of studies [247, 315]. A final result 
from the phase I clinical trial of orally administrated PX-866 
showed inhibition of PI3K pathway as well as the drug’s 
tolerability, which supported phase II testing [321]. 
5.3.2. Feedback Loops  
 Negative feedback loops are one of the causes for the 
development of drug resistance. The best known example of 
such a regulation involves the inhibition of mTOR with 
rapamycin which causes an activation of the Akt [322] 
and/or ERK/MAPK pathway [323] promoting pro-survival 
and proliferative signaling in different types of tumors (refer 
to Fig. 1). Suppression of mTOR with rapamycin inhibits 
S6K, resulting in up-regulation of IRS-1 protein level and 
activation of the IGF-IR/IRS-1/PI3K signal transduction 
pathway, which in turn leads to Akt phosphorylation [322]. 
On the other hand, the activation of the RTK/IRS-1/PI3K 
axis can be directed towards the Ras/MAPK pathway 
followed by Akt and Erk phosphorylation and activation of 
downstream signaling which attenuate the anti-proliferative 
and anti-apoptotic effects of rapamycin [323]. This dual 
feedback mechanism can be avoided by using a combina-
torial treatment of an mTOR inhibitor with growth factor 
receptor, MEK or PI3K inhibitors. Dual PI3K/mTOR inhibi-
tors also appear to fulfil the required criteria. As suggested 
by Manara et al. or Maira et al. BEZ235 might be a good 
candidate for this application [263, 265].  
 Although examples of overcoming protein kinase drug 
resistance by PI3K inhibitors are described adequately, we 
cannot forget that the resistance to PI3K inhibitors can also 
occur. However, the mechanism is likely to be different from 
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that of the protein kinase family (e.g. BCR-Abl, c-Kit, 
PDGFR, EGFR) in which it is driven by the point mutation 
of the “gatekeeper” residue located at the affinity pocket, 
where the most potent inhibitors bind. Analogously to other 
protein kinases, mutation of the Ile848 residue was proposed 
to govern drug resistance in class I PI3Ks. Interestingly, 
prediction studies of possible drug-resistance mutations in 
p110α identified other residue than Ile848, namely Ile800, 
which accounts for 5-30 fold resistance to most PI3K 
inhibitors. However, additional studies are required to draw a 
full picture of resistant mutations in p110α [172]. 
5.4. PI3Ks Structural Studies Impact on Drugs Design 
 Structural characterization of the PI3K isoforms in both 
free form or in complex with regulatory subunits or ATP-
competitive small molecule inhibitors shed a new light on 
the drug discovery programs (extensively discussed in 
[324]). Improvement of the specificity and potency of the 
anti-cancer drugs is currently the main driving force of the 
PI3Ks structure elucidation. Employment of more selective 
compounds in the clinic avoids undesirable phenotypes and 
toxic side effects which are usually induced by pan-class I 
PI3K inhibitors.  
 The ATP-binding pockets of class I PI3Ks are highly 
conserved [314]. Therefore, it became an important task to 
determine structural differences among the isoforms which 
can be utilized for designing more specific drugs. For a long 
time class I p110γ was the only PI3K isoform whose 
structure had been described [325]. Later on, a full-length 
structure of the most frequently mutated PI3K isoform in 
human cancer, p110α, was characterized in a complex with 
the N-terminal-SH2 (nSH2) and inter-SH2 (iSH2) domains 
of the p85α subunit [149]. These studies also provided new 
insights into the location of some of the oncogenic mutations 
in p110α that is of a great value for designing mutant-specific 
inhibitors [326]. The recent publication of p110δ structure 
uncovered new structural determinants which control 
selectivity across PI3Ks [327]. Detailed analysis of the 
p110δ ATP-binding site organization when occupied by 
small molecule inhibitors revealed that the selectivity toward 
the enzyme is driven by its conformational flexibility and the 
sequence diversity of active site residues that are located 
away from the direct ATP binding pocket. The availability of 
this information resulted in the synthesis highly specific 
inhibitors for p110δ with greatly improved potencies [327]. 
The advantages derived from structure-based drug design are 
therefore convincing and encouraging further investigations. 
5.5. Combinatorial Treatments 
 Using small molecule PI3K inhibitors as single agents for 
the effective treatment of different human diseases may not 
always bring substantial and long-lasting benefits. Deve-
lopment of acquired resistance including the induction of 
multiple secondary mutations or activation of the substi-
tuting kinases, and feedback loops resulting from numerous 
crosstalks between different pathways, make this task even 
more difficult. A growing understanding of the complex 
interactions between signaling networks has led to the 
development of rationally designed, effective combination 
therapies. Numerous preclinical investigations documenting 
the effectiveness of combinations of PI3K inhibitors with 
other therapeutic strategies (including conventional chemo-
therapy and radiation) are already published and are being 
investigated in the clinics (reviewed in [328]). Recent reports 
have indicated that a combination of GDC-091 with the anti-
HER2-directed antibody trastuzumab or pertuzumab dec-
reased the growth of HER-2-amplified (trastuzumab-
resistant) breast cancer cells [329]. The BEZ235 inhibitor 
significantly enhanced the efficacy of temozolomide in 
PTEN-null glioblastoma multiforme mouse model by 
causing a regression of the tumor mass [263]. BEZ235 was 
also suggested to be used with trastuzumab for treatment of 
breast cancer patients with HER2 and/or PIK3CA mutations 
[264, 266], or in combination with MEK inhibitors for 
PTEN- or KRAS-mutated breast and lung cancers, respect-
ively [266, 330]. These and plenty of other examples 
including SF1126 [249], IC87114 [293] and CAL-101 [287] 
combinatorial treatments with taxotere, VP16 (a topoiso-
merase II inhibitor) and bortezomib respectively, provided a 
proof-of-concept for the vertical and horizontal blockade of 
crosslinked signaling pathways, as proposed by Yap et al. 
[331] and Workman et al. [324]. The vertical blockade is 
especially effective in preventing secondary drug resistance 
driven by negative feedback loops. It involves one or more 
drugs which target the same signaling pathway at different 
levels, such as dual PI3K/mTOR inhibitors (e.g. BEZ235), or 
selective EGFR and PI3K inhibitors combined together 
[264]. The concept of using multi-targeted single agents or 
cocktails of highly selective inhibitors was described by 
Knight et al., [332] and supported by Zunder et al. [172], 
who suggest that multi-targeted drugs of PI3K pathway (e.g. 
PI-103 and BEZ-235) are less likely to cause drug resistance 
than selective PI3K inhibitors. On the other hand, PI3K and 
MEK inhibitors can serve as an example of the horizontal 
way of suppression of molecular targets, which involves the 
use of drugs which inactivate two or more different parallel 
signaling pathways [330, 333]. However, besides the many 
advantages derived from combinatorial strategies they have 
also raised many questions and concerns about the toxicity 
of such treatments (reviewed in [328]). There is always a 
risk of developing undesired effects resulting from 
disturbances in the homeostasis in healthy cells. Therefore, a 
careful analysis of previous results is needed to design the 
best combinatorial approaches. 
 In addition, an early selection of patients who would 
benefit form the combination therapy is crucial for an effect-
ive treatment. Even though we have nowadays acquired an 
increased knowledge from structural inhibitor studies, mouse 
models and clinical trials, it is still a big challenge to select 
patients who will benefit the most from a specific treatment. 
In the future, biomarkers will become a major aspect for 
developing successful treatments, and our growing com-
prehension of the molecular map of human cancer is giving 
us the hope that this will soon be possible.  
6. CONCLUSIONS 
 The ubiquitous expression of PI3Ks in different cells, 
tissues and organs underscores their significance and 
multiple functions in an organism. In connection with others 
signal transduction pathways, the PI3K/Akt axis forms a 
complex signaling network controlling a wide variety of 
biological processes. Deregulation of the PI3K/Akt pathway 
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results in a disruption of cellular homeostasis, which further 
leads to different pathological states reflected in the 
development of various human diseases. Accordingly, the 
PI3K enzymes have become promising targets for 
therapeutic intervention in cancer, as well as inflammatory, 
autoimmune and cardiovascular disorders. Small molecule 
inhibitors targeting PI3K isoforms have evolved over the 
years from natural, but quite toxic and unstable compounds 
to better tolerated and more potent synthetic agents. These 
inhibitors have become a major force in the arsenal of 
anticancer therapies, as well as potential new drugs for the 
treatment of other human diseases. As known from nume-
rous preclinical studies and the first reports from clinical 
trials, PI3K inhibitors may work efficiently as single agents, 
but also in combination with other chemotherapeutics. The 
future choice of a clinical approach involving these inhibi-
tors will strongly depend on the genetic background of the 
patients and, therefore, biomarker profiles will be essential in 
predicting which patients will most likely benefit from a 
specific agent. The availability of such information will be of 
great value for the design of more personalized therapies.  
 The translation of the increasing knowledge about PI3K 
signaling to clinical settings is a challenging task for the 
future. Fortunately, an increasing number of encouraging 
reports from the first clinical trials give hope that this goal is 
achievable. 
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ABBREVIATIONS 
2-O-Bn-InsP5 = 2-O-benzyl-myo-inositol 1,3,4,5,6- 
  pentakisphosphate  
4E-BP  = Eukaryotic translation initiation factor  
  4E-binding protein 1 
p97/VCP = p97/valosin-containing protein 
ALL = Acute lymphoid leukaemia 
AML = Acute myeloid leukaemia  
CLL  = Chronic lymphocytic leukemia 
DNA-PK = DNA-dependent protein kinase 
EGFR = Epidermal growth factor receptor 
ErbB-3 = V-erb-b2 erythroblastic leukemia viral  
  oncogene homolog 3 (avian) 
ERK = Extracellular signal-regulated kinase 
FKHR = Forkhead human rhabdomyosarcoma  
  transcription factor 
fMLP = formyl-methionyl-leucyl-phenylalanine 
GLUT-4 = Glucose transporter type 4 
GPCR = G protein-coupled receptor 
Grb2 = Growth factor receptor-bound protein 2 
GSK3β = Glycogen synthase kinase 3 beta 
HER2 = Human epidermal growth factor  
  receptor 2 
IGF1 = Insulin-like growth factor 1 
IGF-1R  = Insulin-like growth factor-1 receptor 
IL = Intereukin 
IRS  = Insulin receptor substrate 
LOH = Loss of heterozygosity 
MAPK = Mitogen-activated protein kinase 
MI = Myocardial infarction 
MM  = Multiple myeloma 
mTORC1 = Mamalian target of rapamycin  
  complex 1 
mTORC2 = Mamalian target of rapamycin  
  compelx 2 
PDK1 = 3-phosphoinositide-dependent  
  protein kinase 1 
PI3K = Phosphatidylinositol 3-kinase,  
  PI3-kinase 
PIK3CA = Phosphoinositide-3-kinase, catalytic,  
  alpha polypeptide 
PIK3CB = Phosphoinositide-3-kinase, catalytic,  
  beta polypeptide 
PIP3 = Phosphatidylinositol-3,4,5-trisphosphate 
PtdIns = Phosphatidylinositol 
PtdIns(3)P = Phosphatidylinositol-3-monophosphate 
PtdIns(3,4,5)P3 = Phosphatidylinositol-3,4,5-trisphosphate 
PtdIns(4,5)P2 = Phosphatidylinositol-4,5-bisphosphate 
PTEN = Phosphatase and tensin homologue  
  deleted on chromosome 10 
PXDK  = Pyridoxal kinase 
RA = Rheumatoid arthritis 
Ras = Ras guanine nucleotide exchange  
  factor 2 
RGD  = Arginine–glycine–aspartic acid targeting  
  moiety 
RTK = Receptor tyrosine kinase 
S6K = p70 ribosomal S6 kinase; ribosomal  
  protein S6 kinase, 70kDa, polypeptide 1 
SLE = Systemic lupus erythematosus 
Vps34 = Vacuolar protein-sorting defective 34 
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